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Abstract
Matrix metalloproteinases (MMP’s) and cathepsins are thought to play key roles in
oral squamous cell carcinoma (OSCC) invasion and metastasis. Three OSCC human cell
lines, BHY, HN and HSC-3, have been studied based on their reported ability to invade
adjacent bone or metastasize to lymph nodes and/or distant organs. The working
hypothesis of this study is that OSCC that demonstrate different actions have different
proteolytic enzyme and gene expression profiles.
Immunocytochemistry and flow cytometry were used to determine the expression
levels of certain proteolytic enzymes. Complementary DNA (cDNA) microarray
technique was used to determine the gene expression profiles of each of the three OSCC
cell lines.
The immunocytochemistry and flow cytometry results showed that the BHY cell
line expresses MMP- 9 and extracellular matrix metalloproteinase inducer (EMMPRIN).
The BHY cell line expressed 139 upregulated genes and 117 downregulated genes. The
HN cell line expressed 214 upregulated and 262 downregulated genes. Finally, the HSC3 cell line expressed 128 upregulated and 117 downregulated genes. There were 13 genes
that were upregulated and 83 genes that were downregulated in all three OSCC cell lines.
Eight pathways were upregulated and 3 pathways were downregulated in the BHY cell
line. In the HN cell line 10 pathways were upregulated and 9 were downregulated.
Finally, in the HSC-3 cell line 3 pathways were upregulated and 6 pathways were
downregulated.

iii

MMP-1, MMP-9 and EMMPRIN appear to play a role in the invasion of OSCC to
bone. KIAA, was upregulated in our study in the HN cell line. Upregulation of KIAA
may be involved in the late stage of OSSC. PAM gene was the only downregulated gene
in the HN cell line. The TM4SF10 gene was downregulated in all three OSCC cell lines.
The COL1A2 and COL4A1 genes were upregulated in the HSC-3 cell line and they may
cause the lymph node metastasis of OSCC. Based on this study OSCC involves multiple
molecular genetic events that take place in many chromosomes and genes. Upregulation
of the Jak-STAT signaling pathway may be involved in bone invasion of OSCC. The
MAPK signaling pathway was upregulated in all three OSCC cell lines.
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CHAPTER 1
INTRODUCTION
Oral squamous cell carcinoma (OSCC) is the most common cancer of the oral
cavity accounting for ninety percent of all diagnosed oral malignancies. OSCC accounts
for approximately 6 % of all human malignancies (6, 96). There is little published
information on the capability of some OSCC to invade adjacent bone while other OSCCs
do not. Additionally, some OSCCs exhibit metastasis to cervical lymph nodes and/or
distant organs while others do not readily metastasize.
In the United States, OSCC is the sixth most common cancer in males (6, 57) and
the twelfth most common cancer in females. Approximately 21,000 new cases are
diagnosed annually in the United States, and 6,000 of these patients die of this disease
each year. Some risk factors for developing OSCC include tobacco use, alcohol
consumption, human papilloma virus and syphilis. Other intrinsic factors may include
general malnutrition such as vitamin A deficiency and iron deficiency anemia. The
treatment of OSCC is radical surgical excision and/or radiation therapy, depending on the
clinical stage of the disease. A variety of chemotherapeutic agents are used as adjunctive
therapies, but none of them has significantly improved survival rates. As with most
tumors, the survival rate decreases with evidence of bone invasion and cervical
metastases (6). OSCC may invade tissue locally (1, 2, 3), and often to adjacent bone (1,
4, 7). Also, OSCC often metastasizes to cervical lymph nodes (1, 2, 3) and distant organs
(5). In addition, if the tumor invades nearby bone the survivability is significantly lower
(6). Resection of OSCC with bone invasion dramatically affects functions such as
15

swallowing and speaking, and patient esthetics. Thus, reconstruction of the area is a
necessity. Tumor usually invades bone through osteolysis, by greatly increasing the
number of active osteoclasts at the invasion site (7). This strongly suggests that tumor
cells involved with bone invasion promote differentiation and activation of osteoclasts
(7). Proteolytic enzymes such as various matrix metalloproteinases (MMP’s) (1, 2, 3, 8,
13) and cathepsins (1, 4) are thought to play key roles in OSCC invasion and metastasis,
and have been shown to be expressed by OSCC cells (4, 8, 9, 10).
Some studies have focused on the effect MMP-1 (1, 10, 18), MMP-2 (1, 9, 10, 17),
MMP-3 (2, 17, 18) and MMP-9 (1, 9, 10, 19) along with cathepsin B, H, L, and D (1, 4)
on the ability of OSCC to invade bone. Production of MMP-1 and MMP-9 appear to play
a role in the invasion of OSCC to bone (8, 10). These two metalloproteinases are
necessary for the complete degradation of the collagen matrix of bone, and have been
shown to be expressed by OSCC (10). MMP-2 does not appear to be related to OSCC
invasion, but is highly expressed in some OSCCs (9). Over expression of MMP-3 in
OSCC is associated with diffuse invasion and a high incidence of metastasis (2). In tumor
cells, extracellular matrix metalloproteinase inducer [EMMPRIN (CD 147)] can stimulate
the production of MMPs. It also participates in invasion and metastasis by facilitating
tumor cell motility though the surrounding matrix (13). Cathepsin B, H and D have been
strongly implicated in the invasion of OSCC, with over expression of these proteins
thereby appearing to promote tumor growth and invasion (4). Cathepsin B and L are the
two most important cysteine proteinases implicated in tumor cell invasion and metastasis
(12).
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Why does one patient with a certain type of cancer respond well to treatment, while
other patients with histologically and anatomically identical disease do not? Why do
some tumors grow more aggressively than others even though they are the same type of
tumors? The key to resolving the enigma of individual tumor behavior clearly lies in
understanding its molecular structure. cDNA microarray analysis is one of the strongest
tools for mapping molecular signatures because with this technique, instead of working
on a "one gene in one experiment", it is possible to observe the whole human genome on
a single chip. Thus, researchers can have a better picture of the interactions among
thousands of genes simultaneously. Briefly, with this technique it is possible to evaluate
the gene expression profile of any type of cell or tissue.
In this study, 3 OSCC human cell lines, BHY, HN and HSC-3, were chosen for
study based on their reported ability to invade adjacent bone or metastasize to cervical
lymph nodes and/or distant organs. Also, a normal human nasal epithelial cell line
(HNEC) was chosen as a control group. The working hypothesis of this study was that
OSCC’s that demonstrate different actions have different proteolytic enzyme, gene and
pathway expression profiles. OSCC’s that invade adjacent bone will have different
expression profiles from OSCC’s that metastasize to cervical lymph nodes and/or distant
organs. Thus, identification of the gene expression differences of these three cell lines
will help to determine which genes and pathways are responsible for lymph node or
distant organ metastasis or bone invasion of OSCC. Genes, pathways or their related
proteins that are associated with tumor metastasis or invasion will provide a basis for
further studies investigating metastatic progression and local invasiveness of this tumor,
and can be evaluated as therapeutic targets.
17

The four cell lines; BHY, HN, HSC-3 and HNEC were morphologically
characterized and the level of differentiation and any possible organelle abnormalities
studied using transmission electron microscopy. Micro positron emission tomography
(PET)/computerized tomography (CT) imaging techniques were used to image the
invasion and/or metastatic potential of each cell line in immuno-compromised scid mice.
This technique also showed the differences in jaw bone invasion and distant organ
metastasis of these three OSCC cell lines in a biological system. The 3 OSCC cell lines
and HNEC were studied in vitro with both immunocytochemistry and flow cytometry to
determine if MMP-1, MMP-2, MMP-3, MMP-9, and EMMPRIN and cathepsin B and L,
were expressed. Finally, gene regulation of the three OSCC cell lines was investigated
and compared to the HNEC cell line by using the cDNA microarray analysis method.
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CHAPTER 2
LITRATURE REVIEW
2.1. Oral Squamous Cell Carcinoma (OSCC)
Oral squamous cell carcinoma (OSCC) is a malignant transformation of
keratinocytes in stratified squamous epithelium (6). It is the most common cancer of the
oral cavity (6, 9, 46, 52). This malignancy is an important public health problem
worldwide with more than 500,000 new cases diagnosed each year (6). OSCC can
metastasize to cervical lymph nodes (1, 2, 3, 9, 52) and distant organs (5, 9), and invade
the jawbone which results in significantly decreased survival (6, 9).
The etiology of OSCC can be genetic from alterations of proto-oncogenes and
tumor suppressor genes (25, 58, 70, 104, 107). Other common etiologies of OSCC are:
• Alcohol consumption and smoking (58, 104). Smoking and drinking alcohol in
combination increases the risk of developing oral cancer by 15 times (6).
• Viral infections such as; Human Papilloma Virus (HPV), Herpes Viruses, Epstein
Barr Virus (EBV), Human Immunodeficiency Virus (HIV).
• Candidiasis (58, 104).
• Exposure to high amounts of X-rays and UV rays (104).
Diagnosis of OSCC can be made by intraoral examination and biopsy, PET/CT
imaging, and toluidine blue staining. Toluidine blue staining may permit early diagnosis
of OSCC. The development of OSCC occurs in a stepwise fashion. It begins with
dysplasia, progressing to carcinoma in situ, and finally to invasive and metastatic
squamous cell carcinoma (10).
19

Clinically, early OSCC may present as a white lesion (leukoplakia), a red lesion
(erythroplakia), or a combination of both (erythroleukoplakia). Superficial ulceration of
the mucosal surface may develop. As the lesion progresses, it may become an exophytic
mass with a fungating or papillary surface. Some tumors demonstrate an endophytic
growth pattern that is characterized by a depressed, ulcerated surface with a raised, rolled
border (6). Pain is not a reliable indicator because most oral cancers are asymptomatic, or
may be associated with only minor discomfort in the early stages (6). Head and neck SCC
mainly occurs in the oral cavity and larynx. Two thirds of the patients diagnosed with this
tumor are in advanced stages (III and IV). OSCC is generally seen after the age of 40 and
2/3 of the cases occur in males (6).
Histopatologically, OSCC demonstrates larger nucleii and cell size, and prominent
nucleoli. The nucleus-to-cytoplasm ratio is increased in OSCC. Hyperchromatic
(excessively dark-staining) nuclei, dyskeratosis (premature keratinization of cells), and
increased and / or aberrant mitotic activity are also common pathological chacteristics of
OSCC (6).
The treatment of OSCC is complex and multidisciplinary. Surgery, radiotherapy,
and chemotherapy or the combinations of these are the mainstay of treatment (100).
During surgical treatment, resection of the tumor with an uninvolved margin is vital to
success (6). If there is invasion of underlying bone, resection of bone with its periosteum
should be performed. Instead of surgery, radiation and chemotherapy may be employed.
Multiple chemotherapeutic agents and combinations can be used. Platinuim and 5fluorouracil are the common drugs that have been used for chemotherapy. Following
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surgical treatment, 6000-6400 cGy of external beam radiation therapy is commonly
administed in daily 200 cGy fractions. (209).
The prognosis of OSCC is poor (9, 44). Early recurrence and rapid progression is
common (3) and the 5-year survival rate is approximately 50% (93, 97). Twenty five
percent of all patients develop a second cancer within 5 years from diagnosis (97). The
prognosis of patients with OSCC is directly correlated with the histologic status of the
cervical lymph nodes (9). Proteolytic degradation of the extracellular matrix (ECM) is
required for tumor cells to invade the basement membrane, stromal matrix and vascular
tissue (8, 33).

2.2. BHY, HN, HSC-3 and HNEC Cell Lines
The 3 OSCC cell lines chosen for this project included BHY, HN, and HSC-3. As a
control group, normal human nasal epithelial cell (HNEC) was chosen.
2.2.1. BHY cell line
The BHY cell line was isolated from a 52-year-old Japanese male. The primary
squamous cell carcinoma was located on the lower alveolus, and the tumor was highly
differentiated. In this patient the tumor invaded the mandible but did not metastasize.
Kawamata et al. showed that BHY cells actively invade mandible when injected into the
masseter muscle of nude mice, but did not metastasize to cervical lymph nodes or any
distant organs (1).
2.2.2. HN cell line
The HN cell line was isolated from a 60-year-old Japanese male. The primary
squamous cell carcinoma was located on the soft palate, and was moderately
differentiated. The tumor had metastasized to cervical lymph nodes, lungs and brain but
21

had not invaded bone. Kawamata et al. reported that HN cells injected into the masseter
muscle of nude mice weakly invaded the surrounding masseter muscle but not the
mandible; however, these cells did metastasize to cervical lymph nodes (1).
2.2.3. HSC-3 cell line
The HSC-3 cell line was isolated from a 64-year-old Japanese male. The primary
squamous cell carcinoma was located on the tongue with lymph node metastasis, and was
moderately differentiated. This cell line is highly metastatic to cervical lymph nodes (10,
23, 52).
2.2.4. HNEC cell line
The HNEC cell line was isolated from a 27-year-old Caucasian male, and represents
a normal human nasal epithelial cell line.

2.3. Invasion and Metastasis of OSCC
Metastasis is the process by which cancers spread to regional and distant sites in the
body (110). Invasion is the movement of cancer cells into the surrounding normal tissues.
Both metastasis and invasion are multi-step processes that require a variety of genetic
alterations in the tumor cells. Bone is one of the most common sites of tumor metastasis
(7). In the oral cavity, OSCC frequently invades maxillary and/or mandibular bone.
However, the metastatic and invasion mechanisms of OSCC are poorly understood. It has
been shown that bone resorption by osteoclasts is an important step of bone invasion and
metastasis in OSCC (14, 15, 16). Osteoclasts, rather than carcinoma cells, mediate bone
destruction in carcinoma invasion and metastasis (7, 14, 15). In so doing, tumor cells
promote differentiation and activation of osteoclasts (7). Osteoclast precursor cells are
directly apposed to tumor cells in some instances, which means that tumor cells may
22

participate in the differentiation of osteoclasts. However, stromal cells or extracellular
matrix (ECM) usually exist between these two cells (Figure 1 1 ). Direct contact of
osteoblasts or stromal cells with stem cells is needed for osteoclast differentiation.
Therefore, the interaction between stromal cells and osteoclast precursor cells is
important in the process of osteoclast formation. Heparin-sulfate proteoglycan (HSPG)
and fibronectin are the two representatives of the components of the extracellular matrix.
HSPG can be observed in the stroma around the tumor nests, but not in the tumor cells.
HSPG is also positive in the stroma away from the bone surface. HSPG binds a bone
resorption-activating factor that is released from osteoblasts. Fibronectin shows the same
pattern of localization as seen with HSPG. Since many osteoclast precursor cells can be
observed in a stroma rich ECM component, they may play an important role in providing
a micro-environment for osteoclast differentiation and activation (7). In addition,
interleukin-6 (IL-6) secreted by oral cancer cells may enhance bone invasion of cancer
cells mediated by induction and activation of osteoclasts (7, 20).
The proliferation and progression of cancer may be caused by abnormalities in
various positive and negative cell cycle regulators (25, 68, 133). Cell cycle progression is
positively regulated by multiple cyclins and cyclin-dependent kinases (CDKs).
Cyclin/CDK complexes are activated through phosphorylation by the CDK-activating
kinase, but are negatively regulated by a number of CDK inhibitors including p27 (25,
68). In oral carcinogenesis, p53 over-expression is an early event (25, 46, 68, 70). Loss of
the p27 protein is also closely associated with early invasion and metastasis in OSSC.
Aggressive cancers express low levels of p27 because of its decreased stability. Thus
1

All figures are located in the Appendix B.
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metastatic OCSS shows reduced expression of p27 in comparison with that in the primary
lesion as well as in non-neoplastic mucosa (25, 26, 27, 28, 29, 30, 31, 32, 68).
Tumor growth, invasion and metastasis also depend upon angiogenesis, formation
of new blood vessels from pre-existing endothelium (46, 51, 52, 55). Vascular endothelial
growth factor (VEGF) (50, 51, 52, 53, 56) and fibroblast growth factor (FGF) (50) are
considered the most important mediators in tumor angiogenesis. Shang et al. showed that
VEGF concentration is increased in patients with OSCC (51). Moriyama et al. reported
that the intensity of VEGF expression is significantly higher in metastatic positive
patients than in metastatic negative patients with OSCC (53). VEGF promotes
angiogenesis both in vivo and in vitro (46, 47, 50, 51). In addition to inducing cascades of
angiogenic events, VEGF is also known as a vascular permeability factor (46, 50, 52, 56).
When blood vessel permeability increases, VEGF permits creation of an extravascular
fibril gel that supports endothelial cell growth and thus the tumor (50, 51). The tumor
suppressor gene, p53 is a cell cycle regulator and DNA damage sensor. Loss of p53
function is associated with increased angiogenesis by upregulation of VEGF expression
(46). There are 4 members of VEGF family, including VEGF A, B, C, and D. Shintani et
al. found that VEGF A and B can be detected on both lymph node positive and negative
cases, whereas VEGF C and D can only be detected in lymph node positive tumors. This
suggests a possible relationship between the expression level of VEGF C and D and
development of lymphatic tumor spread (47). Thrombospondin-1 (TSP-1) is a 450 kd
glycoprotein synthesized and incorporated into ECM by numerous cell types and reported
to suppress tumor growth and progression by its inhibition of angiogenesis. The level of
TSP-1 is inversely associated with the pattern of tumor invasion and lymph node
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metastasis. The reason for this might be that TSP-1 suppresses the proliferation and
migration of vascular endothelial cells in vitro, and suppresses neovascularization in vivo
(54).
In addition to VEGF, interleukin-8 (IL-8) is also a potent angiogenic factor and it
plays an important role in cancer progression and metastasis (48, 125, 126). IL-8 is
responsible for most of the angiogenic activity induced by human OSCC (49, 126). Lalla
et al. showed that at a specific dose, fibrin causes upregulation of IL-8 expression in
human OSCC cells in vitro, whereas it doesn’t stimulate IL-8 formation in nontumorigenic oral epithelial cells. This means that fibrin can be a pluripotent activator in
OSCC. IL-8 transfected cells, show an upregulation in MMP-2 and MMP-7 levels that
causes the enhancement of invasion and metastasis (48, 126). Beside this, perilymphatic
recombinant interleukin-2 (IL-2) application combined with surgery and radiotherapy
increases the disease free interval and survival of OSCC patients with T2-T4, N0-N3, M0
staging (127).
2.3.1. The effect of MMPs and EMMPRIN on invasion and metastasis of OSCC
Proteolytic enzymes play an important role in tumor invasion and metastasis by
degrading the ECM (9, 13, 41, 42, 97). They are secreted by a variety of normal cells and
tumor cells; however, the difference between normal and pathological processes is in the
regulation of their activity (1). One of the groups of proteolytic enzymes is the matrix
metalloproteinase (MMP) family, which is a family of zinc-dependent proteinases (9, 38,
42). The MMP family consists of 16 related members. Based on their structural and
functional properties, they can be classified as collagenases, gelatinases, stromelysins,
and membrane type MMPs (MT-MMPs) (9, 10, 42). In addition, there are 4 different
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tissue inhibitor matrix metalloproteinases (TIMPs-1 to -4) that inhibit the function of
MMPs (22). MMPs have specific functions in turnover of ECM. They play an integral
role in the biological processes of development, tissue repair, and metastasis by
regulating cell proliferation, differentiation, adhesion and migration. The production of
these proteins by normal cells is regulated by growth factor and cytokines (42). It has
been shown that they play a key role in promoting invasiveness of both normal and
neoplastic cells (13, 21, 38, 42). Also, they play important roles in wound healing, tissue
repair, bone resorption, angiogenesis and developmental tissue morphogenesis (10, 38,
42). Table 1 2 summarizes the role of MMPs in normal and pathological processes (21).
To establish invasion and metastasis, the first step is the active migration of cancer
cells from their tissue of origin. This process involves the degradation of underlying
basement membrane, which is made of collagens, laminin, and heparin sulfate
proteoglycans (42, 44). OSCC can produce several collagen and gelatin-degrading
enzymes such as MMP-1, MMP-2, MMP-7 and MMP-9 (1). Also, tumor cells can
activate the proMMPs (zymogen forms) that are released mainly by the peritumor
fibroblasts and/or the tumor cells themselves at the invasive edge of the tumor (1, 13).
Several mechanisms can account for the secretion of MMPs and thus their mediation in
tumor cell invasion. First, tumor cells can produce MMPs themselves, thus facilitating
their own invasive behavior. Second, the neighboring stromal cells may produce the
proteases required for tumor cell invasion. Third, an interaction between stromal and
tumor cells may exist, resulting in increased MMP production and activation which
enhances invasion (10, 44). After the tumor cells degrade the ECM, they enter the
2
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circulation. They then penetrate through the sub-endothelial basement membrane of
lymphatic channels and capillary vessels (9, 44). This event largely depends on the
activation of ECM degrading enzymes, such as MMPs that are produced by the tumor
cells and the stromal cells (1, 9, 44). The MMPs that are synthesized by stromal cells are
the proforms of MMPs. Then, the tumor cells receiving the proenzymes from the
surrounding stromal cells activate them by their own MT1-MMP (44). Epidermal growth
factor (EGF) has been shown to be a major constituent of serum to induce MMP-1, and to
enhance ECM collagen degradation (2, 10). Collagenase MMP-1 initiates the degradation
of type I collagen, which is one of the most abundant proteins of the ECM. Once cleaved,
type I collagen denatures into gelatin and ultimate degradation of gelatin is accomplished
by the action of gelatinases, which are MMP-2 and MMP-9 (9, 10, 44). Production of
MMP-1 is required for complete collagen matrix degradation and is expressed in OSCC.
Thus, MMP-1 appears to be a major factor in invasive OSCC (10). Another essential step
in the invasive and metastatic nature of tumor cells is the degradation of type IV collagen
in the basement membrane by MMP-2 and MMP-9 (9, 38, 41, 42, 44). However, tumor
cells must also traverse interstitial stroma, composed of collagen III and I. Thus, to be
invasive the tumor cells must be able to degrade interstitial collagen. Degradation of
interstitial collagen is most effectively accomplished by collagenases MMP-1, MMP-8,
MMP-13 and to some extent MMP-2 and membrane type 1 MMP (MT1-MMP) (10,
112).
Similar to other MMPs, MMP-2 is secreted in an inactive form (proMMP-2). Its
conversion to an active form (MMP-2) is due to the MT1-MMP. In fact, proMMP-2
binds to TIMP-2 in combination with the MT1-MMP on the cell surface, forming a
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ternary complex. Then, proMMP-2 in the complex is activated by adjacent MT1-MMP
that is freed from TIMP-2 (43).
Hong et al. reported that the total activity of MMP-2 in OSCCs was 3.64 times
higher than in normal mucosa, but in OSCC without metastasis it was similar to that in
OSCC with metastasis (9). On the other hand, the total activity of MMP-9 in OSCCs was
2.81 times higher than in normal mucosa and in OSCC with metastasis, this was 1.54
times higher than when there was no metastasis (9). Although cancer cells that secrete
MMP-2 and MMP-9 can become invasive, Hong et al. suggest that MMP-9 might play a
more important role than MMP-2 during this process (9). According to the results of
another study, OSCC patients with T3 and T4 tumors had significantly higher MMP-2
levels than T1 and T2 tumors. Also MMP-2 proportion in lymph node metastasis cases
was significantly higher than that in non-lymph node metastasis cases. In contrast to
MMP-2, the activated form/proform ratio of MMP-9 was very low, suggesting that
MMP-9 is not activated in the matrix degrading of OSCC, although both MMP-2 and
MMP-9 protein expression are present in the tumor cells (44). MMP-2 and MMP-9 are
highly expressed in human OSCC with metastasis compared to normal oral keratinocytes
(38, 97). MMP-2 and MMP-3 expression in OSCC is closely related to lymph node
metastasis and vascular invasion (34). In addition, it has been reported that OSCC
producing MMP-2 is prone to metastasize to lymph nodes more frequently than OSCC
with no MMP-2 expression (35). Miyajima et al. showed that MMP-9 production is
closely related to lymph node metastasis (36). Charous et al., however, found that there is
no difference in MMP-2 and MMP-9 expression levels between primary and metastatic
OSCC (37).
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Besides MMP-2 and MMP-9, MMP-3 can also degrade collagen type IV. Thus, it is
important to analyze the expression of MMP-3 in OSCC. EGF stimulates the production
of MMP-3 coordinately with MMP-1 (2). Interestingly, the over expression of the EGF
receptor (EGFR) is a remarkable property of squamous cell carcinoma (2, 56, 70). It is
not clear, however, whether EGFR overexpression is implicated in the increased
production of MMP-3 by oral squamous carcinoma. The expression of the EGFR has a
significant correlation to the T-category of the primary tumor, pathological stage, and
neck metastasis (2). This explains why tumors with EGFR over expression have a poor
prognosis when compared to EGFR negative tumors (56, 133). On the other hand, there
is a significant correlation between the expression of MMP-3 and pathological stage,
mode of invasion and neck metastasis. EGF, platelet-derived growth factor (PDGF),
interleukin-1 (IL-1), oncogenes such as v-src and ras, can induce the production of
MMP-3. The more MMP-3 produced by oral carcinoma cells, the more diffusely and
aggressively the tumor invades to adjacent normal tissue, including lymphatic and blood
vessels (2).
E1AF is an ets-oncogene family transcription factor that is located on chromosome
17q21 and can upregulate the promoter activities of MMP-1, MMP-3 and MMP-9 in
highly invasive OSCC. Cells transfected with an antisense E1AF expression vector cause
down regulation of MMP-1, MMP-3, and MMP-9 and reduce the invasive ability of
cancer cells. Therefore, this gene is closely associated with invasion and metastasis of
cancer cells by activating MMP genes. It has been found that the incidence of E1AF
expression is more frequent in invasive tumors than in expanding tumors. Also, E1AF
mRNA can be detected in cancer cells invading into stromal connective tissue (8). Over
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expression of the integrin αvβ6 (a receptor for fibronectin, vitronectin, tenascin and TGFβ latency-associated peptide) is found consistently in OSCC (116, 117, 123) whereas, it is
not detectible in normal oral epithelium (113, 114, 115). The upregulation of integrin
αvβ6 promotes OSCC invasion, which is associated with upregulation of urokinase-type
plasminogen activator (uPA)/plasmin system, thus the proteases including MMP-9 and
MMP-3 (113, 114). However, integrin αvβ6 does not activate collagenases (MMP-1,
MMP-8 and MMP-13) but down regulates MMP-13 activation (112).
Extracellular matrix metalloproteinase inducer (EMMPRIN [CD147]) is a
transmembrane glycoprotein that belongs to the immunoglobulin superfamily and can
induce the production of MMPs and VEGF by both the stromal and tumor cells (13, 40,
134). It can also mediate a wide range of tumor-promoting molecular events that include
acquisition of anchorage-independent growth and invasive phenotype by tumor cells as
well as tumor-cell-induced angiogenesis (134). Bordador et al. showed that EMMPRIN is
highly expressed in OSCC and may help to regulate OSCC invasion, and modulate the
expression of MMP-2 (13). EMMPRIN is not only highly expressed in OSCC but also in
oral premalignant cells. Even though the level of EMMPRIN is high in oral premalignant
cells, they do not release it to the microenvironment as OSCC does. Primary and
metastatic OSCC show strong cell surface expression of EMMPRIN. Its overexpression
occurs at a very early stage of oral carcinogenesis and plays a contributing role in OSCC
tumorigenesis. Abnormal high levels of EMMPRIN expression by cancer cells have been
attributed to dysregulation of EGFR signaling (134). Generally fibroblasts produce low
level of MMPs, however, tumor associated fibroblasts do produce high levels of MMPs
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as they are stimulated or influenced by EMMPRIN (39). Chromosome 19p13.3 is the
location for the EMMPRIN gene with the size of 10.8 kb (40).
BHY and HN OSCC cell lines both express a large amount of matrix-degrading
enzymes, such as proMMP-1, proMMP-2, proMMP-9, MT1-MMP and uPA, which
converts plasminogen to plasmin (1). Induction of tissue-type plasminogen activator
(tPA) and uPA can mediate the activation of proMMP-2 and proMMP-9 in OSCC and
thus enhance invasiveness (3, 97). In addition, BHY cells can secrete proMMP-7, while
HN cells secrete active MMP-2 (1), which plays an important role in lymph node
metastasis of OSCC (3). Thus, MMPs play an important role in the invasion and
metastasis of oral cancer cells. The level of TIMP-1 mRNA in BHY cells and TIMP-2
mRNA in HN cells is low (1). Although both HN and BHY cells express MT1-MMP
mRNA, the level of MT1-MMP is much lower than that in HT1080 cells, which is a
human fibrosarcoma cell line (1).
Another OSCC cell line used in this study is HSC-3. In response to EGF, HSC-3
cells are able to degrade type I collagen matrix, suggesting that EGF can induce the
secretion and activation of the type I collagen proteolytic enzyme MMP-1 (10). Both
HSC-3 cells grown without EGF and with EGF can produce MMP-9, proMMP-2 and
MMP-2. In the absence of EGF, the MMP-2 and the MMP-9 secreted from HSC-3 are
not capable of degrading type I collagen. In HSC-3, EGF increases the secretion of
collagenase, MMP-1. Then, MMP-1 changes collagen I to gelatin. The gelatinases,
MMP-2 and MMP-9, complete the collagen I degradation by breaking down the gelatin
(10). HSC-3 does not produce MMP-1 constitutively but it is up regulated in response to
EGF and collagen I (10).
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2.3.2. The effect of cathepsins on invasion and metastasis of OSCC
Cathepsins are another group of proteolytic enzymes that are responsible for tumor
invasion and metastasis. There are 13 different cathepsins which are located in
lysosomes. Cathepsin B, H, and L are expressed in all tissues, while cathepsin S is
selectively expressed in antigen presenting cells. Cathepsins become mature enzymes
either by other proteinases or by autocatalysis. Cathepsin K is highly expressed in
osteoclasts and may play a major role in bone resorption. Also, there are low levels of
cathepsin L, S and B in osteoclasts. Catalytic activity of cathepsins is dependent on a pH
below 7.0. They are unstable at neutral and alkaline pH values. Cathepsins are associated
with cancer, inflammation, rheumatoid arthritis, osteoarthritis, multiple sclerosis,
muscular dystrophy, pancreatitis, liver disorders, lung disorders, diabetes, and myocardial
disorders. Cathepsin B cleaves pro-urokinase type plasminogen activator (pro-uPA) and
converts it to active form, which is uPA. uPA activates plasmin-plasminogen, which then
participates in cellular invasion processes including tumor invasion. Increased expression
of cathepsin B correlates with carcinoma progression. It has both endopeptidase and
exopeptidase activity and can degrade multiple components of ECM including laminin,
fibronectin, and type IV collagen. In normal cells cathepsin B is localized in lysosomes in
the perinuclear region. In carcinoma cells lysosomes containing cathepsin B are localized
both perinuclearly and at the cell periphery. Cathepsin L is a lysosomal cysteine
proteinase with a major role in intracellular protein catabolism. Cathepsin L has
endopeptidase activity and is involved in epidermal homoeostasis (24).
Cystatins are specific endogenous inhibitors of lysosomal cysteine proteinases,
namely cathepsins B, C, F, H, L, O and X. Vigneswaran et al. found that both cathepsin B
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and L do not show any significant differences in their expression levels between
metastatic and primary OSCC cell lines at mRNA and protein levels. However, they also
found that the cystatin M gene is elevated 40-fold in a metastatic OSCC cell line
compared to the primary OSCC cell line. Increase in cystatin M mRNA, results in a
decrease in the cathepsin B to cystatins ratio in the metastatic cell line relative to the
primary OSCC cell line. It is possible that cystatins, when over-expressed in tumor cells,
may facilitate metastasis by interfering with TNF-related apoptosis inducing ligand
(TRAIL). TRAIL is a type-II transmembrane protein that induces apoptotic cell death in
tumor cells but not in normal cells. Over expression of cystatins in oral cancer cells can
enhance their metastatic potential by rescuing them from NK-cell mediated apoptosis, an
event mediated by inhibiting the pro-apoptotic function of cathepsin B in these cells.
Cystatins may have bivalent effects in the progression of malignant tumors. On one hand,
reduced expression of cystatins, when combined with over expression of cysteine
proteases cathepsin B and/or L, can lead to deregulated proteolytic imbalance promoting
tumor growth and invasion. However, over expression of cystatins, combined with
normal expression levels of cathepsin B in tumor cells can augment their metastatic
potential by protecting them against TRAIL-mediated apoptosis (12).
Cathepsin L has a major role in the process of bone resorption by activating
osteoclasts (1). It is known that procathepsin L can be activated in acidic conditions.
Thus, procathepsin L secreted from BHY cells can be activated at the point of bone
invasion, and the activated cathepsin L might degrade the demineralized bone matrix (1).
BHY cells express a large amount of procathepsin L, whereas HN cells don’t express any
detectable level of cathepsin L (1).
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Kawasaki et al. found that cathepsin D and B expression are closely correlated with
OSCC invasion and progression. They could not find any relation between cathepsin L
expression and invasion of OSCC (4). Cathepsin B is active against large substrates such
as laminin and fibronectin under physiological conditions of pH and temperature. It can
degrade extracellular matrix components. Turk et al. showed that cathepsin B, H, and L
are involved in cancer progression by either direct degradation of extracellular matrix or
by activation of other proteases, such as uPA (45). A requirement for cathepsin D to be
active is a value of pH <5.5; however, cathepsin B can work at neutral pH. Thus,
cathepsin B mainly degrades the basement membrane (4).

2.4. Microarray Studies on OSCC
When oral mucosa is exposed to mutagens, OSCC may arise. This mainly happens
if metabolism of carcinogen or pro-carcinogen, repairing mechanism of DNA damage,
controlling mechanisms of cell signaling and cell cycling are defective (58, 70). Genetic
damage affects many chromosomes and genes, and in some cases it ends up activating
oncogenes and inactivating tumor suppressor genes (96). Cancer arises from damage to
the DNA of genes located at various points on the short (p) or long (q) arms of a number
of chromosomes. OSCC is a consequence of multiple molecular genetic events in many
chromosomes and genes (58). The consequence of this chromosomal damage is cell
dysregulation with disruption in cell signaling, the cell growth cycle, and mechanisms to
repair cell damage or eliminate dysfunctional cells (58, 70, 94, 133). After the formation
of such chromosomal changes, cell growth becomes autonomous, and invasive
mechanisms develop leading to malignant lesions (58, 133).
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Carcinogen residues bind to DNA or surrogate proteins and can cause carcinogen
exposure. The most important carcinogens are aromatic amines found in tobacco smoke
and cooked foods. Various enzymes known as xenobiotic-metabolising enzymes, are
involved in the activation or degradation of carcinogens and pro-carcinogens. The most
common of these enzymes are: alcohol dehydrogenase, cytochrome p450, glutathione-Stransferases, and N-acetyl transferase. Alcohol dehydrogenase catalyses the oxidative
metabolism of a range of chemicals and activates the pro-carcinogens (58). Alcohol
dehydrogenase type 3 genotypes appear predisposed to OSCC (59, 60, 61). Cytochrome
p450 can activate many environmental pro-carcinogens by exposing or adding functional
groups. Glutathione-S-transferase is involved in the detoxification of activated
metabolites of carcinogens (58). This enzyme is also present in oral tissue (62). N-acetyl
transferase deactivates carcinogenic aromatic amines through N-acetylation (58).
There is clear evidence of cellular DNA damage in patients with oral cancer.
Damage to DNA can be repaired by several mechanisms, the main of which include
nucleotide excision repair, base excision repair and O6-methylguanine DNA
methyltransferase. DNA repair capacity varies between individuals as a result of
inheritance, environmental factors, and physiological factors (58). In OSCC, several
chromosomes, including those involved in the repair of DNA damages, show changes
(63, 64, 65, 66, 67).
Cell signaling is important for messages to be able to pass from the plasma
membrane to the nucleus. Harvey ras gene (H-ras) and epidermal growth factor receptor
gene (erbB1) are two important genes involved in cell signaling, cell growth control and
cancer (58, 124). H-ras gene may activate MMP-9 and MMP-13, which are involved in
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angiogenesis of the tumor itself (135). It is reported that Rab-Ia, which is a member of the
Ras oncogene, is highly over expressed in squamous cell carcinoma of the tongue and
oral premalignant lesions (109). The H-ras gene is located on chromosome 17p and is
responsible for protein p21, which is an enzyme with guanosine triphosphatase activity.
p21 acts like a signal transduction protein, transmitting mitogenic signals from the cell
surface to the cell interior. erbB1 which maps to 7p13-q22, encodes a receptor involved
in cell signaling (58, 124). H-ras shows antitumorigenic response mediated by the upregulation of both p14ARF and p16INK4A, which activate the tumor suppressor genes, p53
and retinoblastoma (Rb). The p16INK4A tumor suppressor gene product acts as a negative
regulator of cellular proliferation by interacting with CDK4 and inhibits its kinase
activity (94, 118). Its inactivation is frequent (94, 106) and is one of the earliest events in
head and neck cancers (118). p15INK4B displays high homology to p16INK4A, acts as an
inhibitor of CDK4 and CDK6 and shows a tumor suppressor role. p15INK4B is
transcriptionally activated by transforming growth factor-β (TGF-β) (94) and is most
frequently inactivated in OSCC (106).
The cell cycle consists of a series of phases that take place during cell division. By
using a number of proteins, cell regulatory genes modulate the cell cycle in a highly
sophisticated way (68). During cell division, the transition from one phase to the next is
checked at a checkpoint before the cycle can progress. The cell cycle consists of a
stationary G0 phase, which upon receipt of appropriate cell signals, is followed by G1, S,
G2 phases, and mitosis. Checkpoint genes not only control transition between phases of
the cell cycle but also coordinate cell cycle progression with cell signals. When DNA is
damaged, there may be an arrest of the cell cycle which can facilitate DNA repair. G1
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arrest prevents replication of a damaged DNA template and G2 arrest allows segregation
of damaged chromosomes (58).
One of the main factors that regulates the cell cycle includes cyclins and their
kinases that are called cyclin dependent kinases (69, 94). Protein kinase complex consists
of a cyclin, CDK, and proliferating cell nuclear antigen (PCNA). Progression from the
G0 phase of the cell cycle through the G1 phase is mediated by two CDK complexes,
which are CDK4-cyclin D, and CDK2-cyclinE (69). These complexes are regulated by
phosphorylation/de-phosphorylation. Cyclin D1 takes place in controlling of cell cycle by
transiting the cells from G1 to S phases by regulating CDK-4 (119). Thus, cyclin and
CDK are the most important regulators of cell cycle progression (58, 68, 94). The
upregulation of cyclin D1 is commonly seen in OSCC, especially in patients with tobacco
chewing history. Its’ over expression is related to high cell proliferation activity, poor
survival and progression of lymph node spread in OSCC. In mammalian cell cycle
control, disorder takes place more commonly in G1 phase. Cyclin D1 expresses in G1
phase and accelerates the cell cycle progression. Human cyclin D1 maps to chromosome
11q13 (119). Another important pathway for cell proliferation is extracellular-signal
regulated kinases (ERK MAPKs) pathway, which is one of the mitogen-activated protein
kinases (MAPKs). The activation and over expression of ERK MAPKs play an important
role in cancer progression (129).
Retinoblastoma (Rb), p21, p27 and p53 are the other factors that regulate the cell
cycle (58, 68). Loss of the functional Rb gene is one of the initial genetic events in
malignant transformation (108, 118). Rb is a key component of the G1 checkpoint (58,
68, 94). p21 binds to and inhibits cyclin/CDK complexes (58) to effect arrest of the G1/S
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phase of the cell cycle (68). It is regulated by p53 in response to DNA damage (68, 94),
interacting with PCNA to block its DNA synthesis function (70). A major effect of p53 is
to block the cell cycle by stimulating the p21 gene (68). p27 also plays a role in G1 arrest
induced by TGF-β in normal cells. It regulates proliferation by binding and inhibiting the
G1 cyclin/CDK complexes. The product of the p53 gene is a main inhibitor of the cell
cycle. It acts as a transcription factor and controls cell cycle progression and thus cell
replication (58, 96). If a cell is damaged and repair is impossible, p53 triggers apoptosis
(68). Loss of heterozygosity and mutation at the p53 gene are frequent events in OSCC
(94, 105). Mutational inactivation of p53 has been reported to be the determinant of
resistance to anticancer agents or radiation treatment (105). p53 blocks the cell cycle by
switching on the GADD45 gene in cells when the cell is under stress. The GADD45
protein product binds PCNA and inhibits entry into the cell cycle S phase (58). Also,
p14ARF and p16INK4A play active roles in the p53 and Rb growth-control pathway (95).
In OSCC, changes in chromosomes 3, 9, 11 and 17 are common (70, 96). The main
targets of these changes are in chromosome 3, 3p24, 3p21.3, and 3p14, where the tumor
suppressor genes are located; in chromosome 9, 9p21 where p16 is located; in
chromosome 17, 17p13 where p53 is located. Over-expression of oncogenes, genes
mainly involved in cell signaling like the ones on chromosome 11 and 17, are common in
OSCC (70). In head and neck squamous cell carcinoma there are frequent structural
rearrangements of the following chromosomal regions: 3q, 5p13-q11.2, 5q32-q34, 7p12q11.2, 8p12-q12, 9p, 10p, 13p13-q12, 14q11.1-q11.2, 15p13-q11.2, 16p11.1-q11.1,
18q22-q23, and 22p13-q11.2. Loss of heterozygosity on regions of chromosomes 3, 4, 5,
6, 8, 9, 11, 13, 17, and 19 are common in head and neck squamous cell carcinoma (103,
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107, 122), especially on the long arms of the loci (107). Chromosome 3 aberrations can
be identified on both potentially malignant oral lesions (71, 72, 73) and OSCC (74, 75,
76, 77, 78, 79, 96). The short arm of this chromosome (3p) is often deleted in OSCC (80,
81). In 31% of OSCC cases there is an abnormality in the long arm of chromosome 4 (4q)
at 4q25 (82, 83, 96) and 4q31-32.1 (84). Chromosome 5 anomalies can be seen in 2573% of OSCC (77, 85, 86, 87, 107). There are changes at both 5q and 5p (88). These
changes may be early in carcinogenesis, preceding p53 mutations (89). In chromosome 6,
loss of heterozygosity can be found in 21-38% of OSCC on 6p (84, 90, 96) and 23-25%
on 6q (84, 90). Genotypic changes in chromosome 7 have been described in OSCC,
tissue adjacent to OSCC, and oral premalignant tissue. The EGFR, on 7p, is over
expressed in epithelium adjacent to and in OSCC (70). Chromosome 8p deletions and
loss of heterozygosity have been reported in 40 % of OSCC (70, 96). The most common
chromosomal defect in OSCC can be seen on chromosome 9, specifically the loss of
heterozygosity on 9p. Deletion of the long arms of chromosomes 10, 11 and 13 and
frequent loss of heterozygosity have been identified in OSCC on 10q, 11q and 13q in
50% of cases (70, 107). A small number of OSCC appear to lose heterozygosity on 12p
and 12q, and 16p and 16q. p53, which is located on chromosome 17, is a tumor
suppressor gene with one of the highest frequency of mutations in cancers (70). Almost
60 % of OSCC cases have p53 gene mutations (70, 92). In carcinomas, the mutations of
p53 are often the same in the primary tumor and lymph node metastasis and in
immediately adjacent epithelium as well as in recurrences (70). Loss of heterozygosity at
various genetic loci is a sign of losing tumor suppressor genes, as is microsatellite
instability causing nucleotide expansion or deletion (111). Loss of heterozygosity has
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been detected in OSCC mostly at 18p (91), 21q and with 73% at chromosome 22 (70).
Allelic imbalance, especially on chromosome arms 3p, 9p, 11q, 13q and 17p, is an early
event in oral carcinogenesis (70, 92, 111). In more advanced stages with invasion loss of
heterozygosity of 6p, 8p, 8q, and 4q is commonly seen (111). Allelic loss on several
chromosomes, together with the sequence loss of several tumor suppressor genes is
consistent with the hypothesis that oral carcinogenesis involves multiple molecular steps
(70, 92). Allelic imbalance can be detected in the plasma/serum DNA of OSCC,
suggesting that circulating tumor-associated DNA in the blood of patients with OSCC
can be a key determinant in predicting tumor recurrences or metastasis (106).
Only 10% of the genes encoded by the human genome are expressed in any given
cell type. A small subset of these genes, with a role in normal housekeeping functions,
are expressed in abundance, the vast majority are present in a very low copy number.
This makes the task of detecting tissue specific genes much more difficult. It is essential
to understand which genes are responsible for normal cell physiology and which ones are
responsible for the disease process. In this regard identification of genes that are
expressed in normal, precancerous, and cancer cells may help us discover the molecules
that are related with tumor development, invasion and metastasis. Leethanakul et al.
found that at least 168 novel genes are responsible for formation, metastasis, and invasion
of OSCC. The most common and highly expressed genes in both normal oral squamous
epithelium and OSCC are shown in table 2 and 3 (93).
A cluster of genes located at 1q21 region (involucrin, SPRR 1A, 1B, 2B, 3, NICE1, S100 A1, 6, 8, 9, 14) are responsible for epidermal differentiation and are
downregulated in OSCC compared to normal oral mucosa. Downregulation of these
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genes is consistent with dedifferentiation of squamous epithelial cells, which is associated
with malignant transformation. Another cluster of genes (tenascin X, dermatopontin, and
collagen 14) downregulated in OSCC includes several extracellular matrix proteins
regulating epithelial adhesion and collagen fibril formation. Genes that are upregulated in
OSCC are associated with extracellular matrix function, interferon response,
proliferation, and immune response. Also, genes implicated in invasion (snail homologue
2, met proto-oncogene), RAS signaling, (r-ras homologue 2), cell surface/extracellular
matrix interaction (collagen type IV α5 and α6, laminin γ2, α3, β3, integrin α3, α6, β4, β6),
and angiogenesis (VEGF C, placental growth factor) are highly expressed in OSCC (98,
128).
Irie et al. found that there are 86 genes that are upregulated and 67 genes
downregulated in metastasis negative cases. However, in metastasis positive cases 183
genes are upregulated and 96 genes are downregulated. The prognosis of the patient is
directly related to the expression level of the VEGF gene. When the expression level of
this gene is elevated, the prognosis of the patient is worse. In metastatic cases the
expression of neutrophil gelatinase-associated lipocalin (NGAL) is high. NGAL
modulates MMP-9 activity, which is important during the formation of metastasis in
OSCC (99).
In oropharyngeal squamous cell carcinoma, calgranulin B (CAGB), CD24,
lymphoepithelial kazal-type-related inhibitor (LEKTI), zinc finger protein (ZNF-185),
transglutaminase-3 (TGM3), ETS homololous factor (EHF) and headpin are
downregulated. In contrast, periostin and human homologue of the Drosophila white gene
(ABCG1) are found to be upregulated by microarray analysis (100). LEKTI and headpin
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are known to be proteinase inhibitors and periostin and CD24 have been involved in cell
adhesion. It is known that proteinases and cell adhesion molecules play important roles in
the biological processes of cancer including cell adhesion and metastasis. TGM3 is
involved in stabilizing the cell cornified envelope. This process causes the transition of
keratinocytes to become corneocytes by apoptosis. Therefore the downregulation of
TGM3 could interrupt a critical step to apoptosis, thereby tumor cell survival. ABCG1
belongs to the family of adenosine triphoshate-binding cassette transporters. Upregulation
of this gene can cause the resistance to chemotherapy. The function of ZNF-185 is
unknown, however, it may play a role in regulating cellular proliferation and
differentiation (100). TNFRSF5, which encodes CD40, is involved in proapoptosis
signals in cancer cells when they are treated with chemotherapeutic drugs (132).
Decorin is associated with negative regulation of cell growth. It has a prominent
role in TGF-β and EGFR activation pathways. These pathways are important in cellular
proliferation, angiogenesis, and immunomodulation. The expression level of this gene is
extremely high in dysplastic oral epithelial cells and oral cancer cells (101). The
GALNT6 and SMARCC2 genes, mapping to 12q13.13 and 12q13-q14, respectively, are
upregulated with poor prognosis and metastasis in lung, and head and neck cancer
patients. Upregulation of PRKAR2A and CLDN1 genes, which are located on
chromosome 3 regions: 3p21.3 and 3q28-q29 respectively, is commonly seen in head and
neck cancers. Gain of 3q is one of the earliest genetic markers for invasion and metastasis
and correlates with a poor prognosis (102, 122).
Shimada et al. compared 4 tongue SCC patient tissues with normal tissues by using
cDNA microarray technique. This comparison showed that 16 genes are highly
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upregulated in all cases (Table 4) (109). Genes differentially regulated in metastases have
been identified and the expression of 17 genes that is common to both primary tumors
and metastasis have been found. Therefore primary tumors may carry expression patterns
for the presence of lymph node metastasis or the potential for metastasis (110).
In OSCC the genes that are most commonly found with altered expression are those
that encode cytoskeletal and extracellular matrix protein, inflammatory mediators,
proteins involved in epidermal differentiation, and cell adhesion molecules. The
downregulation of genes that encode ribosomal proteins, and upregulation of genes that
encode MMPs and inflammatory response can be seen in almost every OSCC (111). In a
study on 9 OSCC patients using microarray technique, 47 genes have altered expression
with 28 being upregulated and 19 downregulated. The list of these genes is in table 5
(136).
Choi et al. reviewed more than 20 current articles that incorporated cDNA
microarray analysis in the study of head and neck SCC. They identified 84 genes with
common alterations; 32 of them are upregulated (Table 6), 33 of them are downregulated
(Table 7) and 19 of them have conflicting expression data (Table 8) (111). Several major
biological systems or pathways are altered in head and neck SCC. These include cell
cycle control, MMP, and inflammatory response systems. Genes encoding for ECM and
integral membrane proteins, proteins involved in epidermal development and
differentiation, and cell adhesion molecules most frequently have altered expression in
head and neck SCC (Table 9) (111).
There is a significant difference in macrophage content between normal epithelium
and OSCC tissue. There is also a marked difference in the macrophage content of
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primary OSCC tissue between patients with positive lymph nodes and patients with
negative lymph nodes. Despite correlations with lymph node metastasis of OSCC, the
macrophage count does not correlate directly with survival or recurrence (120).
Chen et al. found that the highest frequency of gene gain is for TP63, Serpine1,
FGF4/FGF3, c-Myc, and DMD whereas the highest deletion is for Caspase8 and MTAP.
The gained genes are mainly located on 17q21, 20q, 11q13, 3q27-29 and X
chromosomes. Among these, gains of EGFR at 7p; FGF4/FGF3, CCND1 and EMS1 at
11q13; and AIB1 at 20q are significantly associated with lymph node metastasis (121).
The expression level of ECM glycoproteins tenascin and osteopontin increases
during tumor progression. Tumor derived osteopontin is able to inhibit macrophage
function and enhance survival of OSCC metastasis. Also, the expression level of
arachidonate 5-lipoxygenase increases during OSCC progression and metastasis.
However, 4 potential tumor suppressor genes, which are BRUSH-1, MXI1, oxidative
stress response (OSR1) gene, and occluding, expression levels decrease (122). There is a
great frequency of minichromosome maintenance protein 2 (MCM-2), which is essential
for DNA replication, expression in surface layers of moderate/severe dysplasia and
OSCC compared to benign keratosis/mild dysplasia. Thus, MCM-2 can be a marker for
early detection of OSCC and dysplasia (130).
By using proteomic analysis Turhani et al. found that there were 14 proteins with
increased expression and 6 proteins with decreased expression in OSCC (Table 10).
These proteins have various functions. They are involved in cellular transport, like
HSP27 and heat shock 20 kDa like protein p20; in regulatory functions, like creatine
kinase, pyruvate kinase M1, and NME1; and glycolic pathway, like phosphoglucerate
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mutase 1. Also, some of the proteins are highly tissue specific, like galectin-7, which is
involved in cell-cell and cell-matrix adhesion (131).
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CHAPTER 3
MATERIAL AND METHODS
3.1. Cell Lines and Cultures
3.1.1. HNEC cell line
The cryopreserved HNEC cell line was obtained from PromoCell, Germany. This
cell line was isolated from a 27-year-old Caucasian male. Five ml of Airway Epithelial
Cell Growth Medium (PromoCell) with 100μg/ml streptomycin and 100 U/ml penicillin
was incubated in a 25 cm2 coring cell culture flask with a vent cap (Fisher) in a
humidified atmosphere of 95% air and 5% CO2 at 37°C for 30 minutes. The frozen cells
were thawed in a 37°C water bath until about 90% of the contents were thawed. The tube
was removed from the water bath and agitated until all the contents were completely
thawed. 250,000 to 375,000 suspended cells were distributed in the pre-incubated 5ml
medium in a 25cm2 cell culture flask and incubated for 5 to 6 days in a humidified
atmosphere of 95% air and 5% CO2 at 37°C. After the first 24 hours, 80% of the cells
were adhered to the surface of the flask, and the medium was replaced with the fresh 30
minute pre-incubated airway epithelial cell growth medium with 100μg/ml streptomycin
and 100 U/ml penicillin. Replacement of medium was then repeated every 2 to 3 days.
After 5 to 6 days the cell culture was examined under an inverted microscope. If the
monolayer was sub-confluent (60-80%) and many mitotic figures were visible, cells were
sub-cultured. During sub-culturing HepesBSS, trypsin and trypsin neutralizing solution
(TNS) at room temperature were used. First, the medium was replaced with 5 ml
HepesBSS and cells were washed for 30 seconds by gently swirling the culture flask.
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Then, the HepesBSS was removed and the cell monolayer was covered with 2.5ml
trypsin/EDTA solution and incubated at room temperature untill the cells were released
form the floor of flask. When the cells were completely detached, 2.5ml TNS was added.
The cell suspension was removed, placed into a centrifuge tube and centrifuged at about
220xg for 4 minutes at room temperature. Supernatant was removed and 1.5ml preincubated medium was added and re-suspended. Cell suspension was distributed in the
usual way and in the required density as stated above into the new flasks with preincubated cultures. The medium replacement and incubation were scheduled as
mentioned previously.
3.1.2. BHY cell lines
The cryopreserved BHY cell line was obtained from DSMZ, Germany. This cell
line was isolated from a 52-year-old Japanese male with highly differentiated squamous
cell carcinoma of the lower alveolus that was highly invasive to the mandibular bone and
the muscle layer of the oral floor; however, it did not metastasize (1). Frozen cells were
thawed in a 37°C water bath. Approximately 1x106 cells were cultivated in 75cm2 coring
cell culture flask with a vent cap in a humidified atmosphere of 95% air and 5% CO2 at
37°C for 3 to 5 days. Fifteen ml Dulbecco’s Modified Eagle’s Medium (DMEM) with
10% fetal bovine serum, 100 μg/ml streptomycin and 100 U/ml penicillin was used as the
medium. Following the formation of a monolayer at the bottom of the flask, cells were
sub-cultured. Trypsinization was performed as follows: Media was poured off of the flask
into a 15ml centrifuge tube. Three ml of trypsin/EDTA was placed in the flask and
swirled and poured into a centrifuge tube. Five ml fresh trypsin/EDTA was placed into
the flask and the flask was incubated in humidified atmosphere of 95% air and 5% CO2 at
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37°C for 3 minutes. The warmth of the incubator enhanced the action of trypsin. At the
end of three minutes the flask was removed from the incubator and gently agitated to aid
in the dispersal of the cells. 6-8ml of medium from the centrifuge tube was placed back
into the flask. The serum in the media stopped the reaction of trypsin. Then the media
containing the cells was transferred back into the 15ml centrifuge tube and centrifuged at
1200 rpm for 4 minutes. Supernatant was removed and 5ml medium was added and resuspended. The cell suspension was distributed in the usual way and in the required
density into the new 75cm2 flasks with 15 ml medium.
3.1.3. HN cell line
The cryopreserved HN cell line was obtained from DSMZ, Germany. The HN cell
line was isolated from a 60-year-old Japanese male with moderately differentiated
squamous cell carcinoma of the soft palate that metastasized to cervical lymph nodes,
lungs and brain, but did not invade bone (1). The same media, number of cells,
incubation conditions, cell culturing and trypsinization method was used as stated in the
BHY cell line. However, the incubation period for this cell line was 5 days.
3.1.4. HSC-3 cell line
The cryopreserved HSC-3 cell line was obtained from Japan Health Science
Research Resources Bank (HSRRB) The HSC-3 cell line was isolated from a 64-year-old
Japanese male. The primary tumor was on the tongue with lymph node metastasis, and
was moderately differentiated. This cell line is highly metastatic (10, 23, 52).
Approximately 1x106 cells were cultivated in a 25cm2 coring cell culture flask with a
vent cap. Cells were cultivated in 5ml Eagle’s Minimal Essential Medium (EMEM) with
10% calf serum, 100μg/ml streptomycin and 100 U/ml penicillin in a humidified
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atmosphere of 95% air and 5% CO2 at 37°C for 7 days. The same cell culturing and
trypsinization method was used as stated in the BHY cell line. However, for the first
trypsinization instead of 3ml, 1.5ml was used and for the second trypsinization instead of
5ml, 2.5ml trypsin was used.

3.2. The Invasion and/or Metastatic Characteristics of OSCC Cell Lines
All three OSCC cell lines have different invasion and/or metastatic characteristics
(Figure 2). Micro positron emission tomography (PET)/computerized tomography (CT)
imaging techniques were used to image the invasion and/or metastatic capability of each
of the cell lines in scid mice. The advantage of micro-imaging technology is the ability to
monitor tumor growth in vivo. Immuno-compromised scid mice were used to show the
differences in jaw bone invasion and distant organ metastasis of these three different
OSCC cell lines in a biological system. 5 study groups each with 3 scid mice were
involved in the study. These 5 groups were: BHY group, HN group, HSC-3 group,
human normal nasal epithelial cell line (HNEC) group, and Matrigel only group. The
OSCC cell lines and HNEC cell line were induced in the left masseter muscles of the scid
mice by injecting a suspension of 1x107 cells in Matrigel with a 26G needle. Control
mice received matrigel only in their left masseter muscles. The HNEC group served as a
non-OSCC control group, and the Matrigel only group was included in the study to show
that this gel does not have any effect on the formation of OSCC. Tumors were allowed to
grow for 30 days. On day 30, mice were anesthetized and the tumor characteristics were
evaluated using microPET/CT imaging. Mice were administered 300 μCi of [18F] fluoroD-glucose (18FDG) i.p. and 30 minutes thereafter received an i.v. injection of vascular
CT-contrast agent. The animals were euthanized using an overdose of isoflurane
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inhalation and imaged by micro PET and microCT. MicroPET images were acquired
using a P4 or Focus 220 imaging system, followed by a microCT scan using a MicroCAT
II imager. To reduce the experimental stress and discomfort associated with tumor
formation on the left cheek of the mice, they were put on a soft food diet (ground lab
blocks mixed with water). The clinical conditions of animals were monitored 3 times
each day and the tumors were never allowed to develop more than 0.5 cm in diameter.
Their eating and drinking habits and activity levels were observed 3 times daily. Mice
that developed infection at the injection site, did not eat for 1-2 days, or had tumor
growth greater than 0.5 cm in diameter were excluded from the study.

3.3. Immunocytochemistry
After removal of the monolayer of cells by trypsinization, samples from each cell
line were transferred to microscopic slides by cytospining for 5 minutes at 500 r.p.m.
Slides were fixed in acetone for 10 minutes and then air dried. Cells were rinsed in
10mM phosphate-buffered saline (PBS) for 2 minutes for 3 times. Endogenous
peroxidase activity was blocked with 3% hydrogen peroxide and then cells were washed
with PBS for 2 minutes 3 times. Samples were incubated in 5% non-immune goat serum
for 10 minutes to block non-specific proteins. All samples were washed with PBS
solution for 2 minutes 3 times prior to incubation with the primary antibodies. For each
primary antibody, one sample from each cell line was incubated with that primary
antibody and rinsed in PBS for 5 minutes 3 times. All samples were then incubated with a
proper secondary antibody and rinsed in PBS for 5 minutes 3 times. Finally a
strepABComplex (Vector) was applied and samples were stained with diaminobenzidine
for 10-12 minutes and rinsed with distillated water (Vector). So as to obtain acceptable
50

contrast and stain, the nucleus of cells slides were placed in gill hematoxylin for one
minute. For each cell line a negative control sample was prepared which received all of
the steps in the immunostaining process except for application of primary antibody.
The following primary and secondary antibodies were used:
1) For MMP-1; rabbit anti-human MMP-1 polyclonal primary antibody 1:10
(Chemicon International) and anti-rabbit Ig G secondary antibody ABC Kit (Vector)
2) For MMP-2; rabbit anti-human MMP-2 polyclonal primary antibody 1:10
(Chemicon International) and anti-rabbit Ig G secondary antibody ABC Kit (Vector).
3) For MMP-3; rabbit anti-human MMP-3 polyclonal primary antibody 1:10
(Chemicon International) and anti-rabbit Ig G secondary antibody ABC Kit (Vector).
4) For MMP-9; goat anti-human MMP-9 polyclonal primary antibody 1:25 (R&D
Systems) and anti-goat Ig G secondary antibody ABC Kit (Vector).
5) For cathepsin L; goat anti-human cathepsin L polyclonal primary antibody 1:15
(R&D Systems) and anti-goat Ig G secondary antibody ABC Kit (Vector).
6) For cathepsin B; rabbit anti-human cathepsin B polyclonal primary antibody
1:15 (Serotec) and anti-rabbit Ig G secondary antibody ABC Kit (Vector).
7) For EMMPRIN; mouse anti-human EMMPRIN monoclonal primary antibody
1:20 (Chemicon International) and anti-mouse Ig G secondary antibody ABC Kit
(Vector).
Slides were evaluated microscopically (Leica Leitz DM 12B) and using the SPOT
advanced imaging program. The original magnifications were 100x and 200x.
Immunostaining was scored according to the staining of HNEC cell line. All proteolytic
enzyme expressions of HNEC were considered normal levels of expression, and OSCC
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cell lines proteolytic enzyme expressions were measured accordingly. The same intensity
in tumor cells as normal epithelium cells was designated by (-), less than 10% stronger
intensity in tumor cells than normal epithelium cells was shown by (+), between 10% to
50% stronger intensity in tumor cells than normal epithelium cells was shown by (++),
between 50% to 90% stronger intensity in tumor cells than normal epithelium cells was
shown by (+++) and more than 90% stronger intensity in tumor cells than normal
epithelium cells was shown by (++++).

3.4. Flow Cytometry
Monolayer cells were removed from the flasks by trypsinization. Five groups, each
with 1x105 cells in 0.1 ml of medium, from each cell line were incubated with the 10μl
MMP-1, MMP-2, MMP-3, MMP-9 and EMMPRIN flow antibodies for 20 minutes at
room temperature in the dark for surface staining. The following flow antibodies were
used:
1) For MMP-1; mouse anti-human MMP-1 phycoerythrin conjugated monoclonal
antibody, R&D Systems.
2) For MMP-2; mouse anti-human MMP-2 phycoerythrin conjugated monoclonal
antibody, R&D Systems.
3) For MMP-3; mouse anti-human MMP-3 phycoerythrin conjugated monoclonal
antibody, R&D Systems.
4) For MMP-9; mouse anti-human MMP-9 fluorescein conjugated monoclonal
antibody, R&D Systems.
5) For EMMPRIN; mouse anti-human EMMPRIN phycoerythrin conjugated
monoclonal antibody, Chemicon International.
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All samples were washed with 2ml PBS, centrifuged at 1200 rpm for 4 minutes and
the supernatant was removed. Samples of each cell line that were incubated with MMP-1,
MMP-2, MMP-3 and EMMPRIN antibodies were also incubated with 50μl of
pholloidin/fix and perm solution (15μl pholloidin into 0.5 ml fix and perm solution);
however, samples of each cell line that were incubated with MMP-9 were only incubated
with fix and perm solution for 20 minutes at room temperature in the dark. All samples
were washed with a 2ml permeabilization/wash buffer. Samples were incubated with
10μl of each antibody for 30 minutes at room temperature. Finally, samples were washed
with buffer, centrifuged for 4 minutes at 1200 rpm and supernatants were removed. 0.5
ml formalin (1% formaldehyde) was added and each sample was analyzed by flow
cytometry. A sample from each cell line was prepared and treated only with buffer and
1% formaldehyde as a control group. From each sample 5000 cells were counted by flow
cytometry.

3.5. Ultrastructural Characterization of Three OSCC Cell Lines
Each of the 3 cell lines was grown to confluence in culture flasks. The culture
medium was decanted and the cells were immediately overlaid with 2.5% glutaraldehyde
in cacodylate buffer, pH 7.2. The cells were fixed overnight at 40C, and post fixed in 2%
acqueous osmium tetroxide for 2 hrs. Cells were dehydrated in a graded acetone series
and propylene oxide and embedded with Spurr’s plastic. The embedded cells were cut
out of the flasks with a jeweler’s saw, mounted on plastic studs, and cut for transmission
electron microscopy (TEM) analysis. Cells were stained with uranyl acetate and lead
citrate and examined with a Hitachi H-800 TEM.
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3.6. Total RNA Extraction From The Cell Lines
Total RNA extraction was performed using a RNeasy Midi Kit (Qiagen). Each of
the 4 cell lines was grown in proper culture flasks and media. From each cell line
approximately 1x108 cells were used for total RNA extraction. Cells were trypsinized as
mentioned previously. Cells were pelleted by centrifugation at 300xg for 5 minutes.
Supernatant was aspirated and cells were disrupted by addition of 4ml buffer RLT with
40µl β-ME. The cell pellets were loosened by flicking the tube. Cells were homogenized
by vortexing the samples for 10 seconds, and passing the lysates at least 5-10 times
through 18-20-gauge needle. 4ml 70% ethanol was added to homogenized lysates and
mixed thoroughly by shaking vigorously. Samples were applied to midi columns placed
in 15ml centrifuge tubes and centrifuged for 5 minutes at 3000-5000xg. The flows that
passed through the column were discarded. After centrifugation, 4ml buffer RW1 was
added to the columns and centrifuged for 5 minutes at 3000-5000xg to wash the columns.
Columns were further washed twice by adding 2.5ml buffer RPE and centrifuging for 2
minutes at 3000-5000xg. The RNeasy columns were removed from the centrifuge tubes
and transferred to new 15ml centrifuge tubes. Finally, 250µl of RNase-free water were
directly applied onto the columns and let stand for 1 minute. Tubes were then centrifuged
for 3 minutes at 3000-5000xg in order to obtain the total RNA from the columns. This
final process was performed twice to be able to get a higher amount of total RNA. Total
RNAs were stored at -80˚C in RNA Storage Solution (Ambion) together with SUPERase
RNase Inhibitor (Ambion) with a concentration of 1:40.
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3.7. Checking The Quality and Quantity of Total RNA.
After the extraction of total RNA, 3µl total RNA from each cell line was diluted
with distilled water. The dilution factor was 1:100. The diluted sample was used to
measure the quantity of RNA with a spectrophotometer at 230nm-300nm. The following
formula was used to find the quantity of total RNA:
Dilution factor * Optimal Density at A260 * 40µg/ml.
Aldolase and β-actin genes, which are housekeeping genes, and SuperScript III
First-Strand Synthesis System for RT-PCR Kit (Invitrogen) was used to check the quality
of total RNA of each cell line.
3.7.1. Synthesis of cDNA from total RNA
For each cell line, 1µl of oligo(dT)20 (50µM), 5µg total RNA, 1µl 10mM dNTP mix
(10mM each dATP, dGTP, dCTP, dTTP at neutral pH), 1µl of random decomer and
sterile distilled water to 13µl were added to a nuclease-free microcentrifuge tube. This
mixture was heated to 65˚C for 5 minutes and incubated on ice for at least 1 minute. The
contents of the tube were collected by centrifugation and 4µl 5X First-Strand buffer, 1µl
0.1M DTT, 1µl RNaseOUT Recombinant RNase Inhibitor (Invitrogen), and 1µl of
SuperScript III RT (200 units/µl) was added. By pipetting gently up and down the
contents were mixed and incubated at 25˚C for 5 minutes. Then, a further incubation at
50˚C for 90 minutes was done. The reaction was inactivated by heating the mixture at
70˚C for 15 minutes. The synthesized cDNA was used as a template for amplification in
PCR.
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3.7.2. PCR reaction
50µl of PCR reaction for each cell line was prepared as follows: 5µl 10X PCR
buffer [200mM Tris-HCl (pH 8.4), 500 mM KCl], 1.5µl 50mM MgCl2, 1µl 10mM dNTP
mix, 1µl amplification primer 1, 1µl amplification primer 2, 0.4µl Taq DNA polymerase
(5U/µl), 2µl cDNA, and 38.1 autoclaved distilled water were added in a PCR reaction
tube and mixed gently. Denaturation of cDNA was done at 94˚C for 2 minutes.
Annealing temperature was 88˚C for aldolase gene reaction and 62˚C for β-actin gene for
30 seconds. 30 cycles of PCR reaction was performed. The PCR product of each cell line
was run on a gel in order to observe the expression of aldolase and β-actin genes.
The primers of the aldolase gene are 5'-GGAATTCCATATGCCCTACCAATAT
CCAGC-3', and 5'-GGAATTCGGATCCTTAATAGGCGTGGTTAG-3. The primers of
the β-actin gene are 5’-TCCTGGCCTCACTGTCCAC-3’, and 5’-GTCCGCCTAGAA
GCACTT-3’.

3.8. Synthesis of mRNA From Total RNA
PolyATtract® mRNA Isolation Systems (Promega) was used to extract the mRNA
from the total RNA. This procedure is designed for use with 1-1.5mg of total RNA. In a
sterile, RNase-free 3ml tube, 1-1.5mg of total RNA and RNase-Free Water to a final
volume of 2.43ml were combined. The tube was placed in a 65°C heating block for 10
minutes. 10µl of the Biotinylated-Oligo(dT) Probe and 60µl of 20X SSC solution were
added to the total RNA and mixed gently and incubated at room temperature until
completely cooled. This is the annealing reaction.
Stock solutions of 0.5X SCC (0.125ml of 20X SSC with 4.875ml of RNase-Free
Water) and 0.1X SSC (50µl of 20X SSC with 9.95ml of RNase-Free Water) were
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prepared. Streptavidin-paramagnetic particles, which come with the kit, were rinsed 3
times with an equal volume of 0.5X SSC. Streptavidin-paramagnetic particles were
resuspended by flicking the bottom of the tube until they were completely dispersed and
captured by placing the tube in a magnetic stand for 30 seconds. Washed streptavidinparamagnetic particles were resuspended in 0.5ml of 0.5X SSC.
The entire contents of the annealing reaction were added to the tube containing the
washed streptavidin-paramagnetic particles. This mixture was incubated at room
temperature for 10 minutes and gently mixed by inverting every 1-2 minute. Streptavidinparamagnetic particles were captured using a magnetic stand and the supernatant was
carefully removed without disturbing the streptavidin-paramagnetic pellet. The particles
were washed four times with 0.1X SSC by gently flicking the bottom of the tube. After
the final wash the supernatant was removed as much as possible without disturbing the
streptavidin-paramagnetic particles. To be able to elute mRNA, the final streptavidinparamagnetic pellet was resuspended in 1.0ml of the RNase-Free water. Streptavidinparamagnetic particles were magnetically captured and eluted mRNA was transferred to
2ml tube. After synthesis of mRNA from each cell line, cDNA Synthesis System
(Promega) was used to synthesize cDNA from mRNA.

3.9. cDNA Microarray Analysis
Each tumor cell line was compared with the HNEC cell line by using the cDNA
microarray technique. Operon Human Version 3.0 microarray slides, which contains
25.000 human genes, were used for this study (Figure 3). cDNA Synthesis System
(Promega) was used to synthesize cDNA from mRNA. From each cell line, 5 µg of
cDNA was labeled and processed to hybridization. To be able to eliminate the Cy dye
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bias reverse labeling was performed. Basically, for each tumor cell vs. HNEC cell, the
cancer cells were first labeled as Cy5 dye and HNEC as Cy3 dye, and then the HNEC cell
line as Cy3 dye and the tumor cell lines as Cy5 dye. Two microarray hybridizations were
performed in parallel for each group. Reverse labeling has been proved to be important in
improving data correlation between the samples and data quality as shown by statistical
analysis. Labeled tumor cell lines and HNEC cell line cDNAs were hybridized on
microarray slides by using the hybridization buffer. All slides were washed by using the
washing buffer and scanned in a GenePix 4000 scanner (Axon Instrument). The images
were saved for further data analysis.
Typically, microarray data analysis includes image processing, data normalization,
statistical analysis, data cluster and visualization, and data management. The microarray
image was processed using the GenePix Pro software. The spots with fifty percent of
pixels higher than two times background standard deviation were filtered to be positive
and subjected to further analysis. Both bulk normalization and Lowess normalization
were applied to analyze our data. With bulk normalization, we averaged all the filtered
spot for each channel, and used the ratio to normalize the signal ratio at each spot. Bulk
normalization is enough for most of the applications; however, we also considered using
Lowess normalization, in which intensity dependent dye bias can be removed.
Self-organizing maps and hierarchy clustering were performed to further understand
gene function and interaction. We clustered the data by gene, which gives expression
patterns among the different OSCC cell lines and helps to understand the gene interaction
as well as shared pathways. We also clustered the data by OSCC cell lines, which
provides the information about how each cell line is relevant to one another at the global
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gene expression level. Based on the expression levels of the genes in microarray analysis,
different pathways were analyzed on each OSCC cell lines by using Kyoto Encyclopedia
of Gene and Genomes (KEGG).
In order to narrow down specific genes, we used the ANOVA model to obtain the
estimates and confidence intervals for all genes in each experiment set. For the genes of
interest, the confidence intervals will help us to decide whether to choose this gene for
further study or not. All of the above data analysis can be done in Bioconductor.
Microarray data was confirmed by real-time PCR. We designed gene specific
primers for genes of interest and performed the SYBR based RT-PCR to confirm the
relative abundance of gene expression as observed in the microarray analysis. Ubiquitin
was used as internal control. Standard curve analysis and an internal control were applied
to obtain the absolute quantification.

3.10. Real Time PCR Analysis
The results of cDNA microarray analysis were confirmed to the most highly
expressed three genes from each cell line by using Real Time PCR analysis. The
expression level of MAGEA9, Q96AL8, and GFI1 genes in BHY cell line; NMES1,
MAGEA1 and Q96AL8 genes in HN cell line; and MAGEA8, MAGEA1 and EREG
genes in HSC-3 were compared with the expression levels of these genes in HNEC cell
line. Glucose-6-phosphate gene was used as the control gene.
The same total RNA samples, which were extracted from the cell lines for cDNA
microarray analysis, were used for Real Time PCR analysis. Before the synthesis of
cDNA from total RNA, the qualities of total RNA samples were examined by running the
samples in the gel (Figure 4a). Synthesis of cDNA from total RNA was performed and
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the quality and quantity of cDNA was checked by running the samples in the gel with
their glucose-6-phosphate gene expression levels (Figure 4b).
The total Real Time PCR reaction was 25µl, which contained 5µl of cDNA and
20µl of the mixture. The Real Time PCR mixture was prepared as follows: 8µl primer
mixture, 80µl IQSM (IQ Supermix, BioRad) and 72µl water. Human GFI1, MAGEA8,
MAGEA1, MAGEA9, EREG, and NMES1 Real Time PCR primer sets (Superarray)
were used. The forward and reverse primer of Q96AL8 gene was set up by using Blast
Sequencing Computer Program. BioRad Real Time PCR machine iQ5 was used to run
the 95°C, 15 minutes; 40 cycles of (95°C, 30 sec; 55°C, 30 sec; and 72°C, 30 sec)
reaction. iQ5 RT-PCR data analyzing computer program was used to analyze the results.
The forward and reverse primer sequences used for the Real Time PCR reactions
were as follows:
MAGEA1 forward primer sequence: 5’GGCCATTCTTCACTCTGAAGA3’.
Reverse primer sequence: 5’TTGAACAATTCCAAAAGAGAACAAAG3’.
MAGEA8 forward primer sequence: 5’GTTCCTGTTCTATTGGGCGATTT3’.
Reverse primer sequence: 5’CCATTAGAAGGAACATTGGAACAA3’.
MAGEA9 forward primer sequence: 5’GGCATGTCCTTCTGTTCCAT3’. Reverse
primer sequence: 5’GGAGCTTGGCTCTTCCTCTT3’.
Q96AL8 forward primer sequence: 5’CAACAGTGTGTTTCGTCAAAAGG3’.
Reverse primer sequence: 5’CCACATGGCAGCCAGGAT3’.
EREG forward primer sequence: 5’CAGGCAGTTATCAGCACAAC3’. Reverse
primer sequence: 5’CACAGGATTCCATACCCAAG3’.
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NMES1 forward primer sequence: 5’GGTTCAAATGTATTTTTCTCCCAT3’.
Reverse primer sequence: 5’TTTGGGCTCTGGATAAGGAAT3’.
GFI1 forward primer sequence: 5’TTCTCTCGCTGCGGAGTCT3’. Reverse
primer sequence: 5’AGGCACTAGAAATGACTTGA3’.
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CHAPTER 4
RESULTS
4.1. The Invasion and/or Metastasis Characteristics of OSCC Cell Lines
PET/ CT imaging techniques were used to image the invasion and/or metastatic
capacities of each OSCC cell line in immuno-compromised scid mice. The 5 study
groups included, BHY, HN, HSC-3, HNEC, and Matrigel only groups, with 3 scid mice
each in the study. The HNEC group served as a non-OSCC control group, and the
Matrigel only group was included in the study to show that this gel does not have any
effect on formation of OSCC.
The PET/CT images of HNEC and Matrigel only groups showed no evidence of
tumor formation in any of the mice in these groups (Figures 5, 6, and 7). The PET images
of these two groups showed no activity at the injection area due to the Matrigel or HNEC
presence (Figures 5 and 6). Thus, these two different groups of animals served as reliable
control groups.
All three mice of the BHY cell line group showed invasion of the OSCC to the left
mandibular bone in the images (Figures 8 and 9). However, only two mice of the HN
group showed lymph node and distant organ metastasis, such as lung and kidney (Figures
10 and 11). The other mouse in HN group had cervical lymph node metastasis of the
OSCC. The HSC-3 cell line group represented lymph node metastasis in all three mice in
the group (Figures 12 and 13). The results of the imaging study matched with the
characteristics of the OSCC cell lines that have been reported (1, 10, 23, 52).
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4.2. Immunocytochemistry
Except for the MMP-9 expression of HSC-3, seven proteolytic enzyme expressions
of OSCC cell lines were higher than HNEC. The expression levels of proteolytic
enzymes in the OSCC cell lines are shown in Table11.
MMP-1 was expressed with 50-90% stronger intensity in OSCC cell lines, than in
HNEC (Figure 14). MMP-2 was expressed with more than 90% stronger intensity in HN
and HSC-3 than HNEC; however, in BHY this percentage was 83 (Figure 15). HSC-3,
HN, and BHY showed 95%, 81%, and 73% stronger MMP-3 intensity than HNEC,
respectively (Figure 16). MMP-9 expression of HSC-3 was the same with HNEC, HN
had moderate MMP-9 expression (Figure 17). BHY showed the strongest EMMPRIN and
MMP-9 expression with 93% and 58% respectively (Figure 18). Cathepsin B expressions
of OSCC cell lines were higher than 90% (Figure 19). Cathepsin L expression was the
highest in HSC-3 cell line with 96% and the lowest in BHY cell line with 72% (Figure
20).

4.3. Flow Cytometry
Five thousand cells were evaluated from each cell line using flow cytometry. The
percentages of antibody-stained cells are shown in Table 12. MMP-1, MMP-2 and MMP3 were highly expressed in all three OSCC cell lines and the HNEC cell line (Figure 21).
However, MMP-9 and EMMPRIN expression levels were highest in the BHY cell line
(Figure 22). MMP-9 expression level in the BHY cell line was significantly higher,
compared to the HNEC and HSC-3 cell lines. Also, the HN cell line showed elevated
MMP-9 expression compared to HNEC and HSC-3 cell lines but it wasn’t as high as in
the BHY cell line (Table 12).
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Increased MMP-9 and EMMPRIN expression may play a role in bone invasion by
OSCC. According to flow cytometry results 97-99.9% of OSCC and HNEC cells were
stained with the MMP-1, MMP-2 and MMP-3 antibodies; however,
immunocytochemistry staining for the same proteolytic enzymes showed stronger
intensity in tumor cells than HNEC cells. Thus, normal epithelial cells and tumor cells
secrete MMP-1, MMP-2 and MMP-3 but the difference is the regulation of their activity.

4.4. Ultrastructural Characterization of Three OSCC Cell Lines
At the ultrastructural level, the BHY cells were the most highly differentiated of the
3 OSCC cell lines (Figure 23). There was interdigitation of adjacent cells and numerous
cell junctions were present. HN cells had cytoplasmic projections, but did not show
interdigitation of adjacent cells. Cell junctions were often seen between adjacent cells
(Figure 24). The HSC-3 cells in culture were smaller than the other 2 OSCC cell lines.
They possessed cytoplasmic projections but did not show any sign of interdigitation. Cell
junctions were rarely seen (Figure 25). The control HNEC cell line showed obvious
squamous cell features including interdigitation, numerous cell junctions, and occasional
cytoplasmic tonofilaments (Figure 26).

4.5. The Quality and Quantity of Total RNA
After total RNA extractions from the cell lines, 3µl total RNA from each cell line
was diluted with distilled water, and observed for the quality and quantity of RNAs. The
quantity measurements of total RNA at spectrophotometer at 260nm and calculation of
total amount of each cell line total RNAs are as follows:
Dilution factor X Optimal Density at A260 X 40µg/ml
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For the BHY cell line: the value of optimal density at 260nm at spectrophotometer
is 0.16 (figure 27) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is
0.16 X 40 X 100=640µg/ml. The total volume of BHY total RNA was 2ml, so the total
amount for this cell line was 640µg/ml X 2ml=1280µg.
For the HN cell line: the value of optimal density at 260nm at spectrophotometer is
0.15 (figure 28) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is
0.15 X 40 X 100=600µg/ml. The total volume of HN total RNA was 2ml, so the total
amount for this cell line was 600µg/ml X 2ml=1200µg.
For the HSC-3 cell line: the value of optimal density at 260nm at spectrophotometer
is 0.08 (figure 29) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is
0.08 X 40 X 100=320µg/ml. The total volume of HSC-3 total RNA was 4ml, so the total
amount for this cell line was 320µg/ml X 4ml=1280µg.
For the HNEC cell line: the value of optimal density at 260nm at spectrophotometer
is 0.4 (figure 30) and the dilution rate is 1:100. Thus, the amount of total RNA in 1 ml is
0.4 X 40 X 100=1600µg/ml. The total volume of HNEC total RNA was 2ml, so the total
amount for this cell line was 1600µg/ml X 0.75ml=3200µg.
cDNA of each cell line was synthesized from total RNA and aldolase and β-actin
genes were run in PCR in order to check the quality of total RNA of each cell line. All
cell lines showed the expression of both housekeeping genes on the electrophoresis gel
(Figure 31).

4.6. cDNA Microarray Analysis of Three OSCC Cell Lines
The genetic structure comparison of tumor cell lines with HNEC cell line by using
the cDNA microarray technique showed that each OSCC cell line has its unique gene
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expression structure. After the normalization process each OSCC cell line demonstrated
different upregulated and downregulated genes. The BHY cell line expressed 139
upregulated genes and 117 downregulated genes (Table 13 and 14). The HN cell line
expressed 214 upregulated and 262 downregulated genes (Table 15 and 16). Finally, the
HSC-3 cell line expressed 128 upregulated and 117 downregulated genes (Table 17 and
18).
The clusterization of data showed that there were 13 genes that are upregulated and
83 genes that were downregulated in all three OSCC cell lines (Figures 32 and 33). Each
cell line was compared with the other two cell lines based on the most upregulated and
the most downregulated 20 genes of that cell line. This permitted an understanding of the
genetic differences between these three cell lines better and thus the most responsible
genes that are related to the formation of their genetic characteristics. Figure 34 and table
19 shows the 20 most upregulated and downregulated genes in the BHY cell line and the
expression levels of these 20 genes in the other two OSCC cell lines, HN and HSC-3.
Figure 35 and table 20 shows the 20 most upregulated and downregulated genes in the
HN cell line and the expression levels of these 20 genes in the other two OSCC cell lines,
BHY and HSC-3. And figure 36 and table 21 shows the 20 most upregulated and
downregulated genes in the HSC-3 cell line and the expression levels of these 20 genes in
the other two OSCC cell lines, BHY and HN.
There were 57 genes that were upregulated and 42 genes that were downregulated
in both BHY and HN cell lines (Figure 37). The comparison of BHY with HSC-3
showed that there were 24 upregulated genes and 49 downregulated genes on both BHY
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and HSC-3 cell lines (Figure 38). Finally, there were 24 common upregulated and 44
downregulated genes in HN and HSC-3 cell lines (Figure 39).
Based on the expression levels of the genes in the microarray analysis, different
pathways were analyzed on each OSCC cell line by using the Kyoto Encyclopedia of
Gene and Genomes (KEGG). The pathway analysis was done based on the number of
genes that were upregulated or downregulated within the pathway, the importance of the
upregulated or downregulated genes for that specific pathway (impact factor) and how
significant the change was of upregulated or downregulated gene expression (p values).
First, both upregulated and downregulated genes’p values were considered in pathway
analysis. Seven, 9 and 8 pathways were influenced in BHY (figure 40), HN (figure 43)
and HSC-3 (figure 46) cell lines respectively (p<0.05). When only upregulated genes’ p
values were evaluated 8, 10, and 3 pathways were upregulated in BHY (figure 41), HN
(figure 44) and HSC-3 (figure 47) cell lines respectively (p<0.05). Finally, only
downregulated genes’ p values were evaluated and 3, 9, and 6 pathways were
downregulated in BHY (figure 42), HN (figure 45) and HSC-3 (figure 48) cell lines
respectively (p<0.05).

4.7. Real Time PCR Analysis
Prior to cDNA synthesis, the quality of the extracted total RNA was determined
using gel electrophoresis (Figure 4a). Also, the quality and quantity of cDNA, used for
Real Time analysis, was checked by measuring the glucose-6-phosphate gene expression
levels (Figure 4b).
The Real Time PCR analysis results confirmed the cDNA microarray analysis
results (Figure 49). The upregulation values of MAGEA9, Q96AL8 and GFI1 genes in
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the BHY cell line were 3.34, 5.18 and 7.06 respectively. The upregulation values of
NMES1, MAGEA1 and Q96AL8 genes in the HN cell line were 8.33, 3.58, and 10.67
respectively. Finally, the upregulation values of MAGEA8, MAGEA1 and EREG genes
in the HSC-3 cell line were 1.63, 0.90, and 3.71 respectively. When we compare the
results of the Real Time-PCR with the results of the cDNA microarray analysis, the only
questionable upregulation in the cDNA microarray analysis was the expression level of
the MAGEA1 gene in the HSC-3 cell line with an error bar of 0.89 (Figure 49). However,
all others have reasonable error bars as seen in figure 49, which means that the cDNA
microarray analysis results in this study were reliable. The p values of all the Real Time
PCR analysis results were <0.0001 except the value of the MAGEA1 gene in the HSC-3
cell line.
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CHAPTER 5
CONCLUSIONS & RECOMENDATIONS
5.1. The Invasion and/or Metastatic Characteristics of OSCC Cell Lines
This part of the study examined the invasion and/or metastatic potentials of three
different OSCC human cell lines, using micro positron emission tomography (PET) and
computerized tomography (CT) imaging. The advantage of micro-imaging technology is
the ability to monitor tumor growth in vivo. PET/CT revealed good image quality and
allowed us to evaluate and correlate the metabolic alterations of cancer with anatomical
findings. Thus, it is a good imaging technique of the tumors. PET is a method by which
cellular and molecular events can be followed by using injected radiolabelled molecular
probes. The addition of CT to PET is clearly helpful for a better anatomic delineation of
the tumor, treatment monitoring, prognosis assessment and radiation treatment planing.
Immunocompromised scid mice were used to show the differences in jaw bone
invasion and distant organ metastasis of the three different OSCC cell lines in a
biological system. Three animals per group was the minimum number required to
demonstrate infiltrative bone lesions or metastases. There are three anatomical areas to
form a tumor in the oral cavity. They are tongue, floor of the mouth and cheek (137,
138). The masseter muscle is the ideal anatomical area for tumor growth due to its
proximity to the jaw bones. Thus, we injected the cell lines into the masseter muscle.
1x107 cells was the minimum acceptable amount to inject in each mouse according to the
literature (139). As tumors in animals were clearly visualized by FDG-PET/CT (138,
140), we decided to use 18FDG as the tracer. 18FDG is actively taken up and accumulates
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in cancer cells (141). To the best of our knowledge, micro positron emission tomography
(PET)/computerized tomography (CT) imaging has not been used to show the invasion
and metastatic capacity of these three OSCC cell lines.
The results of this experiment provided important information on the invasive and
metastatic capacity of different OSCC cell lines that matched with their reported
characteristics. It was determined that OSCC development can result in jaw bone
invasion and/or distant organ metastasis. The BHY cell line invaded the mandible when
they were injected in the masseter muscle of the scid mice (figure 8). This was also
proven by Kawamata et al. (1). However, the HN cell line showed metastasis to cervical
lymph nodes and distant organs both in our study and according to the literature (figure
10 and 11) (1). The characteristics of the HSC-3 cell line in our study correlated with
other reported studies (figure 12 and 13) (10, 23, 52). As we found differences based on
the invasion and/or metastasis of these cell lines, we focused on the expression levels of
proteolytic enzymes by using immunocytochemistry and flow cytometry, and gene
regulations of these three OSCC cell lines by using the cDNA microarray technique.
Thus, we might determine the genes that are upregulated or downregulated in the process
of metastasis or bone invasion of OSCC.

5.2. Characterization of The Oral Squamous Cell Carcinoma Cells
MMPs play an important role in the invasion and metastasis of oral cancer. OSCC
can induce the secretion of type I collagen proteolytic enzymes, most notably MMP-1
(10). MMP-1 breaks down collagen I to gelatin. Then gelatinases, which are MMP-2 and
MMP-9, complete the collagen I degradation by breaking down gelatin (10). Although
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cancer cells that secrete MMP-2 and MMP-9 can invade bone, it is thought that MMP-9
plays a more important role than MMP-2 during this process (9).
Several studies have focused on the effects of MMP-1 (1, 10), MMP-2 (1, 9, 10,
17), MMP-3 (2, 17) and MMP-9 (1, 9, 10, 19) along with cathepsin B, H, L, and D (1, 4)
on the ability of OSCC to invade bone. Production of MMP-1 and MMP-9 appear to play
a role in the invasion of OSCC to bone (8, 10) and our results substantiate this finding.
These two metalloproteinases are necessary for the complete collagen matrix degradation
of bone, and have been shown to be expressed by OSCC (10). According to Hong et al.
(9) and our study, although MMP-2 was highly expressed in OSCC it is not related to
invasion. Over expression of MMP-3 in OSCC is associated with invasion and a high
incidence of metastasis (2). Also, our results showed that MMP-3 has a stronger intensity
in tumor cells than in HNEC cells. Cathepsin B and L are the two most important
cysteine proteinases implicated in tumor cell invasion and metastasis (12). This study
showed that all three OSCC cell lines highly express both cathepsin B and L. EMMPRIN
is highly expressed in OSCC and may regulate OSCC invasion, and modulate the
expression of MMP-2 (13). We also observed that EMMPRIN is highly expressed in
tumor cells, particularly in BHY cell lines.
MMP-2 expression is significantly higher in cases of lymph node metastasis than
that in non-lymph node metastasis cases (34, 35, 44). This may explain the observation of
the highest expression of MMP-2 in HN and HSC-3 cell lines. MMP-9 production is also
closely related to lymph node metastasis (36) however, Charous et al. (37) found that
there is no difference in MMP-2 and MMP-9 expression levels between primary and
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metastatic OSCC. We believe that higher levels of MMP-2 might correlate with lymph
node metastasis of OSCC.
MMP-3 can degrade type IV collagen. Thus, it is important to analyze the
expression of MMP-3 in OSCC. EGF stimulates the production of MMP-3 coordinately
with MMP-1 (2). Interestingly, the over-expression of epithelial growth factor receptor
(EGFR) is a remarkable property of squamous cell carcinoma (2, 56, 58). It is not clear,
however, whether EGFR overexpression is implicated in the increased production of
MMP-3 by OSCC (2).
This study did not reveal any significant differences in the expression levels of
cathepsin B and L in the three OSCC cell lines. Cathepsin L has a major role in the
process of bone resorption by activating osteoclasts (1). Kawasaki et al. (4) found that
cathepsin B expression is closely correlated with OSCC invasion and progression;
however, they could not find any relationship between cathepsin L expression and
invasion of OSCC. Turk et al. (45) showed that cathepsin B, H, and L are involved in
cancer progression by either direct degradation of extracellular matrix or by activation of
other proteases, such as uPA.
In conclusion, proteolytic enzymes appear to play an important role in OSCC
invasion and metastasis. Increased expression of MMP-9 and EMMPRIN may be
associated with bone invasion of OSCC. We believe, however, that there are more genes
and related proteins involved in the bone invasion pathway of OSCC. Future studies will
refine gene profiles of OSCC’s with different biologic behavior leading to targeted
clinical treatments.

72

5.3. cDNA Microarray Analysis of The Three OSCC Cell Lines and
Comparison of The Results With Real Time PCR Analysis
cDNA microarray analysis helped us better understand which genes are involved in
bone invasion, lymph node metastasis and distant organ metastasis of OSCC. Regulation
of gene expression is the cellular control via the functional product of the gene. It is the
basis for cellular differentiation, morphogenesis and formation of the most significant
pathology, such as cancer.
5.3.1. The quality and quantity of total RNA
Before the cDNA was synthesized from the total RNA, spectrophotometry was used
to be ensured that there was enough total RNA. The quantity and the quality of the total
RNA was important. Thus, aldolase and β-actin genes were two good housekeeping
genes to use for checking the quality of total RNA. The first step was the synthesis of the
cDNA from the total RNA and the second step was running a PCR reaction using the
proper primers for aldolase and β-actin genes in order to observe their expressions
(Figure 31).
A housekeeping gene is typically a constitutive gene that is transcribed at a constant
level. Its products are needed for maintenance of the cell and its expression level is
unaffected by experimental conditions. Thus, the expression levels of housekeeping
genes are a good source of evaluation of the quality of the total RNA. So far 575
housekeeping genes have been identified (142). Aldolase and β-actin genes are in the
group of the most commonly used housekeeping genes (143). The major function of the
aldolase gene is in sugar metabolism in the cell in which they are expressed. Thus, this
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gene is important in cell motility. The β-actin gene is one of the six different actin
isoforms that is involved in cell motility, structure and integrity.
Column 1 in figure 31 did not show any band as it was the negative control group.
However column 2, which was the positive control group, and columns 3 to 6, which
were BHY, HNEC, HN and HSC-3 cDNA samples respectively, showed similar bands
corresponding to the 161 kb molecular weight of the aldolase gene. Column 7 with the βactin negative group did not show any band. Columns 8 to 12, which were β-actin
positive, BHY, HNEC, HN and HSC-3 cDNA samples respectively, showed the same
bands with 42 kb which is the molecular weight of that gene. The gel electrophoresis in
figure 31 showed that the total RNA samples that were used for cDNA microarray
experiment was in good quality.
5.3.2. cDNA microarray analysis of three OSCC cell lines
Good quality and quantity of total RNA allowed us to obtain pure cDNA samples
from each tumor cell lines and the HNEC control cell line. Each OSCC cell line cDNA
was compared with the HNEC cell line based on the expression levels of 25,000 genes
using the cDNA microarray technique. Operon Human Version 3.0 microarray slides
were used for the cDNA microarray experiment. Any single microarray output is subject
to substantial variability. Thus, the comparison of gene expression of each tumor cell
lines was repeated four times using four microarray slides. By pooling data from
replicates, we can provide more variable analysis of gene expression data. Based on the
literature, in a microarray experiment at least 3 replicates produce more consistent and
reliable findings (144), however, we preferred to do 4 replicates.
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It has been shown that some genes have more affinity to Cy3- or Cy5 dyes (145).
Reverse labeling has been proved to be important in improving data correlation, thus each
group of cDNA was reverse labeled. Reverse labeling helped us to eliminate gene dye
affinity error. Also, the Lowess normalization method was used in order to remove
intensity dependent dye bias.
Based on the cDNA microarray results, each OSCC cell line has a unique gene
expression structure. The HN cell line had the highest amount of gene alteration of all
three OSCC cell lines with 214 upregulated and 262 downregulated genes (Table 15 and
16). The BHY and HSC-3 cell lines had almost the same amount of upregulated and
downregulated genes. This correlates with the metastatic and invasion capacities of these
three cell lines (Figure 2). According to Leethanakul et al. study (93) the 23 genes that
are most commonly expressed in normal oral squamous epithelium (table 2) were neither
upregulated nor downregulated in any of the three OSCC cell lines. However, according
to the same study the two genes of the 23 genes (table 3) that are most commonly
expressed in OSCC were downregulated only in the HN cell line (table 16) and neither
upregulated or downregulated in the BHY and HSC-3 cell lines. These two genes are
RPS6KA2 and GSTP1. RPS6KA2 is a ribosomal protein S6 kinase, 90kDa, polypeptide
2 and located at the 6q27. This gene is highly expressed in lung tissue and skeletal
muscle. It may play an essential regulatory role in protein synthesis during cell
proliferation. It was shown that this gene is downregulated in renal cell carcinomas (146).
GSTP1 is glutathione S-transferase and located at 11q13. Its function is the conjugation
of reduced glutathione to a wide number of exogenous and endogenous hydrophobic
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electrophiles. Increased risk for oral cancer was observed in individuals who are
homozygous for the GSTP1 gene and this risk increases with smoking (147).
Shimada et al. found 16 genes that were upregulated in tongue cancer (table 4).
Only one of these genes, which is KIAA, was upregulated in our study in the HN cell line
(table 15), which is the most aggressive of the three OSCC cell lines. KIAA was found to
be upregulated in OSCC tissues. The KIAA family of proteins bear a trans-membrane
region capable of binding to other KIAA protein containing domains (such as PDZ, SH3,
rhoGEF, and spectrin) known to be localized to sub-membranous sites indicating that
they participate in cellular junction formation, receptor or channel clustering, and
intracellular signaling events (148). Upregulation of KIAA may be involved in the late
stages of OSSC.
Tomioka et al. reported that 19 genes were downregulated in 9 patients with OSCC
(136). CDH11, PAM, and TM4SF10 are the three genes of those 19 genes that were
donwrregulated according to our results. CDH11 was downregulated in both HN and
HSC-3 cell lines (table 16 and 18). CDH 11 is the cadherin 11 gene and has the
chromosomal position of 16q22.1. Cadherins are calcium dependent cell adhesion
proteins. They preferentially interact with themselves in a homophilic manner in
connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.
CDH11 is also downregulated in ameloblastoma (149). PAM (peptidylglycine alphaamidating monooxygenase) was only downregulated in the HN cell line. This gene is
located at 5q14-q21. There is no study that has been performed that examines the
relationship of this gene with OSCC. Gene TM4SF10, transmembrane 4 superfamily
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member 10, was downregulated in all three OSCC cell lines. Its location is on the short
arm of human chromosome X at p21.1 (150).
Choi et al. listed 32 genes (table 6) that were upregulated in head and neck SCC
(111). COL1A1, COL4A1, COL4A2, and COL5A1 are four of these genes (111, 151).
According to our study, however, COL7A1, COL8A1, COL4A1, and COL16A1 were
downregulated in the HN cell line (table 16). In the BHY cell line COL5A1 was
upregulated (table 13) and COL8A1 was downregulated (table 14) and in the HSC-3 cell
line COL4A1 was downregulated (table 18). The LY-2 cell line which was isolated from
lymph node metastases of OSCC expressed down regulation of the COL1A2 and
COL4A1 genes (152). This correlates with our HSC-3 cell line gene expression results.
COL4A1 is collagen, type IV, alpha 1 and located at 13q34. Type IV collagen is the
major structural component of glomerular basement membranes, forming a meshwork
together with laminins, proteoglycans and entactin/nidogen. COL5A1 is collagen, type V,
alpha 1. Type V collagen is a member of group I collagen (fibrillar forming collagen). It
is a minor connective tissue component of nearly ubiquitous distribution. Type V
collagen binds to DNA, heparan sulfate, thrombospondin, heparin, and insulin. The
genomic location of the gene is 9q34.2-q34.3. COL8A1 is collagen, type VIII, alpha 1.
The molecular function of this gene is unknown. The genomic location of the COL8A1 is
3q12.3. COL1A2 is collagen, type I, alpha 2. Its genomic location is 7q22.1. Type I
collagen is a member of group I collagen (fibrillar forming collagen). COL1A2 are
specifically repressed by EGFR signaling, thereby facilitating oncogenic transformation.
Therefore, it is likely that COL1A2 interferes with the progression of human carcinomas
expressing aberrant forms of one or more EGFR family receptor tyrosine kinases (153).
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COL1A1 is collagen, type I, alpha 1 with location of 17q21.33. Type I collagen is a
member of group I collagen (fibrillar forming collagen). COL7A1 is collagen, type VII,
alpha 1. The genomic location of this gene is 3p21.1. It is a stratified squamous epithelial
basement membrane protein that form anchoring fibrils which may contribute to
epithelial basement membrane organization and adherence by interacting with
extracellular matrix proteins such as type IV collagen. COL5A2, COL3A1, COL10A1,
COL4A1, FN1, and INHBA were well correlated with periostin expression. Higher
expression of periostin was frequently observed in HNSCC tissues compared with normal
tissues. By evaluation of periostin expression in HNSCC patients, a strong correlation of
periostin expression with FAP, SULF1, COL5A2, COL3A1, COL10A1, COL4A1, FN,
and INHBA was observed (154). However, in our study none of these genes and periostin
were upregulated in any of the three OSCC cell lines.
Other upregulated genes that were listed by Choi et al. (table 6) were FN1, ITGA6,
IL-6, IL-8, POSTN, SERPINE1, SOD2, and THBS2. FN1, which is fibronectin 1, is
located at 2q34. Fibronectin binds cell surfaces and various compounds including
collagen, fibrin, heparin, DNA, and actin. It is involved in cell adhesion, cell motility,
wound healing, and maintenance of cell shape. The upregulation of this gene in head and
neck SCC was shown (151), however, according this study this gene was downregulated
in all three OSCC cell lines (tables 14, 16 and 18). Neither upregulation nor
downregulation of ITGA6 was observed in this study, whereas the downregulation of
ITGB6 in BHY and HSC-3 cell lines were recorded (table 16 and 18). ITGB6 is the
integrin beta-6 precursor that is Located at 2q24.2. It is a fibronectin receptor for
carcinoma cells and plays a critical structural role in the hemidesmosome of epithelial
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cells (155). Both IL-6 (interleukin 6) and IL-8 (interleukin 8) genes were upregulated in
the three OSCC cell lines in this study (tables 13, 15, and 17). The genomic location of
IL-6 is at 7p.21. It is a cytokine with a wide variety of biological functions: it plays an
essential role in the final differentiation of B-cells into Ig-secreting cells, it induces
myeloma and plasmacytoma growth. It is also involved in the regulation of immune
response, hematopoiesis, platelet production, acute phase reaction and bone resorption
(susceptibility factor for osteopenia), playing a role in the aggressiveness of nonHodgkin’s lymphoma by stimulating MMP-2 and MMP-9. IL-8, which is located at
location 4q13-q21, is a chemotactic factor that attracts neutrophils, basophils, and T-cells,
but not monocytes. It is released from several cell types in response to an inflammatory
stimulus. IL-6 and IL-8 are important cytokines involved in tumor growth and
angiogenesis in a variety of cancers, including OSCC (49, 126). The impact of IL-6 and
IL-8 expression in cancer cell lines has been reported. But the in vivo relationship
between the IL-6/IL-8 expression and clinical parameters is still unknown (156). POSTN
(periostin) is located at 13q13.3. It binds to heparin and induces cell attachment and
spreading and plays a role in cell adhesion. Periostin overexpression enhances
invasiveness in oral cancer as its expression is well correlated with the invasion pattern
and metastasis. Moreover, blood vessel density of periostin-positive cases was higher
than those of periostin-negative cases (157), however, in this study it was downregulated
(tables 14, 16 and 18). SERPINE1 (serpin peptidase inhibitor, clade E member 1) is
located at 7q21.3-q22. Both SERPINE1 and SOD2 expression increase in OSCC with a
poor prognosis (121). These two genes were only upregulated in the HN cell line (table
15) that has the most aggressive metastatic behavior. No THBS2 upregulation was found
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in this study, but downregulation of the THBS1 gene was observed in the HSC-3 cell line
(table 18). The THBS1 gene product is an adhesive that mediates cell-to-cell and cell-tomatrix interactions. It can bind to fibrinogen, fibronectin, laminin, type V collagen and
integrins. Downregulation of this gene was observed in human lung and breast cancer cell
lines and associated with the malignant progression of murine melanoma cell lines.
Although the role of THBS1 in cancer progression is not yet clear, it is suggested that
production of THBS1 by tumor cells is correlated with a reduction in angiogenesis (158).
Choi et al. also listed the 33 most common downregulated genes of head and neck
SCC (table 7) (111). AIM1, ALDH9A1, ANXA1, DUSP5, IL1RN, KRT13, KRT15,
KRT4, and ZNF185 are some of them. We did not appreciate any remarkable change in
expression level of the AIM1 gene, but the expression level of AIM2 (Absent in
melanoma 2) gene, located at 1q22, was upregulated according to this study’s results
(table 13, 15, and 17). Although AIM2 is known to inhibit fibroblast cell growth in vitro,
its antitumor activity has not been shown. The expression level of ALDH9A1 gene was
not downregulated but ALDH1A3 (aldehyde dehydrogenase 1 family, member A3) gene
which is located at 15q26.3, was downregulated in HN cell line (table 16). The ALDH
family consists of 16 different enzymes in the human. Several of these have been
characterized in recent years but for many, a specific function remains to be revealed. The
function for ALDH1A3 may be a back-up enzyme in retinoid metabolism. Apart from
ALDH1A3, no true retinoid-metabolising enzyme was identified. Downregulation of the
ANXA1 gene in OSCC was shown previously (table 7) (111). Our study confirmed the
downregulation of the ANXA6 (annexin A6) gene in the HN cell line (table 16). The
location of this gene is 5q32-q34. This gene may regulate the release of Ca2+ from
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intracellular stores. ANXA1 is overexpressed in breast cancer and hepatocellular
carcinoma but markedly down-regulated in esophageal, prostate, gastric carcinomas and
HNSCC. The loss of the ANXA1 protein expression is an early event in the initiation of
premalignant lesions in HNSCC. Also, possible tumor suppressor roles have been
proposed for the ANXA6 gene in melanoma and squamous cell carcinoma (159).
DUSP6, which was downregulated in the HN cell line (table 16), is located at 12q22-q23.
Its function is to inactivate MAP kinases. There are five studies that have been performed
regarding the expression levels of DUSP6 in head and neck SCC. Four of these studies
showed downregulation of this gene whereas one of them showed the upregulation of the
gene (table 8) (111). Of the down-regulated genes, DUSP1, which has known
proliferation and differentiation functions, has been shown previously to be downregulated in follicular carcinomas and in advanced epithelial ovarian cancer. Individual
genes that differentiate between papillary and follicular carcinomas are the DUSP6 and
DUSP5. DUSP5 has been reported previously to be upregulated in premalignant lesions
and underexpressed in invasive pancreatic carcinoma (160). IL1RN was only
downregulated in the HN cell line (table 16). This gene (interleukin 1 receptor antagonist)
is located at 2q14.2. It inhibits the activity of IL-1 by binding to its receptor, however it
has no IL-1 like activity. It is downregulated in OSCC (151). KRT23 in the BHY cell line
(table 14); KRT8, KRT16, and KRT6B in the HN cell line (table 16) and KRT23,
KRT15, and KRT6B (table 18) were downrregulated in the HSC-3 cell. There are six
studies that have been performed regsarding the expression levels of KRT16 in head and
neck SCC. Four of these studies showed downregulation of this gene whereas two of
them showed the upregulation of the gene (table 8) (111). KRT genes are basal cell
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epithelial markers. Immortal OSCC show increased expression of genes encoding several
cell cycle regulators, compared with mortal OSCCs (e.g., CCNA2, CCNB1, CCNB2;
CDC2, CDC6, CDC20, CDCA7; CDKN3; several MCMs; PCNA; BIRC5), but reduced
expression of genes encoding terminal differentiation markers such as several keratins,
involucrin (IVL), and the family of small proline-rich proteins (SPRR), as well as the
S100 family of calcium-binding motility proteins. In contrast, a variety of adhesion,
invasion, and extracellular matrix proteins are upregulated in mortal OSCC (161). ZNF25
and ZNF625 gene were downregulated in the BHY cell line and ZNF569, ZNF606 and
ZNF83 genes were downregulated in the HSC-3 cell line. ZNF genes are located at 19q.
These genes are involved in the regulation of cellular proliferation, differentiation and
transcriptional regulation. Downregulation of ZNF 185 in head and neck cancers has
been shown previously (100).
Other common genes that are altered in head and neck SCC are MMP-1, MMP-2,
MMP-3, MMP-9, MMP-10, MMP-13, MMP-25, LAMP3, LAMA3, LAMB3, LAMC2,
CDH2, CXCL6 and HRAS . MMP-13 is an important matrix matelloproteinase, which is
known also as collagenase 3. The collagenases can mediate tumor invasion through
several mechanisms, which include constitutive production of enzymes by the tumor
cells, induction of collagenase production in the neighboring stromal cells, and
interactions between tumor/stromal cells to induce collagenase production by one or both
cell types. Thus, evidence indicates that elevated expression of the interstitial
collagenases is associated with a poor prognosis in a variety of cancers, and therefore,
these MMPs can serve as a marker of tumor progression. Human MMP-13 was first
identified in breast carcinoma. Squamous cell carcinomas of the head and neck, in
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particular, are noted for their propensity to rapid progression and poor clinical outcome.
In these tumors, MMP-13 has been seen mostly in tumor cells at the invading front. Only
malignant squamous cell tumors, but not premalignant and benign lesions, express MMP13, supporting the concept that MMP-13 can serve as a prognostic marker in these
carcinomas with characteristically poor outcomes (162). Recently, MMP-1 has been
described in a wide variety of advanced cancers. Some reports document MMP-1
production by tumor cells and correlate this with the invasive potential of the tumors,
whereas other investigations support the belief that MMP-1 is predominantly expressed
by the surrounding stromal fibroblasts. Tumor cells are constantly changing both their
genotype and their phenotype as they respond to genetic, physiological, and
pharmacological pressures. As a result of this genetic instability, errors in gene regulation
accrue as the tumor continues to metastasize and progress (162). Many matrix
metalloproteinases (MMPs), such as MMP-1, -2, -7, -9, -13, and -14 have been
implicated in cancer invasion. The absence of MMP-7, -9 and -12 from epithelial cells
may serve as a good prognostic marker of non-invasive oral carcinoma (163). Blocking
the activity of invasion-specific MMPs might offer novel therapeutic modalities in earlystage oral carcinoma. The tissues of OSCCs with lymph node metastasis exhibited
increased expression levels of MMP-1, MMP-3, uPA, integrin- 3, paxillin, tenascin C
and IL-6 transcripts. Functional gene groups of proteolytic enzymes and integrin-related
molecules are involved in cervical lymph node metastasis. MMP-1 and integrin-3 in
particular can provide an accurate biomarker system for predicting the risk of cervical
lymph node metastasis in OSCC (164). Previous studies have indicated that E1AF
transactivates multiple MMP genes, such as MMP-1, MMP-3 and MMP-9, and plays an
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important role in tumor invasion. Expression of MMP-1, MMP-9 and E1AF has been
found to be correlated with the invasive potential of oral squamous cell carcinoma (165).
According to our cDNA microaray analysis study in the BHY cell line MMP-1, MMP-3,
MMP-9 and MMP-10 (table 13); in HN cell line MMP-2, MMP-13, and MMP-25 (table
15); and in HSC-3 cell line MMP-2 and MMP-3 (table 17) were highly expressed.
LAMP3, lysosomal-associated membrane protein 3, is another gene that is altered in
OSCC. Its location is 3q27 and it may change the lysosome function after the transfer of
peptide-MHC class II molecules to the surface of dendritic cells. LAMP3 expression is
upregulated in laryngeal squamous cell carcinoma (166). LAMP3 might also play an
important part in metastasis (167). In our study this gene was upregulated both in the
BHY and HN cell lines (table 13 and 15). LAMA3, laminin alpha 3, gene is located at
18q11.2. It mediates the attachment, migration and organization of cells into tissues
during embryonic development by interacting with other extracellular matrix
components. Functions of this gene include adhesion or migration, depending on whether
or not it has been proteolytically remodeled by MMPs such as MMP-2 and/or MT1MMP. This gene expression upregulates in wound sites (168). It has an important role in
regulating tissue organization, gene expression, and survival of epithelium (169). A
number of reports suggest its involvement in the spread and metastatic activities of cancer
cells (170). The HN cell line was the only one of the three cell lines that showed
upregulation of LAMA3 gene (table 15). CDH2, cadherin 2, type 1, is located at 18q11.2.
It is one of the first to be considered as an invasion-promoter gene. The upregulation of
this gene is common in diffuse type gastric cancer and lobular breast cancer (171). This
gene was only upregulated in the HN cell line (table 15). CXCL6, chemokine (C-X-C
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motif) ligand 6, is located at 4q21. Mortal SCC cultures express a variety of chemokines
in culture, such as IL-8, CXCL5, CXCL6, CXCL7, and CCL20, in contrast to immortal
SCCs (161). This may be one reason why this gene is only upregulated in HN cell lines.
HRAS, Harvey-ras, gene is involved in cell signaling, cell growth, and cancer (58, 124).
This gene was upregulated in BHY and HN cell lines.
Based on this study OSCC involves multiple molecular genetic events that take
place on many chromosomes and genes. Also this study showed that the loss of
heterozygosity on regions of chromosomes 3, 4, 5, 6, 8, 9, 11, 13, and 19 is common in
OSCC. The genes that showed alterations in this study have a role in extracellular matrix
degradation, cell adhesion, epidermal development and differentiation, signal
transduction, transcriptional regulation, cell growth and proliferation, proteolysis,
basement membrane degradation, and cytoskeleton.
Thirteen of the 20 most upregulated BHY genes were upregulated, and the other 7
were neither upregulated nor downregulated in the HN cell line. However, only 3 of the
20 most upregulated BHY genes were upregulated, and the other 17 were neither
upregulated nor downregulated in the HSC-3 cell line. When the 20 most downregulated
BHY genes were evaluated, 11 of them in the HN cell line and 14 of them in HSC-3 cell
lines were also downregulated. The other 9 in the HN, and the other 6 in the HSC-3 cell
lines were neither upregulated nor downregulated (table19). Twelve of the 20 most
upregulated HN genes were upregulated, 7 of them were neither upregulated nor
downregulated and one of them was downregulated in the BHY cell line. However, only
5 of the 20 most upregulated HN genes were upregulated, 14 of them were neither
upregulated nor downregulated and one of them was downregulated in the HSC-3 cell
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line. When the 20 most downregulated HN genes were evaluated, 9 of them in the BHY
and 10 of them in HSC-3 cell lines were also downregulated. Ten of them were neither
upregulated nor downregulated and one of them was upregulated in the BHY cell line.
Ten genes of the 20 most downregulated HN genes were neither upregulated nor
downregulated in HSC-3 cell lines (table 20). Ten of the 20 most upregulated HCS-3
genes were upregulated, and the other 10 were neither upregulated nor downregulated in
the BHY cell line. Nine of the 20 most upregulated HSC-3 genes were upregulated, and
the other 11 were neither upregulated nor downregulated in the HN cell line. When the 20
most commonly downregulated HSC-3 genes were evaluated, 13 of them in BHY and 14
of them in HN cell lines were also downregulated. The other 7 of them in BHY, and the
other 6 of them in HN cell lines were neither upregulated nor downregulated (table 21).
These comparisons and the microarray gene clusterizations in figures 34, 35, and 36
showed that the upregulated genetic structure of the BHY cell line was more similar to
the upregulated genetic structure of the HN cell line (Figure 34A and 35A). Whereas the
upregulated genetic structure of the HSC-3 cell line showed more similarity to the
upregulated genetic structure of the BHY cell line (Figure 36A). Based on the gene
clusterization, the downregulated genetic structure of the BHY cell line was more similar
to the downregulated genetic structure of the HSC-3 cell line (Figure 34B, 35B and 36B).
The results of this study represented thirteen genes that were upregulated in all of
the three OSCC cell lines (figure 32). Twelve of them were known genes whereas one of
them has not been previously described. Basically, the functions of these genes are:
mitotic progression and chromosome segregation, apoptosis inhibition, cell growth,
transduction and intercellular transmission of polarity information during tissue
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morphogenesis and/or in differentiated tissues, embryonal development and tumor
transformation and progression, condensation of nucleosome chains into higher order
structures.
There were 83 genes that were downregulated in all three OSCC cell lines (figure
33). Most of the genes have vital functions for cell function. Some of these 83 genes,
such as EVA1, DSC2, POSTN, CSPG2, SRPX, ANGPTL4, FN1, ITGAV, COL8A1 and
AMPH have important functions related to cell-cell or cell-basement membrane
interaction (figure 33). Downregulation of such genes in malignancies helps the tumor
cells to spread to surrounding tissues and organs. The EVA1 gene is involved in the
formation of homotypic adhesion molecules that help the cells attach to the extracellular
matrix. The DSC-2 gene is a component of intercellular desmosome junctions. It is
involved in the interaction of plaque proteins and intermediate filaments mediating cellcell adhesion. It may also contribute to epidermal cell positioning by mediating
differential adhesiveness between cells. POSTN induces cell attachment and adhesion.
The CSPG2 gene may play a role in intercellular signaling and in connecting cells with
the extracellular matrix. It may take part in the regulation of cell motility, growth and
differentiation. The SRPX gene is also involved in cell-cell adhesion. The ANGPTL4
gene inhibits proliferation and migration of cells and reduces vascular leakage. FN1 is
involved in cell adhesion, cell motility, wound healing, and maintenance of cell shape.
Inhibition of the gene mediates inhibition of cell adhesion. ITGAV has an important role
in mediating cell-adhesion to extra cellular matrix or to other cells, through heterodimerization and connecting to the cytoskeleton and various signaling molecules within
cells. COL8A1 has a role in the formation of the major component of the basement
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membrane. The AMPH gene may participate in mechanisms of regulated exocytosis in
synapses. It may control the properties of the membrane associated cytoskeleton.
Another group of genes, SRFP1, KFL10, NDN, that play a major role of cell
growth regulation was also within this 83 downregulated gene list (figure 33). SRFP1 has
a role in cell growth regulation and differentiation. KFL10 is involved in the regulation of
cell growth by inhibition. The NDN gene is another growth suppressor that facilitates the
entry of the cell into cell cycle arrest. Functionally it is similar to the retinoblastoma
protein as it binds to and represses the activity of cell-cycle- promoting proteins.
Some of the genes involved with transportation were downregulated in all three
OSCC cell lines. These genes are GJB6, SLC2A1, FOLR3, ANXA6, and RAB4B. GJB6
has a role in forming one gap junction that consists of a cluster of closely packed pairs of
transmembrane channels, the connexons, through which materials of low molecular
weight diffuse from one cell to a neighboring cell. SLC2A1 is the glucose transporter in
the cell. FOLR3 mediates delivery of 5-methyltetrahydrofolate to the interior of cells and
ANXA6 regulates the release of Ca2+ from intracellular stores. The RAB4B gene is
effective in protein transport within the cell.
Genes of immune response such as SERPINB3, SEPP1, and IL1F9 were also within
the 83 commonly downregulated genes in the three OSCC cell lines (figure 33). The
SERPINB3 gene may act as a protease inhibitor to modulate the host immune response
against tumor cells. SEPP1 might be responsible for some of the extracellular antioxidant
defense properties. IL1F9 could constitute part of an independent signaling system
analogous to interleukin-1 alpha, beta receptor agonist and interleukin-1 receptor type I,
that is present in epithelial barriers and takes part in the local inflammatory response.
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The RGS17 and PTPNS1 genes were downregulated signal transduction inhibitor
genes within the 83 downregulated genes (figure 33). RGS17 inhibits signal transduction
by increasing the activity of G protein. PTPNS1 plays an important role in signal
transduction cascades.
Other listed genes have various different functions in the cell. Some of the
important ones are CFHL1, SPRR1B, RHBDL2, MAF, and CALD1. The CFHL1 gene
might be involved in complement regulation and can associate with lipoproteins and may
play a role in lipid metabolism. The SPRR1B gene produces a keratinocyte protein that
first appears in the cell cytosol. RHBDL2 is involved in regulated intramembrane
proteolysis. MAF has a role in transcription and the CALD1 gene plays an essential role
during cellular mitosis and receptor capping.
5.3.3. Pathway analysis of three OSCC cell lines based on cDNA microarray results
Pathway analyses of each OSCC cell line was performed to be able to better
understand the invasion, lymph node metastasis and distant organ metastatic mechanisms
of OSCC. Pathway upregulation in cell lines was most pronounced in metabolic
pathways including cell nucleotide metabolism and oxidative phosphorylation. Signaling
pathways involved in adhesion and communication of cultured cancer cells were
downregulated. Based on the expression levels of the genes in the microarray analysis,
different pathways were analyzed on each OSCC cell line by using the Kyoto
Encyclopedia of Gene and Genomes (KEGG). The pathway analysis was performed
based on the criteria that were described before in chapter 4.

89

5.3.3.1. BHY cell line
Seven pathways based on the p values (p<0.05) of both upregulated and
downregulated genes (Figure 40), 8 pathways based on the p values (p<0.05) of only the
upregulated genes (Figure 41) and 3 pathways based on the p values (p<0.05) of only
downregulated genes (Figure 42) were influenced in the BHY cell line. The most
important pathways that were upregulated in the BHY cell line were; regulation of actin
cytoskeleton, TGF-beta signaling pathway, dentatorubropallidoluysian atrophy, hedgehog
signaling pathway, focal adhesion, Jak-STAT signaling pathway, Parkinson’s disease,
and the mitogen-activated protein kinase (MAPK) signaling pathway.
In regulation of the actin cytoskeleton pathway, the actin cytoskeleton mediates a
variety of essential biological functions in the cell. In addition to providing a structural
framework around which cell shape and polarity are defined, its dynamic properties
provide the driving force for cells to move and to divide. Members of the Rho family of
small guanosine triphosphatases have emerged as key regulators of the actin
cytoskeleton, and furthermore, through their interaction with multiple target proteins,
they ensure coordinated control of other cellular activities such as gene transcription and
adhesion (172). Actomyosin-mediated cell retraction and formation of intercellular gaps
occurs through this pathway (173). Actin filaments play important roles in mitosis, cell
signaling, and motility. Thus they are the targets of anti-cancer drugs. These drugs target
microtubules, and actin filaments to inhibit cell proliferation by blocking mitosis at the
mitotic checkpoint and inducing apoptosis (174). Activation of cell surface proteins
implicated in cell adhesions can cause the alteration of the actin cytoskeleton, which is
required for the function of cell-to-cell or cell-to-extracellular matrix interactions. The
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actin cytoskeleton is a dynamic structural entity and constantly undergoes assembly or
disassembly. The assembled actin filaments can be further cross-linked to form either
actin bundles or actin meshwork. The over activation of this system can cause bone
metastasis in breast cancer (175). This pathway was upregulated in all three OSCC cell
lines.
TGF-beta signaling pathway activation is common in malignancies. Carcinomas
often secrete excess TGF-β1 and respond to it by enhanced invasion and metastasis. Pretreatment of adenocarcinoma cells with TGF-β1 in vitro enhanced their subsequent
metastatic ability when injected into rats. The TGF-β-treated carcinoma cells became
more invasive in vitro, and this was attributed to increased expression of gelatinases (or
matrix metalloproteases), enhancing tumor cell migration and invasion. TGF-β1 not only
has transforming potential, but can also drive malignant progression, invasion and
metastasis both in vitro and in vivo. However TGF-β can act as both a tumor suppressor
and as a significant stimulator of tumor progression, invasion and metastasis. At the
initial stage of the cancer TGF-β acts as a tumor suppressor whereas as the tumor
progresses, genetic changes allow TGF-β to stimulate tumor progression by its
pleiotropic activities on both the cancer cells and on non-malignant stromal cell types of
the tumor (176). This may be a clue that the bone invasion phase of the OSCC is an
advanced phase of the cancer.
Dentatorubropallidoluysian Atrophy (DRPLA) affects both the mind and body. It is
characterized by abrupt muscle jerking, involuntary movements, and eventual dementia.
The protein product of the DRPLA gene is called atrophin-1. Although its function is
unclear, the leading theory is that atrophin-1 is involved in the pathway that helps insulin
91

take effect in the body’s cells. Since insulin helps determine how cells utilize their
energy, it is essential that this pathway work smoothly so that cells can function
efficiently (177). There are some cases in the literature with DRPLA and where patients
died due to lung cancer or prostate cancer, however there is no proven relation between
this pathway and cancer.
The Hedgehog signaling pathway is involved in the mechanisms that control cell
proliferation and cell differentiation during morphogenesis of the endochondral skeleton
of vertebrates. The Hedgehog signaling pathway has a role in the control of chondrocyte
maturation by way of feedback control of a second secreted factor which is parathyroid
hormone-related protein (PTHrP). Patients with solid tumors and hypercalcemia have
increased serum PTHrP. Its production by a tumor is associated with increased tumor size
and rate of growth. This pathway coordinates diverse aspects of skeletal morphogenesis
through PTHrP-dependent and independent processes. Over expression of PTHrP in
chondrocytes causes a delay in chondrocyte maturation and bone formation (178). Tumor
necrosis factor (TNF) enhances PTHrP-induced hypercalcemia which causes bone
resorption. This effect is due to the increased production of committed osteoclast
precursors with a subsequent increase in osteoclastic bone resorption. It was shown that
blockage of this pathway suppresses the growth of breast carcinoma cells (179). The
upregulation of this pathway is a common process for OSCC (180).
The focal adhesion pathway has a role in mechanical adhesion of the cells to the
extracellular matrix which is important for cell growth, survival and migration. Analysis
of primary human prostate cancer cells isolated from 16 surgical specimens showed that
these cells expressed the focal adhesion pathway, whereas normal prostate epithelial cells
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did not. Also, PC3, which is a prostate cancer cell line was found to invade mature bone
and highly express focal adhesion pathway (181). However, to the best of our knowledge
there has been no study relating invasion of OSCC to bone and this pathway.
The Jak-STAT signaling pathway was another pathway that was upregulated in the
BHY cell line. A wide variety of extracellular signals activate the signal transducers and
activators of transcription (STAT) class of transcription factors. Many cytokines,
lymphokines, and growth factors signal through a related superfamily of cell surface
receptor tyrosine kinases that are associated with and activate Janus kinases (JAKs)
(182). The urokinase-type plasminogen activator receptor (uPAR) generates a proteolytic
cascade important for matrix degradation in tumor invasion and tissue remodeling.
Binding of uPA to uPAR at the cell surface stimulated cell migration. In contrast to
normal cells, malignant tumor cells usually overexpress uPAR. uPAR, together with its
signaling functions, coordinate tumor cell adhesion and invasive migration through the
extracellular matrix (ECM) and to determine whether tumor cells will, or will not, grow
in vivo. The Jak-STAT signaling pathway is one of the pathways that can be activated by
the uPA- uPAR interaction (183). The activation of this pathway has been shown to be
involved in bone metastasis in prostate cancer (184). One other role of this pathway is
activation of MMP which has a role in bone invasion of OSCC. Upregulation of MMPs
in the BHY cell line can be due to the activation of this pathway.
The mitogen-activated protein kinase signaling pathways transduce a large variety
of external signals, leading to a wide range of cellular responses, including growth,
differentiation, inflammation and apoptosis. It is thought that the balance between distinct
MAPK pathways regulates cell growth, differentiation, survival, and death. They also
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have a role in the regulation of MMP gene expression, especially MMP-1 and MMP-3. In
addition to MMP-1 and MMP-3, increased transcriptional activity of MMP-9 can be
regulated by the MAPK signaling pathway in malignant cells. Invasive cancer cells and
stromal cells at the invading edge of tumors are under physical stress, such as hypoxia
and hyperthermia. Stress activates MAPKs which is responsible for regulation of MMP
expression (185). Inhibition of the MAPK pathway could serve as a therapeutic target to
specifically prevent tumor cell invasion.
Based on the downregulated genes in BHY cell lines there were 3 downregulated
pathways (p<0.05) (Figure 42). These pathways were olfactory transduction, taste
transduction and ECM-receptor interaction pathways. No relation was found in the
literature between OSCC and either the olfactory or the taste transduction pathway.
Pathways that were downregulated in cell lines compared to tumor and normal tissue
included cell communication, cell adhesion molecules (CAMs), and ECM-receptor
interaction. Degradation of ECM is one of the essential steps in invasion and metastasis
of the tumor (186). Integrins and growth factors play an important part in maintaining
tissue architecture. Disruption of the balance of signaling results in dramatic changes in
the way cells interact with each other and with the extracellular matrix, leading to cancer.
The extracellular matrix itself plays a central role in coordinating these signaling
processes. Downregulation of this pathway helps tumor cells migrate to distant organs
thus, metastasis and invasion. ECM-receptor interaction was found to be of relevance to
head and neck SCC (187). This pathway was not only downregulated in the BHY cell
line but also in the HN and HSC-3 cell lines according to the results of this study.
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5.3.3.2. HN cell line
Ten different pathways showed upregulation in the HN cell line (p<0.05) (Figure
44). Seven of them, which are MAPK signaling pathway, regulation of actin
cytoskeleton, antigen processing and presentation, focal adhesion, cell cycle, calcium
signaling pathway, and axon guidance, were closely related with invasion and metastasis
of the cancer.
As previously explained, MAPK pathway regulates cell growth, differentiation,
survival, and death. This pathway was also upregulated in the BHY and HSC-3 cell lines.
As it regulates MMP expression, this pathway may be involved in distant organ and
lymph node metastasis of OSCC. Transfection studies indicate that many genes can
induce metastatic ability, including familiar oncogenes such as RAS and MYC that have
a role in the MAPK signaling pathway. The metastatic process requires a complex set of
cellular functions such as changes in adhesion, and initiation of motility and extracellular
matrix proteolysis, which culminates in the shedding of cells into the circulation either
directly or via the lymphatics. A hyperactive Raf/MAPK pathway is required for
epithelial mesenchymal transition that correlates with metastasis (188). This pathway was
upregulated in all three OSCC cell lines. This may mean that the MAPK signaling
pathway is one of the major pathways related to OSCC invasion and metastasis.
Regulation of the actin cytoskeleton was another important pathway that was
upregulated in all three OSCC cell lines. As it was mentioned before, regulation of the
actin cytoskeleton provides the driving force for cells to move and to divide. Cell-cell
adherence junctions, the most common type of intercellular adhesions, are important for
maintaining tissue architecture and cell polarity, and can limit cell movement and
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proliferation. Cell-cell adherence junctions assemble via homophilic interactions between
the extracellular domains of calcium-dependent cadherin receptors on the surface of
neighboring cells. The cytoplasmic domains of cadherins bind to the submembranal
plaque proteins β-catenin or plakoglobin (γ -catenin), which are linked to the actin
cytoskeleton via α-catenin. The transmembrane assembly of cadherin receptors with the
cytoskeleton is necessary for the stabilization of cell-cell adhesions and normal cell
physiology. Malignant transformation is often characterized by major changes in the
organization of the cytoskeleton, decreased adhesion, and aberrant adhesion-mediated
signaling. Disruption of normal cell-cell adhesion in transformed cells may contribute to
enhance tumor cell migration and proliferation, leading to invasion and metastasis. This
disruption can be achieved by downregulating the expression of cadherin or catenin
family members or by activation of signaling pathways that prevent the assembly of cellcell adherence junctions such as the actin cytoskeleton. Thus, regulation of the actin
cytoskeleton is important in cell-cell adherence junction (173).
Antigen processing and presentation are processes that occur within a cell that
result in fragmentation (proteolysis) of proteins, association of the fragments with major
histocompatibility complex (MHC) molecules, and expression of the peptide-MHC
molecules at the cell surface where they can be recognized by the T cell receptor.
However, the path leading to the association of protein fragments with MHC molecules
differs for class I and class II MHC. MHC class I molecules present degradation products
derived from intracellular (endogenous) proteins in the cytosol. MHC class II molecules
present fragments derived from extracellular (exogenous) proteins that are located in an
intracellular compartment. Dendritic cells are antigen-presenting cells with a unique
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ability to cross prime T cells and generate strong anti-tumor responses. Reichert et al.
reported that dendritic cell infiltrates were low in 20% of OSCC specimens, intermediate
in 42% of OSCC specimens, and high in 37% of OSCC specimens (189). The
upregulation of this pathway only in the HN cell line may suggest that the immune
system reacts against OSCC in advanced stages of the tumor.
The focal adhesion pathway serves as the mechanical linkage to the ECM, and as a
biochemical signalling hub to concentrate and direct numerous signaling proteins at sites
of integrin binding and clustering. The activation of this pathway may cause metastasis
by OSCC (23). Integrins are cell surface receptors that mediate the adhesion of cells to
the extracellular matrix. They are essential for tissue organization and survival. They
allow normal, nontransformed cells to sense that they are adhered to the extracellular
matrix, thus providing a cell survival signal. Focal adhesion kinase (FAK) becomes
phosphorylated and activated during integrin-mediated cell adhesion. Focal adhesion
kinase is a signal transducer of integrins. Enhanced expression of focal adhesion kinase
in oral carcinoma cells may cause growth and increased invasive potential of the primary
oral tumor (190). High expression of this pathway may be associated with distant
metastasis of OSCC.
The cell cycle pathway is the series of events in a eukaryotic cell between one cell
division and the next. The cell cycle consists of four distinct phases:G1 phase, S phase, G2
phase (collectively known as interphase) and M phase. M phase is itself composed of two
tightly coupled processes: mitosis, in which the cell's chromosomes are divided between
the two daughter cells, and cytokinesis, in which the cell's cytoplasm physically divides.
Cells that have temporarily or reversibly stopped dividing are said to have entered a state
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of quiescence called G0 phase. Some cells may permanently stop dividing due to age or
accumulated DNA damage. Some cell types in mature organisms, such as parenchymal
cells of the liver and kidney, enter the G0 phase semi-permanently and can only be
induced to begin dividing again under very specific circumstances; other types, such as
epithelial cells, continue to divide throughout an organism's life. The G1 phase is a period
in the cell cycle during interphase, before mitosis, cytokinesis and the S phase. For many
cells, this phase is the major period of cell growth during its lifespan. During this stage
new organelles are being synthesized, so the cell requires both structural proteins and
enzymes, resulting in great amounts of protein synthesis. The metabolic rate of the cell is
high. The S phase, designated by DNA synthesis, is a period in the cell cycle during
interphase, between G1 phase and the G2 phase. Following G1, the cell enters the S stage,
when DNA synthesis or replication occurs. At the beginning of the S stage, each
chromosome is composed of one coiled DNA double helix molecule, which is called a
chromatid. At the end of this stage, each chromosome has two identical DNA double
helix molecules, and therefore is composed of two sister chromatids. During the S phase,
the centrosome is also duplicated. Damage to DNA often occurs during this phase. DNA
repair is initiated following the completion of replication. The G2 phase is the third, final,
and usually the shortest subphase during interphase within the cell cycle. It follows
successful completion of DNA synthesis and chromosomal replication during the S
phase. The G2 phase prepares the cell for mitosis (M phase) which is initiated by
prophase. The G2 checkpoint determines if the cell can proceed to the M phase and
divide. The G2 checkpoint prevents cells from entering mitosis with DNA damage since
the last division, providing an opportunity for DNA repair and stopping the proliferation
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of damaged cells. Because the G2 checkpoint helps to maintain genomic stability, it is an
important focus in understanding the molecular causes of cancer. Mitosis (M phase) is the
process by which a cell separates its duplicated genome into two identical halves. It is
generally followed immediately by cytokinesis which divides the cytoplasm and cell
membrane. This results in two identical daughter cells with a roughly equal distribution
of organelles and other cellular components. Mitosis and cytokinesis together is defined
as the M phase of the cell cycle, the division of the mother cell into two daughter cells,
each the genetic equivalent of the parent cell. There are two key classes of regulatory
molecules that determine a cell's progress through the cell cycle: cyclins and cyclindependent kinases (191). The cyclin family members interact with CDKs, and these
complexes are required to pass through specific phases of the cell cycle. D-type cyclins
interact with CDK4 and CDK6 and are necessary for G0/G1 transition. Cyclin E binds to
CDK2 and mediates S phase entry. The cyclin A/CDK2 complex regulates passage
through the S-phase. Later, in conjunction with CDC 2, cyclin A also induces the G2
phase of the cell cycle. Cyclin B1 and CDC2 trigger the molecular events associated with
mitosis (192). Cell cycle pathway upregulation is common in cancers with high
metastatic rates. Cellular proliferation depends on the rates of both cell division and cell
death. All tumors have decreased cell death and increased cell proliferation. Genetic
changes may cause the loss of apoptosis. This change is a major component of
tumorigenesis. Many of the gene products that appear to control apoptotic tendencies are
regulators of cell cycle progression; thus, cell cycle control and cell death appear to be
tightly linked processes. p53 protein is an example of a gene product which affects both
cell cycle progression and apoptosis. The ability of p53 overexpression to induce
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apoptosis may be a major reason why tumor cells frequently disable p53 during the
transformation process. Unfortunately, the same genetic changes which cause loss of
apoptosis during tumor development, may also result in tumor cell resistance to antineoplastic therapies which kill tumor cells by apoptosis (46, 58, 68). The upregulation of
both cyclins and cyclin-dependent kinase genes were observed in the HN cell line.
Cyclins and cyclin-dependent kinases could be another two groups of genes that are
responsible for metastasis of OSCC.
Calcium signaling pathway is another activated pathway in the HN cell line. It has
been shown that prostate cancer frequently metastasizes to bone. Elevated extracellular
Ca+2 can enhance proliferation of skeletal metastases (193). Increased Ca+2 signaling
pathway plays an important role in cancer progression and metastasis (194).
The axon guidance pathway is an important process in the development of the
nervous system. It was shown that semaphorin 4D (Sema4D) protein, which is
responsible in the development of the central nervous system and regulates axonal
growth, is highly expressed in cell lines derived from head and neck squamous cell
carcinomas. Sema4D stimulates endothelial cell migration and angiogenesis (195). A
similar pattern was observed in malignant cells from prostate, colon, breast, and lung
cancer tissues (196, 197). Axon guidance was highly upregulated only in the HN cell
line. This suggests that upregulation of this pathway may occur in advance stages of
OSCC and may have a role in metastasis of OSCC.
Based on the downregulated genes in the HN cell lines there were 9 downregulated
pathways (p<0.05) (Figure 45). These pathways were Hedgehog signaling pathway,
circadian rhythm, olfactory transduction, Wnt signaling pathway, notch signaling
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pathway, ECM receptor interaction, insulin signaling pathway, taste transduction, and
amyotrophic lateral sclerosis.
The hedgehog signaling pathway was a downregulated pathway in this cell line.
The Wnt and hedgehog signaling pathways have long been known to direct growth and
patterning during embryonic development. There are some studies that show the
activation of the hedgehog signaling pathway in various types of malignancies, however,
it remains unclear whether this pathway is activated in all cancer types (179). This
pathway was upregulated in the BHY cell line whereas it was downregulated in the HN
cell line. Thus, this pathway may be involved in bone invasion but not metastasis.
Circadian rhythm is a roughly-24-hour cycle in the physiological processes of living
beings. Jones et al. reported the expression of per-1, which is a circadian rhythm gene, in
oral dysplasias and OSCC for the first time (198). There was significantly reduced
expression of per-1 protein in OSCC compared to normal epithelial controls and
dysplasias based on Jones et al. study (198). Downregulation of this pathway in the HN
cell line was also a result of this study. Thus, circadian rhythm may play a role in oral
carcinogenesis. Circadian rhythm is a changeable process during the day. It was proven
that there is a statistically significant variation in the nuclear expression of all of normal
oral epithelial cell cycle associated proteins during a day. The time of day for maximum
p53 expression for normal epithelial cell (late G1 phase) is in the morning. This is
followed 4 hours later by maximum cyclin E expression (G1/S phase), and 5 hours later
by maximum cyclin A expression (G2 phase), whereas the maximum expression for
cyclin B1 (M phase) is 10 hours later in the evening. The importance of this information
for cancer treatment is the timing of chemotherapy. Several chemotherapic drugs have
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cell cycle phase dependent effects. The greatest radiosensitivity for cells is in G2 and M
phases, which occurs in the late afternoon/evening. Thus, the timing of chemotherapy
and radiotherapy during the day might be important in terms of the effectiveness of the
treatment (199).
Wnt signaling pathway proteins form a family of highly conserved secreted
signaling molecules that regulate cell-to-cell interactions during embryogenesis.
Leethanakul et al. found that most head and neck SCC overexpress members of the Wnt
and notch growth and differentiation regulatory system (200). However, Yeh et al.
concluded that Wnt pathway related genes play a very limited role in the development of
OSCC (201). Deregulation of the Wnt pathway has been shown to occur by several
different mutational mechanisms in human cancers (202).
The notch signaling pathway is a gene regulatory pathway involved in multiple
differentiation processes. The notch protein sits like a trigger penetrating the cell
membrane, with part of it inside and part outside. Proteins when binding to the exterior
part cause the release of a portion of the interior part, which then makes its way to the
cell nucleus to alter gene expression. This pathway is a highly conserved pathway for
cell-cell communication. It is involved in the regulation of cellular differentiation,
proliferation, and specification. According to a study MAPK in head and neck SCC cells
triggered notch signaling activation in neighboring endothelial cells and promotes
angiogenesis (203). The Wnt, TGF-beta, BMP, Notch, and Par polarity pathways are the
major players in homeostatic control of the adult epithelium. Several hereditary cancer
syndromes deregulate these same signaling cascades through mutation. It was shown that
JAGGED1, a NOTCH receptor ligand, is significantly more highly expressed in
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metastatic prostate cancer as compared with localized prostate cancer or benign prostatic
tissues (204). However this pathway was downregulated in the HN cell line based on the
cDNA microarray analysis performed in this study.
ECM receptor interaction was another downregulated pathway in the HN cell line.
As explained previously in the BHY cell line, ECM receptor interaction has a role in
integrins and growth factors signaling process and was downregulated in all three OSCC
cell lines. No correlations have been found between the formation of OSCC and other
downregulated pathways, including insulin signaling pathway, taste transduction, and
amyotrophic lateral sclerosis, in the HN cell line.
5.3.3.3. HSC-3 cell line
The 3 upregulated pathways in the HSC-3 cell line (p<0.05) (Figure 47), were
regulation of actin cytoskeleton, MAPK signaling pathway, and Toll like receptor
signaling pathway, and were closely related with the invasion and metastatic potential of
the cancer. The MAPK signaling pathway and regulation of actin cytoskeleton pathway
was not only upregulated in HSC-3 cell line but also in BHY and HN cell lines as
described previously. This may mean that the MAPK signaling pathway and regulation of
actin cytoskeleton pathway are the major pathways related to OSCC invasion and
metastasis. Toll like receptor signaling pathway was the only pathway that was only
upregulated in HSC-3 cell line. This pathway is a novel pathway that engages the
apoptotic machinery (205). Toll-like receptors recognize many pathogens that are
involved in the induction of anti-cancer immunity. TLR4 signaling, which is a member of
toll-like receptor, is intimately involved in anti-cancer immunity (206).
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Six pathways were downregulated in the HSC-3 cell line (p<0.05) (Figure 48).
These pathways were ECM-receptor interaction, olfactory transduction, taste
transduction, Huntington’s disease, GAP junction and cell adhesion molecules. The
ECM-receptor interaction pathway has a role in integrins and growth factors signaling
process and was downregulated in all three OSCC cell lines. Thus, this pathway could be
a common pathway that downregulates during the invasion and metastatic process of
OSCC.
The gap junction is a junction between certain cell-types that allows different
molecules and ions to pass freely between cells. The junction connects the cytoplasm of
adjacent cells. Cell-cell interaction via gap junctions is a key factor in tissue homeostasis
as they mediate intercellular communication in control of cell growth. Growth rates of
tumor cells are negatively correlated with strength of intercellular communication. Thus,
alteration of the gap junction may cause pathology (207). Downregulation of this
pathway may cause tumor cells to move freely and penetrate into lymph vessels, thus
causing lymph node metastasis.
Cell adhesion molecules are proteins located on the cell surface involved with the
binding with other cells or with the ECM. These molecules have a role in cell division,
migration, and differentiation. The expression of cell adhesion molecules is normally
tightly regulated, thereby controlling cell proliferation, mobility, differentiation, and
survival. Many of these processes are misregulated in malignant tumors, and it has been
shown that many of the characteristics of tumor cells are attributable to the abnormal
expression or function of cell adhesion molecules (208). Like the Gap junction pathway
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inhibition, the inhibition of the cell adhesion molecules might help tumor cells to
metastasize to lymph nodes.
No correlation between OSCC and olfactory transduction, taste transduction, and
Huntington’s disease pathway whatsoever has been found in the literature. Interestingly
olfactory and taste transductions were downregulated in all the three OSCC cell lines.
5.3.4. Real Time PCR analysis
Real Time PCR analysis helps to determine the quantitative differences in mRNA
expression. This method is the most sensitive method and can discriminate closely related
mRNAs. Thus, this makes the technique an excellent one to confirm the results of cDNA
microarray results. The most upregulated three genes from each cell line were chosen to
run the Real Time PCR. The results of cDNA microarray analysis corelated with Real
Time PCR results (figure 49), which makes the results of cDNA microarray analysis
reliable.

5.4. Recommendations
The results of this study will help to better understand the invasion and metastatic
mechanisms of OSCC, however, further studies need to be performed. Studies that will
focus on the specific pathways that are upregulated and downregulated in these three
OSCC cell lines may be a part of the future studies. Based on the results of this study the
pathways that needs to be focused on are cell cycle, Jak-STAT, regulation of actin
cytoskeleton, MAPK signaling, hedgehog signaling, focal adhesion, Wnt signaling and
notch signaling pathways. The effect of chemotherapeutic drugs on these pathways may
be helpful to make a better drug choice in the clinic.
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This study focused on the gene expression profile of three OSCC cell lines with
different invasion and metastatic capacities. Another study may be performed by
investigating the protein expression profile of these cell lines. Thus, invasion and
metastasis of OSCC can be understood in greater detail and also a better drug target can
be identified. Proteomics might be an excellent means for such a study.
The cDNA microarray technique with laser microdissection can also be used in the
clinic by using patients’ tissue samples. Instead of using cell lines, by using tissue
samples more accurete gene expression profile of OSCC can be determined. Also, a gene
data bank can be formed which may assist in determining a better target gene to treat the
OSCC. In addition to this, it may to find a gene for early diagnosis of OSCC. If a gene
data bank can be formed, based be possible on the gene expression profile of each patient
a better assumption can be done about the prognosis of the patients.
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Table 1: Normal and pathological processes involving MMPs (21).
Pathological
1.Tissue Destruction
Rheumatoid arthritis
Osteoarthritis
Cancer invasion
Cancer metastasis
Ulcer
Periodontal diseases

Normal
1.Development
•Blastocyst implantation
•Embryonic development
•Nerve growth
•Bone growth
•Enamel maturation
•Primary tooth root resorption

2.Fibrotic Diseases
Liver cirrhosis
Fibrotic lung diseases
Otosclerosis
Atherosclerosis
Multiple sclerosis

2.Reproduction
•Endometrial cycling
•Graafian follicle rupture
•Cervical dilatation
•Postpartum uterine involution
•Mammary gland morphogenesis
•Mammary gland involution
•Rupture of fetal membrane

3.Weakening of Matrix
Dilated cardiomyopathy
Epidermolysis bullosa
Aortic aneurysm

3.Maintenance
•Remodeling of bone
•Hair follicle cycle
•Wound healing
•Angiogenesis
•Apoptosis
•Macrophage function
•Neutrophil function
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Table 2: Common highly expressed genes in normal oral squamous epithelium (93).
Symbol of gene
GTT1
RPL12
EMP1
CSTB
OCIA
PRKWNK1
BRF1
UBA2
H4FG
ECM1
RPS29
TGM3
KIAA0336
FLJ11090
IK
ATP1B3
LOC55893
FLJ13081
IVL
ATP2A2
FLJ10375
STAG2
PLEC1

Description
GTT1 protein
Ribosomal protein L12
Epithelial membrane protein 1
Cystatin B (stefin B)
Ovarian carcinoma immunoreactive antigen
Protein kinase, lysine deficient 1
Butyrate response factor 1 (EGF-response factor 1)
SUMO-1 activating enzyme subunit 2
H4 histone family, membrane G
Extracellular matrix protein 1
Ribosomal protein S29
Transglutaminase 3 (E polypeptide, protein-glutamine-gammaglutamyltransferase)
K1AA0336 gene product
Hypothetical protein FLJ11090
IK cytokine, down-regulator of HLA II
ATPase, Na+/K+ transporting, beta 3 polypeptide
Papillomavirus regulatory factor PRF-1
Hypothetical protein FLJ 13081
Involucrin
ATPase, Ca++ transporting, cardiac muscle, slow
Hypothetical protein FLJ 10375
Stromal antigen 2
Plectin 1, intermediate filament binding protein
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Table 3: Common highly expressed genes in OSCC (93).
Symbol of gene
RPL37A
ACTB
H3F3A
S100A7
NFE2L2
RPL21
RPS6
GTF2I
HMG1
UCH37
LAMR1
GSTP1
CTNNA1
LOC51142
IL4R
FXYD3
SPRR2A
ANXA5
RPS21
QP-C
RPL4
D6S81E
LEPR

Description
Ribosomal protein L37a
Actin, beta
H3 histone, family 3A
S100 calcium-binding protein A7 (psoriasin 1)
Nuclear factor (erythroid-derived 2)-like 2
Ribosomal protein L21
Ribosomal protein S6
General transcription factor II
High-mobility group (nonhistone chromosomal) protein
Ubiquitin C- terminal hydrolase UCH37
Laminin receptor 1 (67 kD, ribosomal protein SA)
Gluthathione S-transferase pi
Catenin (cadherin-associated protein), alpha1
16.7 Kd protein
Interleukin 4 receptor
FXYD domain-containing ion transport regular 3
Small protein-rich protein 2A
Annexin A5
Ribosomal protein S21
Low molecular mass ubiquinone-binding protein (9.5 kD)
Ribosomal protein L4
HLA-B associated transcript-1
Leptin receptor
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Table 4: 16 genes that are highly upregulated in tongue SCC cases (109).
Gene

Molecular Function

Chromosomal Position

Hypothetical protein
IGHM
SPONI
PKM2

Unknown
Immune system
Extracellular Matrix protein
Catalyses the production of
phosphoenolpyruvate
Immune system
Unknown
Unknown
Unknown
Unknown

Chromosomes 19
14q32.33
11p14-p15.2
15q22

IGKC
KIAA0007
C3orf6
Hypothetical protein
Hypothetical protein
MGC33424
P4HB
CALR
CAPZB
Rabla (RAS oncogene
family)
RALBPI
3ERPINFI

Protein disulphide
isomerase
Calciumstrage, transcription
co-repressor
Actin Binding
RAB small monomeric
GTPase
GTPase activator
Serine protease inhibitor
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2p12
2p23.2
Chromosomes 3
6p22.3
Unknown
17q25
19p13.3-p13.2
1pG6.1
2p14
1sp11.3
17p13.1

Table 5: Upregulated and downregulated gene list of 9 OSCC patients (136).
Upregulated Genes

Downregulated Genes

Category

Gene

Category

Gene

Adhesion
Adhesion
Apoptosis
Apoptosis
Biosynthesis
Cell cycle
Cell cycle
Growth
Growth
Metabolism
Metabolism
Transcription
Transcription
Transcription
Transcription
Transcription
Transcription
Other
Other
Other
Other
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown

CDH3
TGFB1
FADD
LGALS1
C20orf3
DKC1
SH3BP4
PLAU
TGF
BRS3
FLJ13855
EN1
HSF1
HMGB1
MCM4
RFX5
TEAD4
ARPC1B
DSS1
IFI30
NXN
CAV1
FLJ13031
GPCR41
LAPTM4B
LYRIC
MGC2477
MGC45714

Apoptosis
Biosynthesis
Biosynthesis
Biosynthesis
Cell cycle
Metabolism
Metabolism
Metabolism
Metabolism
Metabolism
Transcription
Transcription
Transcription
Other
Other
Other
Unknown
Unknown
Unknown

MAL
IMPDH2
MRPL16
RPL15
DUSP1
ALDH9A1
DPYSL2
H11
MGLL
PAM
FOS
NOTCH1
SF1
GPX3
IK
VAV3
GLTSCR2
LLGL2
TXNIP
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Table 6: Common upregulated genes in head and neck SCC (111).
Upregulated genes name

Symbol

Cadherin 11, type 2, OB-cadherin (osteoblast)
Cathepsin L
Chemokine (C-X-C motif) ligand 10
Chemokine (C-X-C motif) ligand 1 (melanoma growthstimulating activity, alpha)
Collagen, type I, alpha 1
Collagen, type IV, alpha 1
Collagen, type IV, alpha 2
Collagen, type V, alpha 2
Fibronectin 1
Integrin, alpha 6
Integrin, beta 4
Interferon, alpha-inducible protein (clone IFI-6-16)
Interleukin-6 (interferon, beta 2)
Interleukin-8
Matrix metalloproteinase 1 (interstitial collagenase)
Matrix metalloproteinase 3 (stromelysin 1, progelatinase)
Matrix metalloproteinase 10 (stromelysin 2)
Matrix metalloproteinase 12 (macrophage elastase)
Microfibrillar-associated protein 2
Parathyroid hormone-like hormone
Periostin, osteoblast-specific factor
Profilin 2
ras homolog gene family, member C
Runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene)
Secreted phosphoprotein 1 (osteopontin, bone sialoproteinI, early T-lymphocyte
activation 1)
Secreted protein, acidic, cysteine rich (osteonectin)
Serine (or cysteine) proteinase inhibitor, clade E, member 1
Superoxide dismutase 2, mitochondrial
Tenascin C (hexabrachion)
Thrombospondin 2
Transforming growth factor, beta-induced, 68 kD
Trophoblast glycoprotein

CDH11
CTSL
CXCL10
CXCL1
COL1A1
COL4A1
COL4A2
COL5A2
FN1
ITGA6
ITGB4
G1P3
IL6
IL8
MMP1
MMP3
MMP10
MMP12
MFAB2
PTHLH
POSTN
PFN2
RHOC
RUNX1
SPP1
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SPARC
SERPINE1
SOD2
TNC
THBS2
TGFBI
TPBG

Table 7: Common down regulated genes in head and neck SCC (111).
Downregulated genes name

Symbol

Absent in melanoma 1
Actin binding LIM protein 1
Aldehyde dehydrogenase 9 family, member A1
Annexin A1
BENE protein
Carcinoembryonic antigen-related cell adhesion molecule 1
Clusterin
Creatine kinase, mitochondrial 1 (ubiquitous)
Cyclin G2
Cystatin B
Deoxyribonuclease I-like 3
Dual specificity phosphatase 5
Envoplakin
Epithelial membrane protein 1
ECM protein 1
Hydroxyprostaglandin dehydrogenase 15-(NAD)
Interleukin-1 receptor antagonist
Keratin 13
Keratin 15
Keratin 4
KIAA0089 protein (GPD1L: glycerol-3-phosphate dehydrogenase 1-like)
Mal, T-cell differentiation protein
Monoamine oxidase B
Monoglyceride lipase
Neuromedin U
Paired-like homeodomain transcription factor 1
Periplakin
Sciellin
Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1
Serine protease inhibitor, Kazal type 5
Tetranectin (plasminogen binding protein)
Transglutaminase 3 (E polypeptide, protein-glutaminegammaglutamyltransferase)
Zinc finger protein 185 (LIM domain)

AIM1
ABLIM1
ALDH9A1
ANXA1
BENE
CEACAM1
CLU
CKMT1
CCNG2
CSTB
DNASE1L3
DUSP5
EVPL
EMP1
ECM1
HPGD
IL1RN
KRT13
KRT15
KRT4
GPD1L
MAL
MAOB
MGLL
NMU
PITX1
PPL
SCEL
SERPINB1
SPINK5
TNA
TGM3
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ZNF185

Table 8: List of genes with conflicting expression data in head and neck SCC (111).
Genes with conflicting expression data
Carcinoembryonic antigen-related cell adhesion molecule 5
Collagen, type I, alpha 2
Cystatin A (stefin A)
Dual specificity phosphatase 6
FAT tumor suppressor homolog 1
Fibroblast activation protein, alpha
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
receptor)
Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen
CD29 includes MDF2, MSK12)
Keratin 16 (focal nonepidermolytic palmoplantar keratoderma)
Keratin 17
Laminin, alpha 3
Laminin, beta 3
Laminin, gamma 2
Lumican
Plasminogen activator, urokinase
Tumor necrosis factor, alpha-induced protein 3
TYRO3 protein tyrosine kinase
v-fos FBJ murine osteosarcoma viral oncogene homolog
v-myc myelocytomatosis viral oncogene homolog (avian)
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Number
of
studies
5 down,
1 up
9 down,
1 up
6 down,
1 up
4 down,
1 up
6 down,
1 up
4 down,
1 up
5 down,
1 up
4 down,
1 up
4 down,
2 up
5 down,
2 up
4 down,
2 up
5 down,
1 up
6 down,
1 up
4 down,
1 up
10down,
1 up
5 down,
1 up
4down,
1 up
3 down,
2 up
4 down,
1 up

Symbols
CEACAM5
COL1A2
CSTA
DUSP6
FAT
FAP
ITGA3
ITGB1
KRT16
KRT17
LAMA3
LAMB3
LAMC2
LUM
PLAU
TNFAIP3
TYRO3
FOS
MYC

Table 9: Ontology of altered genes in head and neck Carcinoma (111).
Ontology
Extracellular matrix

Number
of genes
identified
22

Cell adhesion

20

Integral to
membrane

16

Epidermal
development/differe
ntiation
Signal transduction

12

Ca2+ binding

10

Cytoskeleton

10

Cell growth and
proliferation
Inflammation

9
9

Zn2+ binding

9

Cell
motility/chemotaxis
Proteolysis
Basement membrane
DNA binding
Skeletal
development
Transcriptional
regulation
Redox activity

8

11

Genes
COL1A1, COL1A2, COL4A1, COL4A2, COL5A2, ECM1,
FN1, LAMA3, LAMB3, LAMC2, LUM, MFAP2,
MMP1, MMP3, MMP10, MMP12, POSTN, SPARC, SPP1,
TGFB1, THBS2, TNC
CDH11, CEACAM1, CEACAM5, FAT, FN1, IL8, ITGA3,
ITGA6, ITGB1, ITGB4, LAMA3, LAMB3, LAMC2,
POSTN, SPP1, TGFB1, THBS2, TNC, TPBG, TYRO3
BENE, CDH11, CEACAM1, CEACAM5, EMP1, FAP,
FAT, G1P3, ITGA3, ITGA6, ITGB1, ITGB4, MAL,
MAOB, TPBG, TYRO3
COL1A1, EMP1, EVPL, KRT13, KRT15, KRT16, KRT17,
LAMA3, LAMB3, LAMC2, PTHLH, SCEL, TGM3

7
6
6
6

ANXA1, CXCL1, CXCL10, IL6, IL8, LAMA3, MAL,
NMU, PLAU, RHOC, TYRO3
ANXA1, CDH11, DNASE1L3, FAT, MMP1, MMP3,
MMP12, SPARC, TGM3, THBS2
ABLIM1, CXCL1, EVPL, KRT4, KRT13, KRT15, KRT16,
KRT17, PFN2, PPL
CXCL1, CXCL10, EMP1, IL6, IL8, KRT16, MYC, PTHLH,
TGFB1
ANXA1, CXCL1, CXCL10, FOS, IL1RN, IL8, MGLL,
SPINK5, SPP1
ABLIM1, MMP1, MMP3, MMP10, MMP12, RUNX1,
SCEL, TNFAIP3, ZNF185
ANXA1, CXCL1, CXCL10, IL8, MMP12, PLAU, SPP1,
TPBG
CTSL, FAP, MMP1, MMP3, MMP10, MMP12, PLAU
COL4A1, COL4A2, LAMA3, LAMB3, LAMC2, SPARC
DNASE1L3, FOS, MYC, PITX1, RUNX1, TNFAIP3
CDH11, COL1A1, COL1A2, PITX1, POSTN, TNA

6

FOS, MYC, PITX1, RUNX1, SOD2, TNFAIP3

5

ALDH9A1, GPD1L, HPGD, MAOB, SOD2
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Table 10: List of proteins with increased and decreased expressions in OSCC (131).
Proteins with increased expression

Proteins with decreased expression

1- Cofilin
2- C-reactive protein
3- Creatine kinase, M-chain
4- Cytokeratin 6B
5- Fatty acid-binding protein
6- Galectin-7
7- Glutathione-S-transferase
8- HSP27
9- Keratin type II
10- NME1
11- Phosphoglucerate mutase 1
12- Pyruvate kinase M1
13- Retinoic acid-binding protein II
14- SCCA-1

123456-

Annexin 1 (ANXA1)
Heat shock 20 kDa like protein p20
Myosin light chain 1
Myosin light chain 2
Myosin light chain 3
Plakoglobin

Table 11: The expression levels of proteolytic enzymes by using immunocytochemistry.
OSCC Cell Lines
Proteolytic Enzymes

BHY

HN

HSC-3

MMP-1
MMP-2
MMP-3
MMP-9
EMMPRIN
Cathepsin B
Cathepsin L

+++
+++
+++
+++
++++
++++
+++

+++
++++
+++
++
+++
++++
+++

+++
++++
++++
+++
++++
++++

(-) Shows the same intensity in tumor cells as normal epithelium cells; (+) less than 10%
stronger intensity in tumor cells than normal epithelium cells; (++) between 10% to 50%
stronger intensity in tumor cells than normal epithelium cells; (+++) between 50% to
90% stronger intensity in tumor cells than normal epithelium cells; (++++) more than
90% stronger intensity in tumor cells than normal epithelium cells.
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Table 12: The expression levels of proteolytic enzymes in three different OSCC cell lines
by using flow cytometry.

OSCC Cell Lines
Proteolytic Enzymes

HNEC

BHY

HN

HSC-3

MMP-1
MMP-2
MMP-3
MMP-9
EMMPRIN
(-) Control (No staining)

97% +
98.8% +
98.4% +
0.5 % +
70.1% +
99.9% -

99.8% +
99.1% +
99.9% +
33.3% +
85.8% +
95.3% -

99.9% +
99.6% +
99.8% +
18.6% +
67.5% +
98.1% -

99.9% +
99.9% +
99.9% +
0.05% +
73.4% +
99.8% -
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Table 13: 139 upregulated genes in BHY cell line. The gene list is from the most
upregulated gene to least upregulated gene.
Average
Name of the upregulated gene value of
Count of
in BHY cell line
CV
slides
Ratio
4 slides STD
H300004818_MAGEA9
2.9835 0.740776 0.248291
4 7.909026
H200001373_Q96AL8_HUMAN 2.9755 0.472755 0.158883
4 7.86529
H200005842_GFI1
2.75875 0.799114 0.289665
4 6.768096
opHsV0400005829_OAS1
2.6725 0.637914 0.238695
4 6.37533
H200007111_NP_689700.1
2.60575 0.633773 0.243221
4 6.087079
H200005801_MAGEA1
2.55525 0.884437 0.346125
4 5.877693
opHsV0400002611_PRAME
2.5525 0.286732 0.112334
4 5.8665
opHsV0400006088_NOV
2.5515 1.062371 0.416371
4 5.862435
H200011702_HOXA10
2.54125 0.590219 0.232255
4 5.820931
H200012712_BIRC3
2.3735 0.457046 0.192562
4 5.181968
H200004378_MAGEA8
2.36275 1.281263 0.542276
4 5.143499
H200000112_DLX2
2.354 0.63516 0.269822
4 5.112397
H200003290_DEPDC1B
2.3485 0.45264 0.192736
4 5.092945
H200000421_DPYD
2.30175 0.37118 0.16126
4 4.930555
H200000404_IRK2_HUMAN
2.298 0.313003 0.136207
4 4.917755
opHsV0400006060_
2.2975 0.500092 0.217668
4 4.916051
H200011805_NMES1_HUMAN
2.2625 0.600718 0.265511
4 4.798222
H300010220_ID2
2.253 0.213936 0.094956
4 4.76673
H200005149_NP_116262.2
2.2435 0.25993 0.115859
4 4.735445
H200006112_NP_006811.1
2.21625 0.780182 0.352028
4 4.64684
opHsV0400002553_MAGEA11 2.20675 0.859448 0.389463
4 4.616342
H200010620_IL6
2.1545 0.45013 0.208925
4 4.452143
H200013568_COL5A1
2.13175 0.640914 0.300651
4 4.382488
H200015644_GDA
2.114 0.824693 0.39011
4 4.328899
opHsV0400011773_
2.09725 0.642212 0.306216
4 4.27893
H200008768_FGF2
2.096 0.885641 0.422539
4 4.275224
opHsV0400000818_IL8
2.09075 0.32249 0.154246
4 4.259695
opHsV0400008521_
2.0825 0.909608 0.436787
4 4.235405
H300018275_NP_620711.2
2.07625 0.734066 0.353554
4 4.217096
H200004597_XM_374020.2
2.0475 0.611487 0.298651
4 4.13389
opHsV0400006084_MAGEB2
2.033 0.494992 0.243478
4 4.09255
H300009117_OSR2
2.01225 0.586449 0.291439
4 4.034109
H200008845_STMN3
2.0065 0.517001 0.257663
4 4.018062
H200011948_EREG
2.0015 0.586814 0.293187
4 4.004161
opHsV0400006083_MAGEA4
1.9765 0.681241 0.344671
4 3.935372
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Table 13 continued
Average
Count of
Name of the upregulated gene in value of
BHY cell line
slides
4 slides STD
CV
Ratio
H200010289_C6orf139
1.97175 0.330586 0.167661
4 3.922436
H300000884_
1.96425 0.607126 0.309088
4 3.902098
H300006722_NP_003513.1
1.96325 0.456425 0.232484
4 3.899394
H300021964_SLCO1B3
1.93075 0.370317 0.1918
4 3.812533
H200005669_LY96
1.922 0.493631 0.256832
4 3.78948
H200012463_MAGEC2
1.917 0.726043 0.378739
4 3.77637
H300006646_ZNF326
1.90925 0.249361 0.130607
4 3.756138
H200000708_MMP13
1.908 0.726138 0.380576
4 3.752885
H200006097_ID1
1.901 0.40408 0.212562
4 3.73472
H200002977_NP_065726.1
1.88775 0.296147 0.156878
4 3.700576
H300020557_GLMN
1.88725 0.507303 0.268805
4 3.699294
opHsV0400007188_
1.8805 1.083741 0.576304
4 3.682026
H200016568_CLDN14
1.8765 0.718913 0.383114
4 3.671832
H300008891_IFIT1
1.8465 0.7824 0.423721
4 3.596267
H200011533_KLF2
1.846 0.510175 0.276368
4 3.595021
H200006581_XK
1.84475 0.958007 0.519315
4 3.591907
H200017806_TDRD7
1.8415 0.569578 0.309301
4 3.583825
H200003668_HERC5
1.83375 0.526164 0.286933
4 3.564624
H300006703_LY6K
1.8335 0.639148 0.348595
4 3.564007
H300009194_ABHD7
1.8225 0.878164 0.481846
4 3.536936
H300002344_NP_777601.2
1.8175 0.603638 0.332126
4 3.524699
opHsV0400003040_LCK
1.81625 1.093485 0.602056
4 3.521646
H300018519_IRF7
1.7895 0.259885 0.145228
4 3.456951
H300015308_
1.786 0.648679 0.363202
4 3.448574
H300009179_MAGEA9
1.77325 0.761064 0.429192
4 3.418231
H200005573_CALB1
1.765 1.087427 0.616106
4 3.39874
opHsV0400008078_
1.7645 0.641701 0.363673
4 3.397562
H200006891_NR4A2
1.73525 0.893226 0.514754
4 3.329372
H200004856_BAL_HUMAN
1.732 0.407424 0.235233
4 3.32188
opHsV0400011488_
1.729 0.991203 0.573281
4 3.31498
H200005324_FYB
1.72525 0.471569 0.273334
4 3.306374
H200001951_LAMP3
1.7175 0.474952 0.276537
4 3.28866
H200007266_LHX1
1.7165 0.637868 0.371609
4 3.286382
opHsV0400001371_PTE2B_HUMAN 1.7125 0.549354 0.320791
4 3.277282
H200002223_TXNRD1
1.70925 0.277703 0.162471
4 3.269908
H200014971_HELLS
1.70325 0.459937 0.270035
4 3.256337
H200006072_RRM2
1.70275 0.284603 0.167143
4 3.255209
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Table 13 continued
Average
Count of
Name of the upregulated gene in value of
BHY cell line
slides
4 slides STD
CV
Ratio
H200005594_CC14A_HUMAN
1.7 0.761705 0.448062
4 3.24901
H300013260_DPYD
1.7 0.677127 0.39831
4 3.24901
H300015190_BIRC3
1.6985 1.104304 0.650165
4 3.245633
H200004706_FOXF2
1.6945 0.947529 0.559179
4 3.236647
H200006824_FZD2
1.6905 0.503315 0.297731
4 3.227685
opHsV0400007038_
1.68775 0.459065 0.271998
4 3.221539
H200008051_ANKRD10
1.68475 0.396982 0.235633
4 3.214847
H300019089_NP_060408.2
1.68 0.448588 0.267017
4 3.20428
opHsV0400003583_BRI3BP
1.67925 0.488002 0.290607
4 3.202614
H300007499_HRASLS3
1.66875 0.61295 0.367311
4 3.17939
H200017104_NP_001007528.1
1.6475 0.402604 0.244372
4 3.132903
H300000210_IFIT2
1.64375 0.614255 0.373691
4 3.12477
opHsV0400002734_NP_848664.1
1.641 0.426324 0.259795
4 3.118819
opHsV0400003034_KLK10
1.63875 0.462452 0.282198
4 3.113959
H200013657_NP_076942.1
1.634 0.45373 0.277681
4 3.103723
H200015606_IL7R
1.62775 0.323239 0.19858
4 3.090307
H200020534_TRIM6
1.61625 0.286686 0.177377
4 3.065771
opHsV0400010212_
1.61425 0.797001 0.493728
4 3.061524
H200017773_GTPBP1
1.6135 0.556646 0.344993
4 3.059933
H300013986_PSG10
1.613 0.520234 0.322525
3 3.058873
H300018167_AMID
1.6125 0.512751 0.317985
4 3.057813
H300021783_NP_149081.1
1.60925 0.356157 0.221318
4 3.050932
H200005813_IL7
1.59975 0.409299 0.255852
4 3.030908
opHsV0400003905_IL7R
1.597 0.760413 0.476151
4 3.025136
H200004431_MLF1IP
1.58425 0.551219 0.347937
4 2.998519
opHsV0400000049_XP_291989.3
1.58175 0.30548 0.193128
4 2.993327
H200007026_GBG11_HUMAN
1.579 0.385193 0.243948
4 2.987627
H200000576_MMP10
1.578 0.272033 0.172391
4 2.985557
opHsV0400013002_
1.57575 0.443983 0.28176
4 2.980904
H300018946_DR1
1.56675 0.381593 0.243557
4 2.962366
H300022249_GP110_HUMAN
1.56 0.391751 0.251122
4 2.948538
H200007011_MMP1
1.534 0.649902 0.423665
4 2.895876
opHsV0400010717_
1.53275 0.676085 0.441093
4 2.893368
opHsV0400007760_
1.532 0.597638 0.390103
4 2.891865
H200013536_C20orf29
1.521 0.718596 0.47245
4 2.869899
H200013521_DDX58
1.513 0.858988 0.567738
4 2.854029
H200007019_MMP3
1.5075 0.368524 0.24446
4 2.843169
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Table 13 continued
Average
Count of
Name of the upregulated gene in value of
BHY cell line
slides
4 slides STD
CV
Ratio
H300001749_AQP11
1.50725 0.380475 0.25243
4 2.842677
H300016431_CT022_HUMAN
1.504 0.343714 0.228533
4 2.83628
H300009288_NP_653185.1
1.5 0.611704 0.407803
4 2.828427
H300002737_GBP4
1.497 0.772955 0.516336
4 2.822552
H200020305_PARP10
1.492 0.318087 0.213195
4 2.812786
opHsV0400005063_
1.49025 0.467101 0.313438
4 2.809377
opHsV0400005091_ACYP1
1.489 0.505898 0.339757
4 2.806943
H200008827_NP_982274.1
1.48725 0.498681 0.335304
4 2.803541
H200005110_SULT1E1
1.4835 1.056875 0.71242
4 2.796263
H300007730_MAGEA6
1.48175 0.313321 0.211454
4 2.792873
H300008499_IRF1
1.4795 0.368059 0.248773
4 2.788521
H300015276_Q96H22_HUMAN
1.4765 0.432985 0.293251
4 2.782728
H200004209_RAMP1
1.4745 0.362929 0.246137
4 2.778873
H200006368_OCTN1_HUMAN
1.47375 0.659172 0.447275
4 2.777429
H300018045_PRIM1
1.47375 0.120801 0.081969
4 2.777429
opHsV0400009665_
1.4735 0.544974 0.36985
4 2.776948
H300013149_CDKN3
1.46925 0.718136 0.488777
4 2.768779
H300021781_CENPA
1.46525 0.37843 0.25827
4 2.761113
H200003417_RAD51AP1
1.46175 0.479901 0.328306
4 2.754423
H300000747_
1.4615 0.462733 0.316615
4 2.753945
H200005018_GATA6
1.45775 0.375212 0.257391
4 2.746796
opHsV0400008467_
1.453 1.443222 0.99327
3 2.737768
opHsV0400007148_
1.451 0.798016 0.549977
4 2.733975
opHsV0400000522_NP_689663.1
1.4505 0.945205 0.651641
4 2.733028
H200011351_AIM2
1.44825 0.49706 0.343214
4 2.728768
H300008871_NP_001008708.1
1.447 0.398061 0.275094
4 2.726405
H300019216_SPAG1
1.44525 0.81659 0.565016
4 2.7231
H200007081_SLCO2A1
1.44425 1.022917 0.708268
4 2.721213
opHsV0400003953_HIST1H1C
1.43925 0.426934 0.296637
4 2.711799
H200010772_GPR160
1.43425 0.350812 0.244596
4 2.702416
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Table 14: 117 downregulated genes in BHY cell line. The gene list is from the least
downregulated gene to most downregulated gene.
Average
Name of the downregulated gene in value of
Count of
BHY cell line
4 slides STD
CV
slides
Ratio
H300000194_CSPG2
-1.5935 0.414519 -0.26013
4 0.331367
H200001115_ZNF25
-1.60125 1.06914 -0.66769
4 0.329591
opHsV0400000079Q6NZ63_HUMAN -1.60525
1.161 -0.72325
4 0.328679
H200005961_DPYSL3
-1.60625 1.348248 -0.83938
4 0.328451
H300012616_ANPEP
-1.6075 1.109451 -0.69017
4 0.328167
H200005275_KLK11
-1.60875 0.747015 -0.46434
4 0.327882
H200002000_RHBDL2
-1.60875 0.80247 -0.49882
4 0.327882
H300013882_AES
-1.6105 0.222317 -0.13804
4 0.327485
H300017884_SLC37A2
-1.6105 0.830395 -0.51561
4 0.327485
H300000561_CBS
-1.611 0.79006 -0.49042
4 0.327371
opHsV0400003752_
-1.61333 1.595829 -0.98915
3 0.326842
opHsV0400008056_
-1.61425 1.405615 -0.87075
4 0.326635
H300009655_
-1.62125 0.757105 -0.46699
4 0.325054
H200019593_ZNF626
-1.62825 1.358063 -0.83406
4 0.32348
H300002980_
-1.63125 0.475368 -0.29141
4 0.322808
H300005674_Q8IZ15_HUMAN
-1.63375 0.569106 -0.34834
4 0.322249
opHsV0400012118_
-1.63425 0.388394 -0.23766
4 0.322138
H200017197_HSD11B1
-1.63925 0.945894 -0.57703
4 0.321023
H300013100_SLC4A3
-1.64067 1.063076 -0.64795
3 0.320708
H200012598_LRRN1_HUMAN
-1.64725 1.302948 -0.79098
4 0.319248
H200010619_CNGB1
-1.65375 1.394051 -0.84296
4 0.317813
opHsV0400000628_ARTS1_HUMAN -1.655 1.123805 -0.67904
4 0.317538
opHsV0400010774_
-1.65525 0.921909 -0.55696
4 0.317483
H300006889_XP_059037.4
-1.65725 0.827554 -0.49935
4 0.317043
opHsV0400001923_IDH2
-1.66275 0.145039 -0.08723
4 0.315837
H200003299_SLC16A4
-1.6675 0.557852 -0.33454
4 0.314798
H300018412_MGST1
-1.67525 0.171506 -0.10238
4 0.313112
H200006867_SHC1
-1.67525 0.206479 -0.12325
4 0.313112
H200009585_NP_001007190.1
-1.68125 0.641676 -0.38167
4 0.311812
H200006995_
-1.69275 0.925138 -0.54653
4 0.309337
H200013065_
-1.6945 0.3687 -0.21759
4 0.308962
opHsV0400002007_NM_000407.3
-1.69925 0.446025 -0.26248
4 0.307946
H200004912_GJB6
-1.70075 0.667052 -0.39221
4 0.307626
H200011169_TCF7L1
-1.7025 0.381282 -0.22395
4 0.307253
H200001141_EFEMP2
-1.71625 0.77124 -0.44938
4 0.304339
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Table 14 continued
Average
Count of
Name of the downregulated gene in value of
BHY cell line
slides
4 slides STD
CV
Ratio
H200012556_THY1
-1.718 0.763368 -0.44434
4 0.30397
H200007876_SLC2A1
-1.73925 0.295673
-0.17
4 0.299525
opHsV0400011936_
-1.7445 1.036602 -0.59421
4 0.298437
H200011421_CDKN1C
-1.762 1.210316 -0.6869
4 0.294839
opHsV0400007762_
-1.76267 1.587394 -0.90056
3 0.294703
H200005983_Q6PJ56_HUMAN
-1.7635 0.973849 -0.55223
4 0.294533
H300009738_Q14922_HUMAN
-1.76775 1.295378 -0.73278
4 0.293666
opHsV0400003654_NP_001004313.1 -1.76925 1.763672 -0.99685
4 0.293361
H200015626_RRAGD
-1.78425 1.706914 -0.95666
4 0.290327
H200013543_Q96MI4_HUMAN
-1.7895 1.351199 -0.75507
4 0.289272
H200001865_TNS
-1.79925 1.745972 -0.97039
4 0.287324
opHsV0400002303_NDN
-1.818 0.954687 -0.52513
4 0.283614
opHsV0400002365_PTPRM
-1.82 0.215937 -0.11865
4 0.283221
H200013711_BTEB1_HUMAN
-1.82125 0.492802 -0.27058
4 0.282976
H300008702_ITGB6
-1.8265 0.969306 -0.53069
4 0.281948
H200000104_ADH7
-1.8265 1.742103 -0.95379
4 0.281948
H200008152_ODZ2
-1.8325 0.203169 -0.11087
4 0.280778
H200004216_PLXDC2
-1.84025 0.7515 -0.40837
4 0.279273
H300014602_IL1R1
-1.8415 1.208037 -0.65601
4 0.279032
H200014313_BEXL1
-1.86125 0.515799 -0.27712
4 0.275238
H200015831_THAP2_HUMAN
-1.86175 1.36207 -0.73161
4 0.275142
H200000465_CD1D
-1.862 1.781241 -0.95663
4 0.275095
H200003796_FNDC4
-1.865 0.738472 -0.39596
4 0.274523
H200004211_COBL
-1.871 1.174565 -0.62777
4 0.273384
opHsV0400006329_PALMD
-1.8845 1.320225 -0.70057
4 0.270838
H200009642_ITGAV
-1.88625 0.352733 -0.187
4 0.270509
H200000047_IGFBP2
-1.89925 0.382519 -0.20141
4 0.268083
H200013755_KLK7
-1.90075 0.692081 -0.36411
4 0.267804
H200011925_COL8A1
-1.90625 0.820488 -0.43042
4 0.266785
H200005569_LIPG
-1.90825 0.367554 -0.19261
4 0.266416
opHsV0400005248_FAM46B
-1.91225 0.347777 -0.18187
4 0.265678
H200000073_GALC
-1.913 0.965822 -0.50487
4 0.26554
H300000923_POSTN
-1.91725 0.686764 -0.3582
4 0.264759
opHsV0400012721_
-1.92225 0.923278 -0.48031
4 0.263843
H200005130_
-1.928 1.441162 -0.74749
4 0.262793
H200005198_GALNT5
-1.93175 1.069411 -0.5536
4 0.262111
opHsV0400012479_
-1.941 1.744599 -0.89881
4 0.260436
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Table 14 continued
Average
Count of
Name of the downregulated gene in value of
BHY cell line
slides
4 slides STD
CV
Ratio
H200008006_SEMA3C
-1.948 0.383193 -0.19671
4 0.259175
H200012177_RAB4A
-1.992 0.911509 -0.45758
4 0.25139
opHsV0400006127_TNFRSF6B
-2.00025 0.446626 -0.22329
4 0.249957
H200000491_PRG1
-2.001 0.48489 -0.24232
4 0.249827
opHsV0400006528_
-2.00375 1.463535 -0.7304
4 0.249351
H300003568_CPS1
-2.016 1.306051 -0.64784
4 0.247243
H200004031_NP_945120.1
-2.022 0.617709 -0.30549
4 0.246217
H200001783_PLEA4_HUMAN
-2.061 0.715854 -0.34733
4 0.23965
opHsV0400011552_
-2.0615 0.559359 -0.27134
4 0.239567
H200016573_ADPN
-2.08425 0.67585 -0.32427
4 0.235819
opHsV0400003414_GSPT2
-2.097 1.624817 -0.77483
4 0.233744
H200001094_NP_057702.1
-2.1075 0.738391 -0.35036
4 0.232049
H300021562_FN1
-2.1185 0.873318 -0.41223
4 0.230286
opHsV0400010233_
-2.1275 1.897333 -0.89181
4 0.228854
opHsV0400011241_
-2.13425 1.663044 -0.77922
4 0.227786
H300006196_MAF
-2.13725 0.559296 -0.26169
4 0.227313
H200020242_C9orf26
-2.151 0.471467 -0.21918
4 0.225156
H200013413_LRP3
-2.151 0.63614 -0.29574
4 0.225156
H200011379_NPDC1
-2.17125 0.710231 -0.32711
4 0.222018
H300006645_Q8IYY5_HUMAN
-2.18875 0.303208 -0.13853
4 0.219341
H300010137_CALML3
-2.208 0.427549 -0.19364
4 0.216434
H300006447_MT1K
-2.23625 1.764254 -0.78893
4 0.212237
H200001726_KRT23
-2.26975 0.479364 -0.2112
4 0.207366
H200009653_RAB4A
-2.2805 0.739566 -0.3243
4 0.205826
H300016644_WASPIP
-2.2925 1.087845 -0.47452
4 0.204121
H300018293_SLC38A5
-2.29475 0.431198 -0.18791
4 0.203803
H200001823_ARMCX1
-2.299 0.708874 -0.30834
4 0.203204
H200011330_RKHD3
-2.3195 1.852087 -0.79849
4 0.200337
H300021749_FOLR3
-2.33525 0.541148 -0.23173
4 0.198162
H200001408_SFRP1
-2.35767 0.264814 -0.11232
3 0.195106
H300021145_ANGPTL4
-2.3915 0.448694 -0.18762
4 0.190584
H200016276_ESPN
-2.4205 1.3472 -0.55658
4 0.186791
H300016617_THY1
-2.42475 1.65256 -0.68154
4 0.186242
H200018944_KLF8
-2.425 0.698834 -0.28818
4 0.18621
H200005423_Q9H7B6_HUMAN
-2.43525 1.371003 -0.56298
4 0.184891
H200001686_TM4SF10
-2.5915 1.26025 -0.4863
4 0.165913
H200004832_C3orf14
-2.64375 1.162073 -0.43955
4 0.160012
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Table 14 continued
Average
Count of
Name of the downregulated gene in value of
BHY cell line
4 slides STD
slides
CV
Ratio
H200011635_LXN
-2.689 1.396491 -0.51933
4 0.155071
opHsV0400010653_
-2.73375 1.220994 -0.44664
4 0.150335
H200005947_GJA1
-2.948 0.575297 -0.19515
4 0.129588
H200017869_
-2.99633 2.483282 -0.82877
3 0.125318
H200014307_FADS2
-3.02275 0.370271 -0.12249
4 0.123044
H300017162_Q9H7B6_HUMAN
-3.079 0.937163 -0.30437
4 0.118339
opHsV0400010227_Q96NA9HUMAN -3.3075 0.735836 -0.22248
4 0.101005
H300000043_RGS17
-3.42475 1.15765 -0.33802
4 0.093121
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Table 15: 214 upregulated genes in HN cell line. The gene list is from the most
upregulated gene to least upregulated gene.
Average
Name of the upregulated gene value of
Count of
in HN cell line
CV
slides
Ratio
4 slides STD
H200011805_NMES1_HUMAN 3.61425 0.344629 0.095353
4 12.2461
H200005801_MAGEA1
3.4955 0.938984 0.268627
4 11.27847
H200001373_Q96AL8_HUMAN 3.39425 0.559974 0.164977
4 10.51407
opHsV0400013404_
3.1775 0.278336 0.087596
4 9.04738
H200004165_FSTL5
2.96775 0.964376 0.324952
4 7.823152
opHsV0400005829_OAS1
2.86425 0.337914 0.117976
4 7.281572
H200010620_IL6
2.84925 0.652263 0.228924
4 7.206256
H200010289_C6orf139
2.83925 0.44019 0.155037
4 7.156479
H300005969_COX7B2
2.744 1.244172 0.453416
4 6.699252
opHsV0400002611_PRAME
2.72925 0.998202 0.365742
4 6.631108
H300006342_NP_775969.1
2.69225 0.843384 0.313264
4 6.463206
H200010916_NP_114156.1
2.59475 0.43994 0.16955
4 6.040843
H200012712_BIRC3
2.52475 0.986658 0.390795
4 5.754737
H300006447_MT1K
2.503 0.519416 0.207517
4 5.66863
H200007081_SLCO2A1
2.49425 1.343249 0.538538
4 5.634353
H200002977_NP_065726.1
2.46325 0.945773 0.383953
4 5.514576
H200004279_ID4
2.42325 0.553582 0.228446
4 5.36378
H200008845_STMN3
2.3605 0.871202 0.369075
4 5.135483
H300022894_NP_002116.2
2.34725 0.319804 0.136246
4 5.088534
opHsV0400000818_IL8
2.341 1.005232 0.429403
3 5.066537
H200011575_BSPRY
2.33875 1.31912 0.564028
4 5.058641
H300022533_HLA-J
2.312 0.155681 0.067336
4 4.96571
opHsV0400003040_LCK
2.278 1.654258 0.726189
4 4.850051
H200001951_LAMP3
2.26225 0.660399 0.291921
4 4.797391
H200010376_CYP24A1
2.2595 0.469224 0.207667
4 4.788255
H200017806_TDRD7
2.24575 0.4908 0.218546
4 4.742836
H200015633_SLC16A9
2.2445 0.649934 0.289567
4 4.738728
H300000210_IFIT2
2.2225 0.6966 0.313431
4 4.667015
H200003668_HERC5
2.205 0.464972 0.210872
4 4.610745
H200006478_ACTH_HUMAN
2.1895 0.428789 0.195839
4 4.561474
H300006703_LY6K
2.18225 0.368532 0.168877
4 4.538608
H200006112_NP_006811.1
2.17775 0.582087 0.267288
4 4.524474
H200011702_HOXA10
2.155 1.423344 0.660485
4 4.453686
H200005362_NP_115724.1
2.13875 1.128071 0.527444
4 4.403803
H200000708_MMP13
2.135 1.48257 0.694412
4 4.392371
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Table 15 continued
Average
Count of
Name of the upregulated gene in value of
HN cell line
slides
4 slides STD
CV
Ratio
opHsV0400003753_PLSCR1
2.128 0.567288 0.266583
4 4.371111
opHsV0400006084_MAGEB2
2.12175 1.118117 0.526979
4 4.352216
H300016329_MMP25
2.12 0.43629 0.205797
4 4.346939
H200013521_DDX58
2.1155 0.525671 0.248485
4 4.333402
H200011983_Q9BT26_HUMAN
2.11175 0.947054 0.448469
4 4.322153
H200006368_OCTN1_HUMAN
2.0795 0.933586 0.448947
4 4.226607
H300022436_HLA-DRB3
2.07225 0.396335 0.191258
4 4.20542
opHsV0400012005_
2.06625 1.134699 0.549159
4 4.187967
opHsV0400008956_
2.06575 0.416258 0.201505
4 4.186516
H200006072_RRM2
2.059 0.43027 0.208971
4 4.166974
H200001243_TRHDE_HUMAN
2.05475 1.08619 0.528624
4 4.154716
H300008891_IFIT1
2.05375 0.571091 0.278072
4 4.151838
H300001406_CNN1
2.04075 0.963906 0.472329
4 4.114594
H300001612_PCOLCE2
2.038 0.648625 0.318265
4 4.106758
opHsV0400008211_XM_375042.2
2.02375 1.433107 0.708144
4 4.066394
opHsV0400006097_PTPRR
2.00625 1.242772 0.61945
4 4.017366
H300018045_PRIM1
2.002667 0.267808 0.133726
3 4.0074
H300001976_NMI
1.99775 0.512455 0.256516
4 3.993767
H200014971_HELLS
1.992 0.413372 0.207516
4 3.977881
H300018428_BID
1.981 0.522077 0.263542
4 3.947666
H200011914_CDC45L
1.961 0.197314 0.100619
4 3.893317
H200010772_GPR160
1.95375 1.3282 0.679821
4 3.873801
H200004597_XM_374020.2
1.95175 0.752455 0.385528
4 3.868435
opHsV0400006060_
1.9475 0.915296 0.469985
4 3.857056
H200007582_CXCL6
1.943 0.714921 0.367947
4 3.845044
H300010511_SOD2
1.943 0.611604 0.314773
4 3.845044
opHsV0400003953_HIST1H1C
1.939 0.293976 0.151612
4 3.834398
H200014073_MCM6
1.93275 0.407792 0.210991
4 3.817822
H300010084_FBXO27
1.928 0.424222 0.220032
3 3.805273
H200015506_CDCA1
1.927 0.807785 0.419193
4 3.802636
H300007731_
1.924 0.499857 0.259801
4 3.794737
H300012772_C10orf94
1.91325 1.093819 0.571708
4 3.766566
opHsV0400011941_
1.896 0.817471 0.431156
4 3.721799
opHsV0400012784_
1.8955 0.275088 0.145127
4 3.720509
H300001248_PROM1
1.8955 1.149884 0.606639
4 3.720509
H200005842_GFI1
1.8945 1.099902 0.580576
4 3.717931
H200011351_AIM2
1.887 0.542437 0.28746
4 3.698653
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Table 15 continued
Average
Count of
Name of the upregulated gene in value of
HN cell line
slides
4 slides STD
CV
Ratio
H300006205_S100P
1.88575 0.585973 0.310737
4 3.69545
H200016569_PCDHB2
1.884 0.913877 0.485073
4 3.69097
H200012959_
1.88175 0.65093 0.345918
4 3.685218
H200000046_CDH2
1.877 1.130349 0.60221
4 3.673105
H200004431_MLF1IP
1.86075 0.273527 0.146998
4 3.631964
opHsV0400006094_HHEX
1.85425 0.975674 0.526183
4 3.615637
opHsV0400006196_
1.849333 0.678552 0.366917
3 3.603336
H300009187_PSMB9
1.84125 0.322845 0.17534
4 3.583204
H200004856_BAL_HUMAN
1.83875 0.337235 0.183405
4
3.577
H300001485_HLA-DPA1
1.833 0.716288 0.390773
4 3.562772
opHsV0400003771_HB2K_HUMAN 1.82175 0.347382 0.190686
4 3.535097
H200006657_MEST
1.81925 0.457504 0.251479
4 3.528977
H200015731_CCL5
1.79575 0.493276 0.274691
4 3.471959
H300019551_UGCGL2
1.79525 0.490762 0.273367
4 3.470756
H200006581_XK
1.79175 1.672909 0.933673
4 3.462346
H300009288_NP_653185.1
1.7885 0.303107 0.169475
4 3.454555
H300022475_CRYZL1
1.78575 0.435806 0.244047
4 3.447977
H200010475_PFDN4
1.78425 0.368762 0.206676
4 3.444394
H200018923_SOD2
1.7835 0.363238 0.203666
4 3.442603
H300021066_Q96H22_HUMAN
1.7805 0.407449 0.22884
4 3.435452
H200020305_PARP10
1.78 0.568335 0.319289
4 3.434262
H300002968_SYT14
1.77975 1.597834 0.897786
4 3.433667
H200013760_KIAA1524
1.77825 0.540236 0.303802
4 3.430098
H300018167_AMID
1.777 0.953326 0.53648
4 3.427128
H200010704_CPVL
1.77575 0.52984 0.298376
4 3.42416
H200000491_PRG1
1.76525 0.284848 0.161364
4 3.399329
H300007730_MAGEA6
1.76425 1.020558 0.578466
4 3.396974
H200014902_Q96RF1_HUMAN
1.764 1.100442 0.623833
3 3.396385
H300011169_GPR160
1.75625 1.453927 0.827859
4 3.378189
opHsV0400003583_BRI3BP
1.751 0.992618 0.566887
4 3.365918
H200004874_HS3ST3A1
1.74225 0.75636 0.434128
4 3.345565
H200008652_ICMT
1.73875 0.232372 0.133643
4 3.337459
H200017455_NP_060582.1
1.73075 0.5441 0.314372
4 3.319003
H200005223_NP_996794.1
1.72925 0.510066 0.294963
4 3.315554
H200016778_FBXO5
1.729 0.526669 0.304609
4 3.31498
H300020866_Q7Z545_HUMAN
1.728 0.976577 0.565149
4 3.312683
H200000405_DCLRE1A
1.72375 0.645755 0.374622
4 3.302938
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Table 15 continued
Average
Count of
Name of the upregulated gene in HN value of
cell line
4 slides STD
slides
CV
Ratio
H200001011_NP_054895.1
1.71825 0.833375 0.485014
4 3.29037
H200002434_QKI
1.7125 0.643398 0.375707
4 3.277282
H200002164_ZC3HDC1
1.71025 0.301587 0.176341
4 3.272175
H300001924_ATAD2
1.70625 0.622159 0.364635
4 3.263115
H200019857_NCOA7
1.69975 0.495825 0.291705
4 3.248447
opHsV0400004769Q9NT91_HUMAN 1.6965 0.531851 0.313499
4 3.241137
H300002301_HES4
1.68925 0.313784 0.185753
4 3.22489
H200000203_
1.686 0.146806 0.087074
4 3.217633
opHsV0400001953_XP_495896.1
1.683333 1.325827 0.78762
3 3.211692
H300015276_Q96H22_HUMAN
1.67325 0.295831 0.176801
4 3.189323
H200012301_TRIM36
1.672 0.745459 0.445849
4 3.18656
H200011999_OIP5
1.66975 0.565244 0.33852
4 3.181595
H200011533_KLF2
1.6645 0.628264 0.377449
4 3.170038
H200008556_IFIT3
1.65625 0.746136 0.450497
4 3.151962
opHsV0400000541_TMED4
1.65525 0.339298 0.204983
4 3.149778
H200017505_FANCL
1.6525 0.397534 0.240565
4 3.143779
H200000621_ANGPT1
1.64775 1.626822 0.987299
4 3.133446
H300015308_
1.6395 0.224063 0.136666
4 3.115578
H200006611_QPCT
1.63775 0.402911 0.246015
4 3.111801
H300009117_OSR2
1.63625 0.558735 0.341473
4 3.108568
H300001290_SUNC1
1.634 0.527525 0.322843
3 3.103723
H200007111_NP_689700.1
1.6325 1.570719 0.962156
4 3.100498
H300017820_GLS
1.63125 0.453618 0.27808
4 3.097813
opHsV0400012444_
1.63 0.557309 0.341907
3 3.09513
opHsV0400002734_NP_848664.1
1.62675 0.832261 0.51161
4 3.088165
H300003538_Q9NYD4_HUMAN
1.6265 1.258498 0.773746
4 3.08763
opHsV0400004371_HLA-DRA
1.62475 0.737985 0.454215
4 3.083887
H200009565_IFIH1
1.6205 0.799292 0.493238
4 3.074816
opHsV0400000732_C6orf148
1.61975 1.121724 0.692529
4 3.073218
H200006282_SERPINA5
1.619 1.310318 0.809338
4 3.071621
H200006302_MAL2
1.61775 0.421879 0.260781
4 3.06896
H200000169_TACSTD1
1.6175 0.876741 0.542035
4 3.068429
H300007499_HRASLS3
1.6165 0.663349 0.410361
4 3.066302
H200005162_BAG2
1.61025 0.6921 0.429809
4 3.053047
H300015490_TRIM14
1.60975 0.854371 0.530748
4 3.05199
H300015757_PPM2C
1.6095 0.64351 0.39982
4 3.051461
H200014344_IL27B_HUMAN
1.60625 1.055639 0.657207
4 3.044594
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Table 15 continued
Average
Count of
Name of the upregulated gene in HN value of
cell line
4 slides STD
slides
CV
Ratio
H200004487_DKK1
1.60575 0.596592 0.371535
4 3.043539
H300005881_CTCFL
1.60425 1.235159 0.769929
4 3.040377
H300020304_PLAC8
1.5955 0.829325 0.51979
4 3.021992
H200016697_EMILIN2
1.5935 1.428029 0.896159
4 3.017806
H200010947_POLE2
1.581 0.423762 0.268034
4 2.991772
H200005687_CDC6_HUMAN
1.58025 0.908132 0.574676
4 2.990217
opHsV0400000033_USP18
1.57925 0.465642 0.29485
4 2.988145
H200006576_RNF144
1.5765 0.782792 0.496538
4 2.982454
H300019419_SP110
1.566 0.855142 0.546068
4 2.960827
H200007266_LHX1
1.566 1.433402 0.915327
4 2.960827
H200000387_MSX1
1.565 0.862229 0.550945
4 2.958775
opHsV0400006517_LIMS3
1.56475 1.375443 0.879017
4 2.958262
H200006824_FZD2
1.56425 0.881607 0.563597
4 2.957237
H200004906_CDCA8
1.558 0.622277 0.399408
4 2.944454
H200019588_CDC2
1.54775 0.564203 0.364531
4 2.923608
H200005202_OAS3
1.54725 0.767262 0.495888
4 2.922595
H200012133_OASL
1.544 0.360654 0.233584
4 2.916019
H300020240_Q7Z7J6_HUMAN
1.54275 1.035721 0.671348
4 2.913493
H200006623_SEMA4D
1.5405 0.920567 0.597577
4 2.908953
H300001211_ARVCF
1.53925 0.769145 0.499688
4 2.906434
opHsV0400007148_
1.53675 0.901378 0.586548
4 2.901402
H200000423_RPA3
1.53675 0.384891 0.250458
4 2.901402
opHsV0400003019_NP_115749.2
1.5365 0.639597 0.416269
4 2.900899
H200011709_DEK
1.5345 0.681863 0.444355
4 2.89688
H200009876_EEF1E1
1.53275 0.359703 0.234678
4 2.893368
opHsV0400007760_
1.52125 0.468175 0.307757
4 2.870396
opHsV0400004148_BGN
1.5195 1.341237 0.882683
4 2.866917
H200002273_NP_620134.2
1.5185 0.378022 0.248944
4 2.86493
H300002362_HOXA7
1.51675 0.845497 0.55744
4 2.861457
opHsV0400010984_
1.51375 0.37722 0.249196
4 2.855513
H200002104_NP_116195.2
1.51275 0.902294 0.59646
4 2.853534
H300002650_LSM5
1.511 0.465699 0.308206
4 2.850075
H200020265_KIAA1914
1.5055 0.458942 0.304844
4 2.839231
H200015533_GMNN
1.504 0.840186 0.558635
4 2.83628
H200001910_RHOBTB3
1.50375 0.422485 0.280954
4 2.835789
H300017088_Q9P2H4_HUMAN
1.50275 0.634124 0.421976
4 2.833824
H200008732_C9orf76
1.50125 0.473563 0.315446
4 2.830879
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Table 15 continued
Average
Count of
Name of the upregulated gene in HN value of
cell line
4 slides STD
slides
CV
Ratio
H300021781_CENPA
1.499 0.448031 0.298886
4 2.826467
H300001620_HLA-DRA
1.49575 0.567848 0.379641
4 2.820107
H200012628_Q9NW34_HUMAN
1.49475 0.546389 0.365539
4 2.818153
H200000353_CSF2
1.49475 1.097309 0.734109
4 2.818153
H200007874_UBE2L6
1.494 0.280316 0.187628
4 2.816688
H200014214_80_
1.492 0.366445 0.245607
4 2.812786
H300000884_
1.48925 0.503138 0.337846
4 2.80743
opHsV0400001961_CRIP1
1.4865 0.428895 0.288527
4 2.802084
opHsV0400006256_ATP6V0A2
1.4855 0.946856 0.637399
4 2.800142
opHsV0400006563_CTHRC1
1.47725 0.686588 0.464774
4 2.784175
opHsV0400006261_ZNF180
1.4765 0.488886 0.331112
4 2.782728
opHsV0400001268_LCP1
1.47475 0.467856 0.317244
4 2.779355
opHsV0400006299_MRPS18C
1.474 0.239612 0.162559
4 2.77791
H300006103_NP_872297.1
1.4725 0.534455 0.362957
4 2.775024
H200006020_NP_001009567.1
1.46925 1.162508 0.791225
4 2.768779
opHsV0400000242_RSAD2
1.46725 0.436163 0.297266
4 2.764943
opHsV0400012866_
1.4665 0.795741 0.542612
4 2.763506
opHsV0400001371_PTE2B_HUMAN 1.46375 0.887962 0.606635
4 2.758244
H200003290_DEPDC1B
1.462 0.88802 0.607401
4 2.7549
H200018907_TRIM22
1.46125 0.430851 0.294851
4 2.753468
opHsV0400000079_Q6NZ63HUMAN 1.4525 0.568938 0.391696
4 2.736819
H200003131_PPM2C
1.447 0.64873 0.448327
4 2.726405
H200014355_NP_945185.1
1.44525 1.123801 0.777582
4 2.7231
H200009537_RBP7
1.44425 0.729837 0.50534
4 2.721213
H300004315_XP_372200.1
1.44375 0.204927 0.141941
4 2.72027
H300013841_RAD51AP1
1.441333 1.307693 0.90728
3 2.715717
H200013413_LRP3
1.43925 0.238458 0.165682
4 2.711799
H300020946_BRIX_HUMAN
1.438 0.890683 0.61939
4 2.70945
H200006095_90_
1.4365 0.413611 0.287929
4 2.706634
opHsV0400002785_Q86TT0HUMAN 1.4365 1.357682 0.945132
4 2.706634
opHsV0400005875_NP_705611.1
1.43375 0.530447 0.369972
4 2.70148
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Table 16: 262 downregulated genes in HN cell line. The gene list is from the least
downregulated gene to most downregulated gene.
Average
Name of the downregulated gene in value of
Count of
HN cell line
4 slides STD
CV
slides
Ratio
H300019074_WRNIP1
-1.59875 1.383307 -0.86524
4 0.330163
H200016212_DLL1
-1.5995 0.75427 -0.47157
4 0.329991
opHsV0400002581_C14orf78
-1.6 1.305228 -0.81577
3 0.329877
H300014158_DOCK9
-1.603 1.419751 -0.88568
3 0.329192
opHsV0400004066_
-1.60625 0.469854 -0.29252
4 0.328451
H300019058_ANXA6
-1.609 0.960446 -0.59692
4 0.327826
H200006821_IL1RN
-1.60925 1.012012 -0.62887
4 0.327769
opHsV0400002604_Q96FP4_HUMAN -1.61175 0.725436 -0.45009
4 0.327201
H200017253_PLXNB1
-1.6135 0.858486 -0.53206
4 0.326805
opHsV0400003246_XP_497922.1
-1.61725 0.884012 -0.54661
4 0.325956
H200006140_CCND2
-1.61975 0.396532 -0.24481
4 0.325392
H200019789_NP_001060.1
-1.6245 0.419842 -0.25844
4 0.324322
H200002453_SRPX
-1.62525 0.903225 -0.55575
4 0.324154
H300003388_ETS2
-1.6265 1.082986 -0.66584
4 0.323873
H200002000_RHBDL2
-1.62775 0.806054 -0.49519
4 0.323592
opHsV0400004958_KLF10_HUMAN -1.62925 1.289555 -0.7915
4 0.323256
H200006008_PRSS11
-1.62925 0.384313 -0.23588
4 0.323256
H200002536_CDYL
-1.63625 0.844779 -0.51629
4 0.321692
H200017078_TUBB6
-1.63775 0.438952 -0.26802
4 0.321357
H300002496_NOTCH2NL
-1.63825 0.768268 -0.46896
4 0.321246
H200006868_DAB2
-1.64125 1.419207 -0.86471
4 0.320579
opHsV0400009653_
-1.64167 1.064244 -0.64827
3 0.320486
H200002949_C6orf117
-1.64175 1.555972 -0.94775
4 0.320468
H300012687_IPYR2_HUMAN
-1.6435 0.991842 -0.60349
4 0.320079
H200006008_PRSS11
-1.64775 0.37658 -0.22854
4 0.319137
H200012241_NP_689893.1
-1.64875 0.668634 -0.40554
4 0.318916
opHsV0400011304_
-1.64975 0.543631 -0.32952
4 0.318695
opHsV0400002608_
-1.657 1.091706 -0.65885
3 0.317098
H200011608_CRYL1
-1.66075 1.226167 -0.73832
4 0.316275
H200008160_NP_001001701.1
-1.66075 0.452508 -0.27247
4 0.316275
opHsV0400005657_
-1.66125 0.922962 -0.55558
4 0.316165
opHsV0400012140_
-1.66675 1.337455 -0.80243
4 0.314962
opHsV0400011469_
-1.66925 1.384516 -0.82942
4 0.314417
opHsV0400002357_GBP6
-1.66925 1.006323 -0.60286
4 0.314417
H200012925_
-1.67225 0.50195 -0.30016
4 0.313764
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Table 16 continued
Average
Count of
Name of the downregulated gene in value of
HN cell line
slides
4 slides STD
CV
Ratio
H300014718_DUSP6
-1.6765 0.836957 -0.49923
4 0.312841
H200010650_DSG2
-1.67675 0.840799 -0.50145
4 0.312786
H300003254_TM4SF1
-1.679 0.469498 -0.27963
4 0.312299
H200000493_DSG3
-1.68525 0.600096 -0.35609
4 0.310949
H200001205_NP_057659.1
-1.68675 0.780043 -0.46245
4 0.310626
H200004941_LPXN
-1.68675 0.865594 -0.51317
4 0.310626
H200001079_EGFL5
-1.68875 0.893202 -0.52891
4 0.310196
H300022632_PAM
-1.6895 0.908499 -0.53773
4 0.310034
H200001094_NP_057702.1
-1.694 0.666506 -0.39345
4 0.309069
opHsV0400005724_
-1.702 1.596677 -0.93812
3 0.30736
H300020881_PTPN13
-1.7025 1.469151 -0.86294
4 0.307253
H200007830_80_
-1.703 1.316424 -0.773
4 0.307147
H300009483_NHLH2
-1.70525 1.646993 -0.96584
4 0.306668
H200005895_NQO2
-1.70675 1.421316 -0.83276
4 0.306349
H200012177_RAB4A
-1.7155 0.919008 -0.53571
4 0.304497
H300019976_IPYR2_HUMAN
-1.71875 0.370455 -0.21554
4 0.303812
H300009845_RNASE7
-1.72025 0.897532 -0.52174
4 0.303496
opHsV0400000833_NET1
-1.7255 1.398363 -0.81041
4 0.302394
H300022102_AMPH
-1.72975 1.302425 -0.75296
4 0.301504
H200004702_SLC6A15
-1.733 0.668861 -0.38596
4 0.300826
H300000194_CSPG2
-1.73325 0.690035 -0.39812
4 0.300774
opHsV0400012025_
-1.735 0.736238 -0.42434
4 0.300409
H300017847_FN1
-1.73575 0.744819 -0.4291
4 0.300253
opHsV0400002147_Q86XE2HUMAN -1.73625 1.403075 -0.80811
4 0.300149
H200003613_NLGN2
-1.7445 1.690551 -0.96907
4 0.298437
opHsV0400004135_NOTCH2
-1.7465 0.867778 -0.49687
4 0.298024
opHsV0400006289_
-1.75025 0.524869 -0.29988
4 0.29725
opHsV0400000971_WBSCR1
-1.751 1.682545 -0.96091
4 0.297096
H300014817_LAMA3
-1.752 0.985253 -0.56236
4 0.29689
opHsV0400010474_
-1.75625 1.164768 -0.66321
4 0.296017
H200005804_CDKN2B
-1.763 1.059426 -0.60092
3 0.294635
H200013653_PADI3
-1.7655 1.54012 -0.87234
4 0.294125
opHsV0400012141_
-1.768 0.323393 -0.18291
4 0.293615
H300014940_B3GNT5
-1.76825 1.385017 -0.78327
4 0.293565
H200003299_SLC16A4
-1.7685 0.985443 -0.55722
4 0.293514
H200007001_IL18
-1.77075 0.600791 -0.33929
4 0.293056
H200015568_NP_060945.2
-1.771 0.833682 -0.47074
4 0.293006
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Table 16 continued
Average
Count of
Name of the downregulated gene in value of
HN cell line
slides
4 slides STD
CV
Ratio
H200000289_LTBR
-1.7725 1.539506 -0.86855
4 0.292701
H200009840_VIM
-1.773 1.472988 -0.83079
4 0.2926
H300013119_NP_065682.2
-1.78775 0.722342 -0.40405
4 0.289623
H300021562_FN1
-1.79 0.725466 -0.40529
4 0.289172
opHsV0400001891_ALDH1A3
-1.793 1.146318 -0.63933
4 0.288571
H300020771_SQSTM1
-1.79875 0.724315 -0.40268
4 0.287424
H200008177_IL1RAP
-1.799 0.359881 -0.20004
4 0.287374
opHsV0400006351_
-1.804 1.021688 -0.56635
4 0.286379
H300017962_CTBP2
-1.8085 1.727057 -0.95497
4 0.285488
H300005700_KRT8
-1.81075 0.937817 -0.51792
4 0.285043
H300006159_OR10Z1
-1.81125 1.342866 -0.7414
4 0.284944
H300003817_NP_006207.1
-1.816 0.369494 -0.20347
4 0.284007
H200009720_GDF15
-1.8165 1.713194 -0.94313
4 0.283909
opHsV0400007052_DMRTA2
-1.817 1.027746 -0.56563
4 0.283811
H200006151_Q5T9X8_HUMAN
-1.8195 1.323231 -0.72725
4 0.283319
H200011042_S100A8
-1.82025 0.464048 -0.25494
4 0.283172
opHsV0400001839_
-1.82375 0.613236 -0.33625
4 0.282486
H300014334_NP_079082.2
-1.82625 1.394609 -0.76365
4 0.281997
H300021172_HOP_HUMAN
-1.8305 1.707345 -0.93272
4 0.281167
H300009457_GADD45B
-1.8385 0.788505 -0.42888
4 0.279612
H200006750_NP_067651.2
-1.84025 0.677885 -0.36837
4 0.279273
opHsV0400005248_FAM46B
-1.84425 0.621962 -0.33724
4 0.2785
H300010985_XP_056455.4
-1.84475 1.191614 -0.64595
4 0.278404
H200007913_GLUL
-1.84525 0.727058 -0.39402
4 0.278307
opHsV0400005180_
-1.84875 1.707691 -0.9237
4 0.277633
H300008877_IRX1
-1.85325 1.157741 -0.62471
4 0.276768
H200014313_BEXL1
-1.85625 0.813239 -0.43811
4 0.276193
opHsV0400000674_SPRE1_HUMAN
-1.864 1.535201 -0.82361
4 0.274714
H300011977_UGP2
-1.867 0.531943 -0.28492
4 0.274143
H300012294_NP_996918.1
-1.86775 1.234636 -0.66103
4
0.274
opHsV0400007640_
-1.87125 1.308335 -0.69918
4 0.273336
H200011819_NP_002956.1
-1.8715 0.452331 -0.24169
4 0.273289
opHsV0400012111_
-1.874 0.467187 -0.2493
4 0.272816
H200009653_RAB4A
-1.8775 1.208294 -0.64357
4 0.272155
H300013341_ARI5B_HUMAN
-1.88067 1.431925 -0.76139
3 0.271558
H200003061_SLC22A15
-1.8835 0.345235 -0.18329
4 0.271025
H200015766_CLCA2
-1.89025 1.41579 -0.749
4 0.26976
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Table 16 continued
Average
Count of
Name of the downregulated gene in value of
HN cell line
4 slides STD
slides
CV
Ratio
H300019778_PFKP
-1.8905 0.441144 -0.23335
4 0.269714
H300002182_FEZ1
-1.89725 0.352279 -0.18568
4 0.268455
H300015033_MAGED2
-1.9015 1.104153 -0.58067
4 0.267665
opHsV0400000309_PRKX
-1.90175 1.079995 -0.5679
4 0.267619
H300003420_XP_114621.3
-1.906 0.795925 -0.41759
4 0.266831
H300015331_CALD1
-1.9095 0.600979 -0.31473
4 0.266185
H200001479_Q8IW73_HUMAN
-1.9105 0.81507 -0.42663
4
0.266
H200000578_SGNE1
-1.9115 1.342315 -0.70223
4 0.265816
H300018512_DDX3Y
-1.91325 1.374225 -0.71827
4 0.265494
H200006912_TRIM29
-1.9135 0.46742 -0.24428
4 0.265448
H200010727_IRS1
-1.9155 0.956011 -0.49909
4 0.26508
H200016641_MN1
-1.9165 1.734132 -0.90484
4 0.264896
H200001041_CA12
-1.92375 1.209104 -0.62851
4 0.263569
opHsV0400008763_
-1.92525 1.671196 -0.86804
4 0.263295
opHsV0400012807_
-1.9255 1.44655 -0.75126
4 0.263249
H300002442_SPAG4L
-1.926 1.575548 -0.81804
3 0.263158
H300019695_BICD2_HUMAN
-1.93333 1.714992 -0.88706
3 0.261824
opHsV0400000862_
-1.937 0.627197 -0.3238
4 0.261159
H200013276_SERPINB7
-1.9395 1.250102 -0.64455
4 0.260707
H200011747_MMP2
-1.94133 1.266238 -0.65225
3 0.260376
H300006466_SGCB
-1.94775 0.48478 -0.24889
4 0.25922
H200006031_IPKA_HUMAN
-1.95125 1.027964 -0.52682
4 0.258592
H200013147_NP_079045.1
-1.95125 1.613092 -0.8267
4 0.258592
H200009840_VIM
-1.95225 1.347477 -0.69022
4 0.258413
opHsV0400000719_KRT16
-1.954 0.677366 -0.34666
4 0.2581
opHsV0400000067_Q8WWJ9_HUMAN -1.964 1.440904 -0.73366
3 0.256317
H300011685_
-1.96925 0.791119 -0.40174
4 0.255386
H200015680_DSC2
-1.97375 0.82822 -0.41962
4 0.25459
H300020530_SERPINB3
-1.974 1.412462 -0.71553
4 0.254546
H200011421_CDKN1C
-1.97425 1.74466 -0.88371
4 0.254502
H200008269_CD99
-1.979 0.568187 -0.28711
4 0.253666
opHsV0400005505_Q8N1M2_HUMAN -1.97975 0.916015 -0.46269
4 0.253534
H200009233_SIA7B_HUMAN
-1.9845 0.563657 -0.28403
4 0.2527
H300004503_NP_076415.2
-1.98675 1.388697 -0.69898
4 0.252307
H300002800_AHNAK
-1.9885 1.011638 -0.50874
4 0.252001
H200005431_DIXDC1
-1.9885 1.306747 -0.65715
4 0.252001
opHsV0400000907_
-1.9915 0.91352 -0.45871
4 0.251477
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Table 16 continued
Average
Count of
Name of the downregulated gene in value of
HN cell line
4 slides STD
slides
CV
Ratio
opHsV0400003043_MYADM
-1.993 1.074113 -0.53894
4 0.251216
H300015953_SH3TC1
-1.99525 0.816961 -0.40945
4 0.250824
opHsV0400003766_NP_710154.1
-1.997 0.569637 -0.28525
4 0.25052
H200010435_SPAG7
-1.99725 1.183802 -0.59272
4 0.250477
H200000006_FECH
-2 1.136739 -0.56837
3
0.25
H300002958_JAG1
-2.0005 0.980535 -0.49014
4 0.249913
H200017303_THIC_HUMAN
-2.0045 1.227046 -0.61215
4 0.249221
H200017197_HSD11B1
-2.008 1.799181 -0.89601
4 0.248618
opHsV0400000692_Q96HF5_HUMAN -2.0175 1.505647 -0.74629
4 0.246986
opHsV0400004098_S100A14
-2.0225 0.647593 -0.32019
4 0.246131
H300008020_XP_294590.1
-2.023 1.021751 -0.50507
4 0.246046
H200014140_PTPNS1
-2.0295 0.915507 -0.4511
4 0.24494
opHsV0400005956_
-2.03025 1.987607 -0.979
4 0.244813
H300010309_MYADM
-2.03125 0.793007 -0.3904
4 0.244643
H200017469_RHCG
-2.0325 1.47413 -0.72528
4 0.244431
opHsV0400006431_SNURF
-2.035 1.122016 -0.55136
4 0.244008
opHsV0400009072_
-2.04975 0.847366 -0.4134
4 0.241526
H200006884_SERPINE1
-2.05525 0.878614 -0.4275
4 0.240607
opHsV0400013047_
-2.077 1.65584 -0.79723
4 0.237007
opHsV0400002303_NDN
-2.102 1.514516 -0.72051
4 0.232935
opHsV0400011802_
-2.11075 0.990842 -0.46943
4 0.231527
opHsV0400003761_SAT
-2.12375 0.674588 -0.31764
4 0.22945
H200020570_SESN3
-2.1265 1.558735 -0.733
4 0.229013
H200004216_PLXDC2
-2.13375 1.498274 -0.70218
4 0.227865
opHsV0400000655_GJB2
-2.13575 1.589741 -0.74435
4 0.227549
opHsV0400007539_
-2.13667 1.170169 -0.54766
3 0.227405
H300019732_PRKY
-2.14125 1.288663 -0.60183
4 0.226683
H300008679_EGLN3
-2.14575 1.567392 -0.73046
4 0.225977
H300006003_SLC25A6
-2.15325 0.568798 -0.26416
4 0.224806
opHsV0400000393_COL16A1
-2.1535 0.408445 -0.18967
4 0.224767
H300009738_Q14922_HUMAN
-2.159 1.707737 -0.79099
4 0.223911
opHsV0400011805_
-2.16475 1.242039 -0.57376
4 0.223021
H200012019_AKR1B10
-2.1675 1.019482 -0.47035
4 0.222596
opHsV0400002365_PTPRM
-2.16825 0.521267 -0.24041
4 0.22248
H200001587_NP_996918.1
-2.169 0.508558 -0.23447
4 0.222365
H200006902_KLF10_HUMAN
-2.16925 0.651168 -0.30018
4 0.222326
H200006867_SHC1
-2.18975 0.62549 -0.28564
4 0.219189
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Table 16 continued
Average
Count of
Name of the downregulated gene in value of
HN cell line
4 slides STD
slides
CV
Ratio
opHsV0400012682_
-2.1915 1.25688 -0.57353
4 0.218924
H300016644_WASPIP
-2.20725 1.987152 -0.90028
4 0.216547
H300002193_ZFP36L2
-2.21575 0.47565 -0.21467
4 0.215275
H200008152_ODZ2
-2.216 0.481832 -0.21743
4 0.215237
H300002481_ZBTB34
-2.23325 1.45323 -0.65072
4 0.212679
H200010061_RPS6KA2
-2.23625 1.708891 -0.76418
4 0.212237
opHsV0400001284_
-2.24625 1.297053 -0.57743
4 0.210771
opHsV0400007647_
-2.25667 1.907378 -0.84522
3 0.209255
opHsV0400000170_MT1L
-2.25975 0.362426 -0.16038
4 0.208808
H300000923_POSTN
-2.26175 1.625951 -0.71889
4 0.208519
H300014335_KRT6B
-2.2635 0.877822 -0.38782
4 0.208266
H300020178_
-2.26375 0.710005 -0.31364
4 0.20823
H200012731_F2R
-2.273 1.46346 -0.64385
4 0.206899
H200007876_SLC2A1
-2.2955 0.738457 -0.3217
4 0.203697
H200015364_GSTP1
-2.301 0.589462 -0.25618
4 0.202922
H300021749_FOLR3
-2.30675 0.871734 -0.37791
4 0.202115
H200014031_HSD17B2
-2.30675 0.762819 -0.33069
4 0.202115
H300000043_RGS17
-2.31825 1.010659 -0.43596
4 0.200511
H200000430_COL7A1
-2.36225 0.65418 -0.27693
4 0.194488
opHsV0400005864_SEPP1
-2.3655 1.345137 -0.56865
4 0.19405
H300022249_GP110_HUMAN
-2.37275 2.22949 -0.93962
4 0.193077
H300022236_Q9BSP9_HUMAN
-2.37325 0.970672 -0.40901
4 0.19301
H200006097_ID1
-2.40875 1.092811 -0.45368
4 0.188319
H300012916_MAOA
-2.4185 1.992456 -0.82384
4 0.187051
H200001408_SFRP1
-2.43325 1.071149 -0.44021
4 0.185148
H200008006_SEMA3C
-2.4605 0.55147 -0.22413
4 0.181684
H300021145_ANGPTL4
-2.475 0.780793 -0.31547
4 0.179867
H200018876_IL24
-2.4765 1.466241 -0.59206
4 0.17968
H200000153_Q9BSP9_HUMAN
-2.48525 1.071613 -0.43119
4 0.178593
H200011925_COL8A1
-2.498 1.49758 -0.59951
4 0.177022
opHsV0400006127_TNFRSF6B
-2.5015 0.365641 -0.14617
4 0.176593
H300003213_GOLPH3L
-2.50675 1.333089 -0.5318
4 0.175952
H200015098_IL1F9
-2.51975 1.041925 -0.4135
4 0.174373
H200004912_GJB6
-2.52425 1.61561 -0.64004
4 0.17383
H200005918_SYK
-2.52775 1.763101 -0.6975
4 0.173409
H200006177_SERPINB2
-2.559 0.795586 -0.3109
4 0.169693
H300005637_NP_689532.1
-2.5665 1.81099 -0.70563
4 0.168813
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Table 16 continued
Average
Count of
Name of the downregulated gene in value of
HN cell line
4 slides STD
slides
CV
Ratio
H200006699_FBN2
-2.58725 0.790933 -0.3057
4 0.166403
opHsV0400012721_
-2.61325 2.010573 -0.76938
4 0.163431
H300013272_DDX3Y
-2.6735 1.555192 -0.58171
4 0.156746
H300010096_AKR1C2
-2.6785 0.993972 -0.37109
4 0.156204
H200014446_P2RY5
-2.68125 1.943099 -0.7247
4 0.155906
H300013882_AES
-2.6825 0.454182 -0.16931
4 0.155771
opHsV0400011550_
-2.686 2.445253 -0.91037
3 0.155394
H200016719_AREG
-2.70425 0.555952 -0.20558
4 0.15344
opHsV0400011776_
-2.7105 2.555899 -0.94296
4 0.152777
H200005781_NP_056234.1
-2.71325 1.705237 -0.62849
4 0.152486
H200000280_SPRR1B
-2.735 1.000044 -0.36565
4 0.150205
H200005198_GALNT5
-2.76025 1.335756 -0.48393
4 0.147599
opHsV0400002884_
-2.76625 2.725509 -0.98527
4 0.146986
opHsV0400010653_
-2.79075 1.439192 -0.5157
4 0.144511
H200003227_CMKOR1
-2.8075 0.905171 -0.32241
4 0.142843
H200012184_COL4A1
-2.82025 0.634544 -0.225
4 0.141586
H200002398_HCLS1
-2.8465 1.290239 -0.45327
4 0.139033
H300006645_Q8IYY5_HUMAN
-2.85 0.85245 -0.29911
4 0.138696
H200012016_EVA1
-2.8505 0.68078 -0.23883
4 0.138648
H200011635_LXN
-2.86425 2.020295 -0.70535
4 0.137333
opHsV0400006073_CFHL1
-2.86475 0.87589 -0.30575
4 0.137285
H200007909_Q86XJ2_HUMAN
-2.872 0.595409 -0.20731
4 0.136597
H200014027_CA2
-2.93825 1.069223 -0.3639
4 0.130466
opHsV0400010774_
-2.9685 1.306912 -0.44026
4 0.127759
H200000301_CDKN2A
-2.97475 1.792289 -0.6025
4 0.127207
H200011169_TCF7L1
-2.99475 1.037295 -0.34637
4 0.125456
H200006236_CDH11
-3.0245 1.237091 -0.40902
4 0.122895
H200006995_
-3.052 0.953395 -0.31238
4 0.120575
H200004653_SULF2
-3.06 1.158361 -0.37855
4 0.119908
H300003117_Q8N4W5_HUMAN
-3.06767 2.914295
-0.95
3 0.119272
H200016561_NP_060910.2
-3.071 1.721832 -0.56067
4 0.118997
H200020242_C9orf26
-3.0795 1.212845 -0.39384
4 0.118298
H300006196_MAF
-3.124 1.538379 -0.49244
4 0.114705
H200007907_FOXO1A
-3.13275 1.02355 -0.32673
4 0.114011
H200014307_FADS2
-3.1405 0.463705 -0.14765
4 0.113401
opHsV0400011317_
-3.20067 3.195774 -0.99847
3 0.108769
H300004073_AKR1C1
-3.28425 0.748321 -0.22785
4 0.102646
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Table 16 continued
Average
Count of
Name of the downregulated gene in value of
HN cell line
4 slides STD
slides
CV
Ratio
H300004901_RPS4Y1
-3.3215 1.307476 -0.39364
4 0.10003
H200014029_EIF1AY
-3.58 1.302563 -0.36384
4 0.08362
H300021913_AKR1C3
-3.734 1.248393 -0.33433
4 0.075154
H200005947_GJA1
-3.869 1.115312 -0.28827
4 0.068441
opHsV0400010227_Q96NA9_HUMAN -3.90075 0.856613 -0.2196
4 0.066951
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Table 17: 128 upregulated genes in HSC-3 cell line. The gene list is from the most
upregulated gene to least upregulated gene.
Average
Name of the upregulated gene in value of
Count of
HSC-3 cell line
4 slides STD
CV
slides
Ratio
H200004378_MAGEA8
3.152 0.849621 0.26955
4 8.88887
H200005801_MAGEA1
3.03575 0.936701 0.308557
4 8.200717
H200011948_EREG
2.597 0.780137 0.300399
4 6.050272
H200011983_Q9BT26_HUMAN
2.59275 1.084013 0.418094
4 6.032475
opHsV0400002734_NP_848664.1
2.547 0.915678 0.359512
4 5.844178
H200004597_XM_374020.2
2.44275 0.932021 0.381546
4 5.436771
H200002223_TXNRD1
2.39975 0.65304 0.272128
4 5.277117
opHsV0400008521_
2.36525 1.704137 0.720489
4 5.152419
H200017455_NP_060582.1
2.2765 0.326759 0.143536
4 4.845011
opHsV0400003034_KLK10
2.27275 0.695054 0.305821
4 4.832434
H200004485_HOXC9
2.267 1.211413 0.534369
4 4.813212
H200009720_GDF15
2.19 0.475102 0.216942
4 4.563055
opHsV0400003019_NP_115749.2
2.1475 0.334409 0.15572
4 4.430594
H300004818_MAGEA9
2.14725 1.140736 0.531254
4 4.429826
opHsV0400001562_IGSF4
2.10425 0.735674 0.349613
4 4.299742
H300006703_LY6K
2.0865 0.680104 0.325955
4 4.247165
H300022245_PHF15
2.05875 0.78175 0.379721
4 4.166252
opHsV0400000415_NP_149024.1
2.045 0.503042 0.245986
4 4.126733
opHsV0400004777_NP_998889.1
2.01425 1.010318 0.501585
4 4.039705
opHsV0400001984_XP_377060.1
1.9955 0.737407 0.369535
4 3.987543
H300015028_NMNAT3
1.9795 0.698805 0.353021
4 3.943564
H300022040_SH3YL1
1.97 0.476095 0.241673
4 3.917681
H300017088_Q9P2H4_HUMAN
1.96975 0.513645 0.260766
4 3.917002
opHsV0400006083_MAGEA4
1.9685 0.824239 0.418714
4 3.91361
H300006491_NP_940887.1
1.95075 0.90601 0.464442
4 3.865754
opHsV0400003953_HIST1H1C
1.9215 0.423402 0.22035
4 3.788167
opHsV0400007760_
1.92075 0.563209 0.293223
4 3.786198
H300008288_NP_443726.1
1.91625 0.43419 0.226583
4 3.774407
H200014299_RHPN2
1.9135 0.454259 0.237397
4 3.767219
H200011351_AIM2
1.90825 1.427721 0.748183
4 3.753535
opHsV0400010848_
1.88475 0.534614 0.283653
4 3.692889
H200006887_PSIP1
1.88475 0.326691 0.173334
4 3.692889
H300001921_PKD1L2
1.87575 1.677794 0.894466
4 3.669924
opHsV0400000818_IL8
1.8655 0.570452 0.30579
4 3.643942
H200006441_OLR1
1.862 1.144727 0.614783
4 3.635112
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Table 17 continued
Average
Name of the upregulated gene in HSC- value of
Count of
3 cell line
slides
4 slides STD
CV
Ratio
H300005599_NP_705835.1
1.86175 0.966071 0.518905
4 3.634483
H300021371_Q9P2H4_HUMAN
1.8485 0.707264 0.382615
4 3.601256
H200013441_KCNJ14
1.846 1.040101 0.563435
4 3.595021
H300020946_BRIX_HUMAN
1.8405 0.397678 0.216071
4 3.581341
H300021118_BBC3
1.824 0.587338 0.322006
4 3.540615
opHsV0400002065_Q86YU6_HUMAN 1.81675 0.672504 0.370169
4 3.522867
H200000454_INHBB
1.80425 1.785077 0.989374
4 3.492476
H200014850_STK39
1.79125 0.621751 0.347105
4 3.461146
H200013135_UCN
1.78225 1.208734 0.678207
4 3.439622
H200006680_EMP1
1.7745 0.571015 0.321789
4 3.421194
H200011423_PKIB
1.764 0.507071 0.287455
4 3.396385
H200010852_ITCH_HUMAN
1.7505 0.444094 0.253696
4 3.364752
opHsV0400003702_COX8C
1.75025 1.599525 0.913884
4 3.364169
H200007980_USMG5
1.74175 0.568977 0.32667
4 3.344406
opHsV0400011949_
1.7305 0.339008 0.195902
4 3.318428
H300003162_ANKRD18A
1.7195 0.567176 0.32985
4 3.293223
H300010199_EIF5A2
1.7175 0.63642 0.37055
4 3.28866
H300011213_Q9NSQ0_HUMAN
1.70825 1.174061 0.687289
4 3.267642
opHsV0400003313_NP_003513.1
1.6915 0.457245 0.270319
4 3.229924
opHsV0400011821_
1.686 0.751921 0.445979
4 3.217633
H200006097_ID1
1.68225 0.546952 0.325131
4 3.209281
H200004662_PELI2
1.682 1.000514 0.594836
4 3.208725
H200000169_TACSTD1
1.68 0.297876 0.177307
4 3.20428
H200021283_NANOS1
1.6795 0.536871 0.319661
4 3.203169
H200017773_GTPBP1
1.6745 1.163442 0.6948
4 3.192087
opHsV0400004721_HIST1H2BH
1.6675 0.606325 0.363613
4 3.176636
H300004810_PTENP1
1.6675 0.556886 0.333964
4 3.176636
H200006754_KRT15
1.653 0.513669 0.310749
4 3.144869
H200004708_PNN
1.641 1.23787 0.754339
4 3.118819
H200010772_GPR160
1.6405 0.936346 0.570768
4 3.117739
opHsV0400010379_
1.63925 0.657288 0.400969
4 3.115039
H200017587_RIOK1
1.639 0.569017 0.347173
4 3.114499
H300004419_HSC20_HUMAN
1.630333 0.374844 0.229919
3 3.095845
H300010303_TMEM41B
1.62875 0.279295 0.171478
4 3.092449
H200008677_SERPINB1
1.623667 0.414045 0.255006
3 3.081572
H200000756_XCL1
1.6205 1.11755 0.689633
4 3.074816
opHsV0400002545_C9orf75
1.6185 0.569555 0.351903
4 3.070556
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Table 17 continued
Average
Name of the upregulated gene in HSC- value of
Count of
3 cell line
slides
4 slides STD
CV
Ratio
H200006453_RNF38
1.6165 0.338344 0.209306
4 3.066302
opHsV0400006608_NP_689497.1
1.6135 0.691395 0.428506
4 3.059933
H300020977_PSIP1
1.606 0.371028 0.231026
4 3.044067
opHsV0400008140_
1.6015 0.515305 0.321764
4 3.034587
H300019484_MRPS18B
1.601 0.471496 0.294501
4 3.033535
H200006623_SEMA4D
1.60025 1.241406 0.775758
4 3.031958
H200000524_SLC25A4
1.599 0.420158 0.262763
4 3.029333
opHsV0400003565_NP_006638.1
1.5965 0.829345 0.519477
4 3.024088
opHsV0400011837_
1.59475 0.943297 0.591501
4 3.020422
H300002440_
1.56625 0.361304 0.230681
4 2.96134
H300000318_HIST1H2BK
1.55725 0.41875 0.268904
4 2.942923
H300001749_AQP11
1.55375 1.13034 0.727492
4 2.935792
H200020534_TRIM6
1.5485 0.425175 0.274572
4 2.925128
H200002977_NP_065726.1
1.5465 0.770006 0.497903
4 2.921076
H200002273_NP_620134.2
1.54575 0.342185 0.221371
4 2.919558
H200011237_C10orf45
1.54325 0.454406 0.294448
4 2.914503
H300013839_Q8N601_HUMAN
1.5355 0.402652 0.262229
4 2.898889
H300018428_BID
1.5315 0.627854 0.40996
4 2.890863
opHsV0400001983_
1.531 0.47726 0.311731
4 2.889861
H300005107_C10orf116
1.53025 0.548939 0.358725
4 2.888359
H300018167_AMID
1.5295 0.785779 0.513749
4 2.886858
H200007656_ELF3
1.51475 0.340044 0.224489
4 2.857493
H300008564_RASSF6
1.51125 0.362357 0.239773
4 2.850569
opHsV0400001907_
1.51075 0.501022 0.331638
4 2.849581
H200014940_SYCP2
1.502 1.161495 0.773299
4 2.832351
opHsV0400005403_HIST1H2BM
1.5 0.980374 0.653583
4 2.828427
opHsV0400003794_Q71RB1_HUMAN 1.49575 0.399363 0.266999
4 2.820107
H200019082_TIMM9
1.4935 0.359623 0.240792
4 2.815712
H300010984_PHF15
1.4935 0.450442 0.301601
4 2.815712
opHsV0400002715_Q68G75_HUMAN 1.49275 0.562713 0.376964
4 2.814249
H300007931_NP_057385.2
1.4915 0.450681 0.302167
4 2.811812
H300020380_TATDN1
1.491 0.640439 0.429536
4 2.810837
opHsV0400003875_Q8NHD1_HUMAN 1.48975 0.663412 0.445317
4 2.808403
opHsV0400001186_NP_254280.1
1.48925 0.294015 0.197425
4 2.80743
H200010529_AMOTL2
1.489 0.369736 0.248312
4 2.806943
H200003398_CWF19L2
1.481 1.349314 0.911083
4 2.791422
H200004072_SIRT1_HUMAN
1.48025 0.515023 0.347929
4 2.789971
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Table 17 continued
Average
Name of the upregulated gene in HSC- value of
Count of
3 cell line
slides
4 slides STD
CV
Ratio
H200006199_EDG2
1.48 0.40603 0.274345
4 2.789487
H200003664_C20orf100
1.4785 0.933017 0.631056
4 2.786589
H200005619_DIPA_HUMAN
1.4765 0.563093 0.38137
4 2.782728
H200001173_NP_932062.1
1.47275 0.496299 0.336988
4 2.775504
H200010289_C6orf139
1.46625 0.579713 0.395371
4 2.763028
H200000560_CEBPG
1.464 0.409896 0.279984
4 2.758722
H300021980_RHOT1
1.46075 0.371909 0.254601
4 2.752514
H200009826_KRTHA4
1.45975 0.9836 0.673814
4 2.750607
H200006824_FZD2
1.4565 0.584051 0.400996
4 2.744418
opHsV0400013404_
1.44975 0.433341 0.298907
4 2.731607
H300000063_ANKRD22
1.44725 0.878237 0.606832
4 2.726878
H200020107_PSMA3
1.4455 0.455472 0.315096
4 2.723572
H200001621_STRBP
1.445 0.783382 0.542133
4 2.722628
H300001211_ARVCF
1.44375 0.753391 0.521829
4 2.72027
H200003385_PARP2
1.44275 0.926379 0.642093
4 2.718385
H300005845_
1.44225 0.643212 0.445978
4 2.717443
H300006484_CYP1A1
1.44 0.984089 0.683395
4 2.713209
H300001097_
1.4365 0.434289 0.302324
4 2.706634
opHsV0400004914_
1.43125 0.553855 0.386973
4 2.696803
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Table 18: 117 downregulated genes in HSC-3 cell line. The gene list is from the least
downregulated gene to most downregulated gene.
Average
Name of the downregulated gene in value of
Count of
HSC-3 cell line
4 slides STD
CV
slides
Ratio
H300004618_LGALS7
-1.59825 0.652359 -0.40817
4 0.330277
H300001203_GLIPR1
-1.6 0.633926 -0.3962
4 0.329877
H300009606_ISG20_HUMAN
-1.60025 0.636049 -0.39747
4 0.32982
opHsV0400001923_IDH2
-1.60425 0.757475 -0.47217
4 0.328907
H200013160_CARD15
-1.60725 1.224737 -0.76201
4 0.328223
opHsV0400003766_NP_710154.1
-1.60875 0.487525 -0.30305
4 0.327882
H200000491_PRG1
-1.60975 0.736354 -0.45743
4 0.327655
H300003923_DIAPH2
-1.6105 0.696324 -0.43237
4 0.327485
opHsV0400003043_MYADM
-1.61525 0.581445 -0.35997
4 0.326408
H200005275_KLK11
-1.6155 1.168752 -0.72346
4 0.326352
H200000280_SPRR1B
-1.6335 1.10972 -0.67935
4 0.322305
H200011042_S100A8
-1.64 1.123603 -0.68512
4 0.320856
H300014335_KRT6B
-1.64675 0.782004 -0.47488
4 0.319359
opHsV0400002054_RARB
-1.647 1.398813 -0.84931
4 0.319303
H200006117_TP53INP1
-1.66175 0.708937 -0.42662
4 0.316056
H300020154_TUBB3
-1.668 0.663706 -0.39791
4 0.314689
H200005378_NP_612398.1
-1.669 0.449427 -0.26928
4 0.314471
H200005918_SYK
-1.66975 1.210319 -0.72485
4 0.314308
H300007287_GCNT1
-1.6715 1.245413 -0.74509
4 0.313927
opHsV0400005920_ITGB6
-1.67825 0.791641 -0.47171
4 0.312461
H200003227_CMKOR1
-1.68625 0.819594 -0.48605
4 0.310734
H200006265_EFEMP1
-1.688 0.832564 -0.49322
4 0.310357
H300016617_THY1
-1.693 1.424375 -0.84133
4 0.309283
H200012016_EVA1
-1.69325 0.522671 -0.30868
4 0.30923
H200001136_NP_775925.1
-1.69675 0.554422 -0.32676
4 0.30848
H200000047_IGFBP2
-1.6995 0.581298 -0.34204
4 0.307893
H300010309_MYADM
-1.6995 0.748583 -0.44047
4 0.307893
opHsV0400006248_SCMH1
-1.70275 1.414602 -0.83077
4 0.3072
H200014262_DSCR1
-1.7075 0.495285 -0.29006
4 0.30619
H300010992_RBPMS
-1.715 0.429382 -0.25037
4 0.304603
H200011819_NP_002956.1
-1.72275 1.028266 -0.59687
4 0.302971
H300010137_CALML3
-1.7315 1.122493 -0.64828
4 0.301139
opHsV0400005864_SEPP1
-1.74075 0.803666 -0.46168
4 0.299214
opHsV0400011936_
-1.747 1.360383 -0.7787
3 0.297921
H200005431_DIXDC1
-1.756 1.022538 -0.58231
4 0.296068
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Table 18 continued
Average
Count of
Name of the downregulated gene in value of
HSC-3 cell line
4 slides STD
slides
CV
Ratio
H300000194_CSPG2
-1.757 0.801492 -0.45617
4 0.295863
H300000923_POSTN
-1.7605 0.694177 -0.39431
4 0.295146
H300018412_MGST1
-1.7615 0.822925 -0.46717
4 0.294941
opHsV0400010804_
-1.76175 0.760455 -0.43165
4 0.29489
H200013413_LRP3
-1.7665 0.715098 -0.40481
4 0.293921
H200014313_BEXL1
-1.771 0.709235 -0.40047
4 0.293006
H200017501_MAGEH1
-1.77275 0.725866 -0.40946
4 0.29265
H300003004_NP_006465.3
-1.788 0.671364 -0.37548
4 0.289573
H200000850_FKBP10
-1.80325 0.670965 -0.37209
4 0.286528
H300003809_CTGF
-1.818 0.659317 -0.36266
4 0.283614
opHsV0400002995_BCL2A1
-1.8235 1.294393 -0.70984
4 0.282535
opHsV0400004303_MXD4
-1.82425 0.722652 -0.39614
4 0.282388
H300003568_CPS1
-1.82675 1.062375 -0.58157
4 0.281899
H200004216_PLXDC2
-1.82975 0.755352 -0.41282
4 0.281313
H200001726_KRT23
-1.834 0.87163 -0.47526
4 0.280486
opHsV0400012721_
-1.85175 1.48234 -0.80051
4 0.277056
H200013065_
-1.85225 0.9005 -0.48617
4 0.27696
opHsV0400010233_
-1.8585 1.76167 -0.9479
4 0.275763
H200011416_A4GALT
-1.8655 0.72525 -0.38877
4 0.274428
H200000073_GALC
-1.87525 1.044675 -0.55709
4 0.27258
H200010239_CTSL2
-1.8785 0.774282 -0.41218
4 0.271966
H200000789_NP_056359.1
-1.88175 0.858455 -0.4562
4 0.271354
H200011433_SNX10
-1.88875 0.754188 -0.39931
4 0.270041
H200010620_IL6
-1.8895 1.383369 -0.73214
4 0.269901
H200013672_ZNF569
-1.895 1.521567 -0.80294
4 0.268874
H200014737_PTGS2
-1.8985 0.67565 -0.35589
4 0.268222
H200008429_Q8TAW3_HUMAN
-1.901 1.625141 -0.85489
4 0.267758
opHsV0400005248_FAM46B
-1.9065 0.885208 -0.46431
4 0.266739
H200009421_NP_775823.1
-1.93 0.606021 -0.314
4 0.262429
opHsV0400012118_
-1.9465 0.605055 -0.31084
4 0.259445
opHsV0400000655_GJB2
-1.95175 0.743374 -0.38088
4 0.258502
H200002119_ADCY6
-1.9525 0.916307 -0.4693
4 0.258368
H200014431_Y0961_HUMAN
-1.9755 0.760543 -0.38499
4 0.254282
opHsV0400011667_
-1.99475 0.714675 -0.35828
4 0.250911
H200011635_LXN
-2.00975 1.066807 -0.53082
4 0.248316
H200009088_ZNF606
-2.012 1.487884 -0.73951
4 0.247929
H200004653_SULF2
-2.01375 0.747939 -0.37142
4 0.247629
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Table 18 continued
Average
Count of
Name of the downregulated gene in value of
HSC-3 cell line
4 slides STD
slides
CV
Ratio
H300013721_TPM4_HUMAN
-2.021 0.612298 -0.30297
4 0.246387
H300003220_THBS1
-2.0215 1.036309 -0.51264
4 0.246302
H300021562_FN1
-2.022 0.948529 -0.4691
4 0.246217
H200005569_LIPG
-2.04625 0.550896 -0.26922
4 0.242113
H300006196_MAF
-2.0505 0.813085 -0.39653
4 0.2414
H200012876_HYAL3
-2.0525 0.589862 -0.28739
4 0.241066
opHsV0400010566_
-2.0745 1.480604 -0.71372
4 0.237418
H200002091_PGBD5
-2.07575 1.316248 -0.63411
4 0.237212
opHsV0400006127_TNFRSF6B
-2.09875 0.750611 -0.35765
4 0.23346
H200006334_ID3
-2.1125 0.668089 -0.31626
4 0.231246
H200006031_IPKA_HUMAN
-2.13125 0.959348 -0.45013
4 0.22826
H200005423_Q9H7B6_HUMAN
-2.133 1.512657 -0.70917
4 0.227983
H200007909_Q86XJ2_HUMAN
-2.14075 0.764061 -0.35691
4 0.226762
H200011334_DER7_HUMAN
-2.14425 1.85577 -0.86546
4 0.226212
H300021749_FOLR3
-2.15275 0.651404 -0.30259
4 0.224884
H200005198_GALNT5
-2.15775 0.771067 -0.35735
4 0.224106
H300018293_SLC38A5
-2.16125 0.50926 -0.23563
4 0.223562
H200016573_ADPN
-2.16325 0.577262 -0.26685
4 0.223253
opHsV0400010774_
-2.16425 0.597593 -0.27612
4 0.223098
H300021145_ANGPTL4
-2.20475 0.76283 -0.34599
4 0.216922
opHsV0400012764_
-2.23 0.580492 -0.26031
4 0.213159
H200006995_
-2.2485 0.791391 -0.35196
4 0.210443
H200006600_PTPRK
-2.2635 0.981011 -0.4334
4 0.208266
H200004031_NP_945120.1
-2.264 0.729965 -0.32242
4 0.208194
H200004612_PDGFC
-2.283 0.625134 -0.27382
4 0.20547
H200001686_TM4SF10
-2.30975 1.356076 -0.58711
4 0.201695
H200018197_ZNF83
-2.31775 0.474314 -0.20464
4 0.20058
opHsV0400012111_
-2.356 0.525024 -0.22285
4 0.195332
H200015098_IL1F9
-2.38625 1.008139 -0.42248
4 0.191279
H200009642_ITGAV
-2.3925 0.630469 -0.26352
4 0.190452
H200004832_C3orf14
-2.4275 0.846863 -0.34886
4 0.185887
H300015331_CALD1
-2.43825 0.623359 -0.25566
4 0.184507
H200012184_COL4A1
-2.46775 0.999759 -0.40513
4 0.180773
opHsV0400000212_SH3BGRL
-2.47625 0.893669 -0.3609
4 0.179711
H300016644_WASPIP
-2.58325 1.607772 -0.62238
4 0.166865
H200005947_GJA1
-2.6245 1.273362 -0.48518
4 0.162161
H200020242_C9orf26
-2.63075 1.189428 -0.45213
4 0.16146
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Table 18 continued
Average
Count of
Name of the downregulated gene in value of
HSC-3 cell line
4 slides STD
slides
CV
Ratio
H300000043_RGS17
-2.63425 0.842874 -0.31997
4 0.161069
opHsV0400010227_Q96NA9_HUMAN -2.65575 1.140632 -0.4295
4 0.158686
H300017162_Q9H7B6_HUMAN
-2.658 0.852331 -0.32067
4 0.158439
H200006236_CDH11
-2.69325 1.264642 -0.46956
4 0.154615
opHsV0400010653_
-2.7575 1.222115 -0.4432
4 0.14788
H200008006_SEMA3C
-2.841 0.770015 -0.27104
4 0.139564
H200014307_FADS2
-3.011 1.080029 -0.35869
4 0.124051
H300008702_ITGB6
-3.28575 0.967254 -0.29438
4 0.102539
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Table 19: The most upregulated and downregulated 20 genes in BHY cell line and the
expression levels of these 20 genes in the other two OSCC cell lines.
Name of the most upregulated 20
gene in BHY cell line. The gene list is
from the more upregulated gene to
less upregulated gene.

Expression
ratio of the
gene in BHY

Expression
ratio of the
gene in HN
cell

Expression
ratio of the
gene in HSC-3
cell

H300004818_MAGEA9
H200001373_Q96AL8_HUMAN
H200005842_GFI1
opHsV0400005829_OAS1
H200007111_NP_689700.1
H200005801_MAGEA1
opHsV0400002611_PRAME
opHsV0400006088_NOV
H200011702_HOXA10
H200012712_BIRC3
H200004378_MAGEA8
H200000112_DLX2
H200003290_DEPDC1B
H200000421_DPYD
H200000404_IRK2_HUMAN
opHsV0400006060_
H200011805_NMES1_HUMAN
H300010220_ID2
H200005149_NP_116262.2
H200006112_NP_006811.1
Name of the most downregulated 20
gene in BHY cell line. The gene list is
from the less downregulated gene to
more downregulated gene.

7.909026
7.86529
6.768096
6.37533
6.087079
5.877693
5.8665
5.862435
5.820931
5.181968
5.143499
5.112397
5.092945
4.930555
4.917755
4.916051
4.798222
4.76673
4.735445
4.64684
Expression
ratio of the
gene in BHY

2.070171
10.51407
3.717931
7.281572
3.100498
11.27847
6.631108
2.455471
4.453686
5.754737
2.806943
1.306312
2.7549
0.622437
0.53016
3.857056
12.48826
1.236704
1.304503
4.524474
Expression
ratio of the
gene in HN

4.429825
2.0145
1.04215
0.71254
1.2456
1.8964
8.2007
0.94251
0.76598
0.5627
8.88886
2.20014
1.46598
1.00124
2.01245
0.8854
0.7645
1.0235
0.450547
0.96325
Expression
ratio of the
gene in HSC-3
cell

H300018293_SLC38A5
H200001823_ARMCX1
H200011330_RKHD3
H300021749_FOLR3
H200001408_SFRP1
H300021145_ANGPTL4
H200016276_ESPN
H300016617_THY1
H200018944_KLF8

0.203803
0.203204
0.200337
0.198162
0.195106
0.190584
0.186791
0.186242
0.18621
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0.742905
0.508299
0.195095
0.202115
0.185148
0.179867
0.726734
0.872665
0.272013

0.223562
0.373907
1.235689
0.224884
0.366148
0.216922
0.342043
0.309283
0.434522

Table 19 continued
Name of the most downregulated 20
gene in BHY cell line. The gene list is
from the less downregulated gene to
more downregulated gene.

Expression
ratio of the
gene in BHY

H200005423_Q9H7B6_HUMAN
H200001686_TM4SF10
H200004832_C3orf14
H200011635_LXN
opHsV0400010653_
H200005947_GJA1
H200017869_
H200014307_FADS2
H300017162_Q9H7B6_HUMAN
opHsV0400010227_Q96NA9_HUMAN
H300000043_RGS17

0.184891
0.165913
0.160012
0.155071
0.150335
0.129588
0.125318
0.123044
0.118339
0.101005
0.093121
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Expression
ratio of the
gene in HN
0.449845
0.607413
2.255192
0.137333
0.144511
0.068441
0.634635
0.113401
0.498011
0.066951
0.200372

Expression
ratio of the
gene in HSC-3
cell
0.227983
0.201695
0.185887
0.248316
0.14788
0.162161
1.469785
0.124051
0.158439
0.158686
0.161069

Table 20: The most upregulated and downregulated 20 genes in HN cell line and the
expression levels of these 20 genes in the other two OSCC cell lines.
Name of the most upregulated 20
gene in HN cell line. The gene list is
from the more upregulated gene to
less upregulated gene.

Expression
ratio of the
gene in HN

Expression
ratio of the
gene in BHY
cell

Expression
ratio of the
gene in HSC-3
cell

H200011805_NMES1_HUMAN
H200005801_MAGEA1
H200001373_Q96AL8_HUMAN
opHsV0400013404_
H200004165_FSTL5
opHsV0400005829_OAS1
H200010620_IL6
H200010289_C6orf139
H300005969_COX7B2
opHsV0400002611_PRAME
H300006342_NP_775969.1
H200010916_NP_114156.1
H200012712_BIRC3
H300006447_MT1K
H200007081_SLCO2A1
H200002977_NP_065726.1
H200004279_ID4
H200008845_STMN3
H300022894_NP_002116.2
opHsV0400000818_IL8
Name of the most downregulated 20
gene in HN cell line. The gene list is
from the less downregulated gene to
more downregulated gene.

12.2461
11.27847
10.51407
9.04738
7.823152
7.281572
7.206256
7.156479
6.699252
6.631108
6.463206
6.040843
5.754737
5.66863
5.634353
5.514576
5.36378
5.135483
5.088534
5.066537
Expression
ratio of the
gene in HN

4.798222
5.877693
7.86529
1.330529
2.39828
6.37533
4.452143
3.922436
1.24387
5.8665
1.7436
1.03434
5.181968
0.212237
2.721213
3.700576
1.00232
4.018062
1.84334
4.259695
Expression
ratio of the
gene in BHY

0.98746
8.200717
2.04345
2.731607
2.18635
1.90835
0.269901
2.763028
1.82643
1.02386
1.19476
1.90345
1.56723
1.87352
1.90032
2.921076
2.28734
1.78253
1.1872
3.643942
Expression
ratio of the
gene in HSC-3
cell

0.53432
0.317483
0.6617
0.307253
0.65293
0.309337
0.493116
2.763506
2.204192

0.724973
0.223098
1.600475
0.398527
0.154615
0.210443
0.247629
0.4214
0.600714

H200014027_CA2
opHsV0400010774_
H200000301_CDKN2A
H200011169_TCF7L1
H200006236_CDH11
H200006995_
H200004653_SULF2
H300003117_Q8N4W5_HUMAN
H200016561_NP_060910.2

0.130466
0.127759
0.127207
0.125456
0.122895
0.120575
0.119908
0.119272
0.118997
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Table 20 continued
Name of the most downregulated 20
gene in HN cell line. The gene list is
from the less downregulated gene to
more downregulated gene.
H200020242_C9orf26
H300006196_MAF
H200007907_FOXO1A
H200014307_FADS2
opHsV0400011317_
H300004073_AKR1C1
H300004901_RPS4Y1
H200014029_EIF1AY
H300021913_AKR1C3
H200005947_GJA1
opHsV0400010227_Q96NA9_HUMAN

Expression
ratio of the
gene in HN
0.118298
0.114705
0.114011
0.113401
0.108769
0.102646
0.10003
0.08362
0.075154
0.068441
0.066951
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Expression
ratio of the
gene in BHY

Expression
ratio of the
gene in HSC-3
cell

0.225156
0.227313
0.4355
0.123044
0.63243
2.305373
0.43224
0.817052
0.6213
0.129588
0.101005

0.16146
0.2414
0.67354
0.124051
0.71256
2.441893
0.39214
1.464847
2.628974
0.162161
0.158686

Table 21: The most upregulated and downregulated 20 genes in HSC-3 cell line and the
expression levels of these 20 genes in the other two OSCC cell lines.
Name of the most upregulated 20
gene in HSC-3 cell line. The gene list
is from the more upregulated gene to
less upregulated gene.

Expression
ratio of the
gene in HSC3

Expression
ratio of the
gene in BHY
cell

Expression
ratio of the
gene in HN
cell

H200004378_MAGEA8
H200005801_MAGEA1
H200011948_EREG
H200011983_Q9BT26_HUMAN
opHsV0400002734_NP_848664.1
H200004597_XM_374020.2
H200002223_TXNRD1
opHsV0400008521_
H200017455_NP_060582.1
opHsV0400003034_KLK10
H200004485_HOXC9
H200009720_GDF15
opHsV0400003019_NP_115749.2
H300004818_MAGEA9
opHsV0400001562_IGSF4
H300006703_LY6K
H300022245_PHF15
opHsV0400000415_NP_149024.1
opHsV0400004777_NP_998889.1
opHsV0400001984_XP_377060.1
Name of the most downregulated 20
gene in HSC-3 cell line. The gene list
is from the less downregulated gene to
more downregulated gene.

8.88887
8.200717
6.050272
6.032475
5.844178
5.436771
5.277117
5.152419
4.845011
4.832434
4.813212
4.563055
4.430594
4.429826
4.299742
4.247165
4.166252
4.126733
4.039705
3.987543
Expression
ratio of the
gene in HSC3

5.143499
5.877693
4.004161
1.2334
3.118819
4.13389
3.269908
4.235405
2.378002
3.113959
2.113304
1.647467
1.642052
7.909026
1.313576
3.564007
1.7834
2.03424
1.819762
1.834962
Expression
ratio of the
gene in BHY

2.806943
11.27847
1.490969
4.322153
3.088165
3.868435
2.587843
1.431969
3.319003
1.801252
1.42652
3.522257
2.900899
2.070171
2.159579
4.538608
0.777007
0.80413
1.706452
1.318594
Expression
ratio of the
gene in HN
cell

0.201695
0.20058
0.195332
0.191279
0.190452
0.185887
0.184507
0.180773
0.179711

0.165913
0.543085
0.379258
0.40669
0.270509
0.160012
0.402902
0.493116
0.383421

H200001686_TM4SF10
H200018197_ZNF83
opHsV0400012111_
H200015098_IL1F9
H200009642_ITGAV
H200004832_C3orf14
H300015331_CALD1
H200012184_COL4A1
opHsV0400000212_SH3BGRL
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0.607413
0.598221
0.272816
0.174373
0.330908
2.255192
0.267479
0.141586
0.427427

Table 21 continued
Name of the most downregulated 20
gene in HSC-3 cell line. The gene list
is from the less downregulated gene to
more downregulated gene.

Expression
ratio of the
gene in HSC3

Expression
ratio of the
gene in BHY

H300016644_WASPIP
H200005947_GJA1
H200020242_C9orf26
H300000043_RGS17
opHsV0400010227_Q96NA9_HUMAN
H300017162_Q9H7B6_HUMAN
H200006236_CDH11
opHsV0400010653_
H200008006_SEMA3C
H200014307_FADS2
H300008702_ITGB6

0.166865
0.162161
0.16146
0.161069
0.158686
0.158439
0.154615
0.14788
0.139564
0.124051
0.102539

0.204121
0.129588
0.225156
0.093121
0.101005
0.118339
0.65293
0.150335
0.259175
0.123044
0.281948

155

Expression
ratio of the
gene in HN
cell
0.216547
0.068441
0.118298
0.200511
0.066951
0.498011
0.122895
0.144511
0.181684
0.113401
0.512811

APPENDIX B: FIGURES
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Figure 1: Schematic drawing showing the relationship between tumor cells, osteoclast
precursor cells, stromal cells, and extracellular matrix. Osteoclast precursor cells are
apposed to tumor cells in some instances (a), but stromal cells and/or extracellular matrix
usually exits between the two cells (b), (c), (d). (T, tumor cells; SC, stromal cells; ECM,
extracellular matrix; OPC, osteoclast precursor cells.) (7).
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BHY
Mandibular Bone

HN
Cervical Lymph
Nodes

Lungs

Brain

HSC-3
Cervical Lymph
Nodes

Figure 2: The organs to which BHY, HN, and HSC-3 cells invade and/or metastasize are
shown in this schematic drawing.
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Figure 3: Operon Human Version 3.0 microarray slides
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Figure 4a: Total RNA samples before the synthesis of cDNA for Real Time PCR. Column 1:
Marker, 2: HNEC, 3: BHY, 4: HN, 5: HSC-3, 6: blank, 7: JP1, 8: JP2.

Figure 4b: Glucose-6-phosphate gene expression levels of cDNA samples used for Real Time
PCR. Column 1:Marker, Column 2: HNEC, Column 3: BHY, Column 4: HN, Column 5: HSC-3.
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Figure 5: A left sagittal PET image of a mouse with HNEC cell line injection. No malignancy
was observed.

Figure 6: A left sagittal PET image of a mouse with Matrigel injection. No malignancy was
observed.
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Figure 7: An axial PET/CT image of a mouse with HNEC cell line injection. No malignancy was
observed. All structures look normal.
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Figure 8: A left sagittal PET image of a mouse with BHY cell line injection. Arrow shows the
mandibular bone resorption due to invasion of OSCC to the bone.

Figure 9: A left sagittal PET/CT image of a mouse with BHY cell line injection.
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Figure 10: A left sagittal PET image of a mouse with HN cell line injection. Yellow arrow shows
lung metastasis, blue arrow shows kidney metastasis and white arrow shows the distant lymph
node metastasis of OSCC.

Figure 11: A left sagittal PET/CT image of a mouse with HN cell line injection. Yellow arrow
shows lung metastasis, blue arrow shows kidney metastasis and white arrow shows the cervical
lymph node metastasis of OSCC.
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Figure 12: A left sagittal PET image of a mouse with HSC-3 cell line injection. White arrow
shows cervical lymph node metastasis.

Figure13: An axial PET/CT image of a mouse with HSC-3 cell line injection. White arrow
shows cervical lymph node metastasis.
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Figure 14: Immunocytochemistry images showing MMP-1 expression. A: HNEC, B:
BHY, C: HN, D: HSC-3. Original magnification is 100x.
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Figure 15: Immunocytochemistry images showing MMP-2 expression. A: HNEC, B:
BHY, C: HN, D: HSC-3. Original magnification is 100x.
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Figure 16: Immunocytochemistry images showing MMP-3 expression. A: HNEC, B:
BHY, C: HN, D: HSC-3. Original magnification is 100x.
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Figure 17: Immunocytochemistry images showing MMP-9 expression. A: HNEC, B:
BHY, C: HN, D: HSC-3. Original magnification is 100x.
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Figure 18: Immunocytochemistry images showing EMMPRIN expression. A: HNEC, B:
BHY, C: HN, D: HSC-3. Original magnification is 100x.
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Figure 19: Immunocytochemistry images showing cathepsin B expression. A: HNEC, B:
BHY, C: HN, D: HSC-3. Original magnification is 100x.
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Figure 20: Immunocytochemistry images showing cathepsin L expression. A: HNEC, B:
BHY, C: HN, D: HSC-3. Original magnification is 100x.
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HNEC
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HSC-3
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MMP-2
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Figure 21: Flow cytometry results of (-) control, MMP-1, MMP-2, and MMP-3
expression in HNEC, BHY, HN and HSC-3 cell lines.
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HNEC

BHY

HN

HSC-3

MMP-9

EMMPRIN

Figure 22: Flow cytometry results of MMP-9 and EMMPRIN expression in HNEC,
BHY, HN and HSC-3 cell lines.
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Figure 23: Electron microscopy picture

Figure 24: Electron microscopy picture

of BHY cells. Original magnification is

of HN cells. Original magnification is

5,000x.

5,000x.

Figure 25: Electron microscopy picture

Figure 26: Electron microscopy picture

of HSC-3 cells. Original magnification

of HNEC cells. Original magnification

is 5,000x.

is 5,000x.
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Figure 27: The quantity measurement of total RNA of the BHY cell line.

Figure 28: The quantity measurement of total RNA of the HN cell line.
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Figure 29: The quantity measurement of total RNA of the HSC-3 cell line.

Figure 30: The quantity measurement of total RNA of the HNEC cell line.
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Figure 31: Aldolase and β-actin genes expression on three OSCC cell lines and HNEC cell line.
Column 1: Aldolase (-) control; Column 2: Aldolase (+) control; Column 3: Aldolase in BHY
cell line; Column 4: Aldolase in HNEC cell line; Column 5: Aldolase in HN cell line; Column
6: Aldolase in HSC-3 cell line; Column 7: β-actin (-) control; Column 8: β-actin (+) control;
Column 9: β-actin in BHY; Column 10: β-actin in HNEC; Column 11: β-actin in HN; Column
12: β-actin in HSC-3; Column 13: IH marker.

Figure 32: Clusterization of the 13 genes that are upregulated in all three OSCC cell lines.
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Figure 33: Clusterization of 83 downregulated genes in all three OSCC cell lines.
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Figure 33 continued.
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B

Figure 34: Clusterization of the top 20-upregulated (A) and downregulated (B) genes of
BHY cell line with other two OSCC cell lines, HN and HSC-3.
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B

Figure 35: Clusterization of the top 20-upregulated (A) and downregulated (B) genes of
HN cell line with other two OSCC cell lines, BHY and HSC-3.
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A
B
Figure 36: Clusterization of the top 20-upregulated (A) and downregulated (B) genes of HSC-3
cell line with other two OSCC cell lines, BHY and HN.
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Figure 37: 57 upregulated genes and 42
downregulated genes on both BHY and HN cell
lines.
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Figure 38: 24 upregulated and 49 downregulated genes on both BHY and HSC-3 cell
lines.
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Figure 39: 24 upregulated and 44 downregulated genes on both HN and HSC-3 cell lines.
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Figure 40: Pathway analysis of the BHY cell line based on both upregulated and
downregulated gene data by using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 41: Pathway analysis of the BHY cell line based on upregulated gene data by
using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 42: Pathway analysis of theBHY cell line based on downregulated gene data by
using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 43: Pathway analysis of the HN cell line based on both upregulated and
downregulated gene data by using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 44: Pathway analysis of the HN cell line based on upregulated gene data by using
Kyoto Encyclopedia of Gene and Genomes (KEGG).

191

Figure 45: Pathway analysis of the HN cell line based on downregulated gene data by
using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 46: Pathway analysis of the HSC-3 cell line based on both upregulated and
downregulated gene data by using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 47: Pathway analysis of the HSC-3 cell line based on upregulated gene data by
using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 48: Pathway analysis of the HSC-3 cell line based on downregulated gene data by
using Kyoto Encyclopedia of Gene and Genomes (KEGG).
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Figure 49: RT-PCR Analysis results. Blue columns represent the BHY, red columns
represent the HN and green columns represent the HSC-3 cell lines.
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